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Abstract 
Breast cancer is one of the leading causes of deaths in women worldwide. 5-flourouracil 
(5-FU) is a classic chemotherapeutic drug that has been widely used in the treatment of breast 
cancer patients. In this study, using several biochemical techniques, we studied the global effects 
of 5-FU treatment on MCF7 breast cancer cells. The dose-response curve obtained after the 
treatment of MCF7 cells with 23 different 5-FU concentrations for 48 hours showed an atypical 
bimodal or biphasic curve, thus indicating a plausible dual mechanism of action for 5-FU. After 
48 hours of treatment with 5-FU, the cells were found to be apoptotic, with a distinct reduction in 
the cell size, compromised anchorage ability but no significant alteration in the cell cycle 
progression. These findings provided evidence of the global inhibitory effects of 5-FU on human 
breast cancer cells in vitro and warranted further evaluation to study the molecular basis of  
aberrant expression of protein-coding genes previously reported after 5-FU treatment. We 
hypothesized that microRNAs (miRNAs), the newly identified class of small regulatory RNAs, 
might play a mediator role in inducing the cytotoxicity of 5-FU, by regulating the expression of 
  
its target genes. Using a combined advanced microarray and quantitative real time PCR (qRT-
PCR) technology, we found for the first time that 5-FU significantly altered the global 
expression profile of miRNAs in MCF7 breast cancer cells. After 48 hours of treatment with a 
low dose (0.01µM), 42 miRNAs were differentially expressed in MCF7 cells (23 up-regulated, 
19 down-regulated). A majority of these miRNAs have been previously associated with cancer 
development, and were predicted to potentially target many oncogenes and tumor suppressor 
genes. To further understand the connection between miRNA dysregulation and 5-FU therapy, 
we investigated the dose- and time-dependent modification in the miRNA expression levels after 
5-FU treatment. Eleven miRNAs (let-7g, miR-10b, miR-15a, miR-16, miR-21, miR-27a, miR-
365, miR-374b, miR-483-5p, miR-574-3p and miR-575) previously identified in the microarray 
to be differentially expressed after treatment were selected to analyze their responsiveness to 
eight different 5-FU dosages of 0.001, 0.005, 0.01, 0.1, 0.7, 1, 5 and 10µM. Of these, miR-10b, 
miR-21, miR-365 and miR-483-5p were shown to be significantly regulated in a beneficial way. 
Time-response data was also generated for miR-10b, miR-21, miR-483-5p, miR-574-3p and 
miR-575 following 12, 24, 36, 48, 60 and 72 hours treatment with 0.1, 0.7 and 10µM 5-FU. The 
data obtained suggested that miRNA expression in MCF7 cells is sensitive to 5-FU therapy at 
low doses and shorter treatment durations. The down-regulation of an important oncomir, miR-
21; and alteration in the expression of three new miRNAs with no previous breast cancer 
association, miR-483-5p, miR-574-3p and miR-575 indicates that miRNA might play an 
important role in 5-FU therapy. In conclusion, miRNAs were shown to play an important 
regulatory role in 5-FU induced cytotoxicity and fit in perfectly in the intricate network of 5-FU 
activity. 
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Chapter 1: Review of Breast Cancer, Chemotherapy and MicroRNAs 
Breast cancer: An Overview 
Breast cancer is one of the leading causes of deaths worldwide. It is the most common 
cause of death in women between the ages of 45 and 55. The American Cancer Society reported 
465,000 deaths worldwide due to breast cancer alone in 2007. Breast cancer incidence in women 
in the United States is about 1 in 8 (~13%). Although it is a common form of cancer in women, 
male breast cancer cases have also been reported and it accounts for about 1% of all cancer 
deaths in men (American Cancer Society). Breast cancer is the cancerous growth of the tissue in 
the breasts, which can be benign or malignant. Benign breast tumors result in fibrocystic 
deposition in the breast, causing lumpiness of the breast. Malignant breast tumors can spread 
(metastasize) to different tissues or organs by the blood stream or lymph system; the most 
common sites are the bones, liver, lungs, and brain. According to the American Cancer Society, 
an estimated 192,370 new cases of breast cancer were diagnosed and approximately 40,170 
women died from breast cancer in the year 2009. 
There are several risk factors associated with breast cancer. Genetic mutation and 
heredity is one of the major reason causing breast cancer; for example, genetic mutations in the 
BRCA1 and BRCA2 genes. However, only about 5-10% of breast cancers are hereditary; other 
causes include age, alcohol consumption, obesity, hormone replacement therapy, and birth 
control pills consumption. Early breast cancer does not show any significant symptoms. Gradual 
development of the cancer results in formation of a lump in the breasts, change in shape, size, 
color or texture of breast or discharge from nipple. Breast cancer can be diagnosed by careful 
physical examination, mammography, ultrasonography, Magnetic Imaging Resonance (MRI) 
and breast biopsy. With recent technological advances, gene expression profiling is also used to 
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detect early breast cancer and predict their prognostic outcomes. Three such gene expression–
based prognostic breast cancer tests have been licensed for use: Oncotype DX (Genomic Health, 
Redwood City, California), MammaPrint (Agendia BV, Amsterdam, the Netherlands), and H/I 
(AvariaDX, Carlsbad, California). 
Types of breast cancer 
There are several types of breast cancer, but the most common types are ductal carcinoma 
and lobular carcinoma. The other types of breast cancers are relatively rare. Some of these 
cancers are in situ carcinomas, which mean that the cancer cells remain confined to ducts or 
lobules and do not grow into deeper tissues in the breast or spread to other organs in the body. 
These are sometimes referred to as non-invasive or pre-invasive breast cancers. The more 
aggressive breast cancers are the invasive or infiltrating carcinomas which have spread to the 
other breast tissues and other organs of the body.  
The following list entails the different types of breast cancers: (American cancer Society, 
Inc.; National Breast Cancer Foundation, Inc.; Breastcancer.org)  
Ductal carcinoma: This is the cancer of the ducts, the passageway which carries milk 
from the milk-producing lobules to the nipple. It can be non-invasive (in situ) or invasive 
(infiltrative). It is the most common type of cancer, accounting for about 85 – 90% of breast 
cancer cases. 
Lobular carcinoma: It arises in the lobules, the milk-producing gland of the breast. It is 
the second most common type of breast cancer, occurring in about 8% of the cases. 
Inflammatory breast cancer: This is an uncommon type of invasive breast cancer, in 
which the cancer cells block the lymph vessels around the breast, making the breast look red, 
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warm and with a pitted appearance. There is usually no lump or tumor found, and it accounts for 
about 1-3% of all breast cancer cases. 
Medullary carcinoma: This is a rare type of invasive ductal carcinoma in which the 
cancer cells are morphologically different and bigger than the normal breast cells, and there is a 
well defined boundary observed between the cancerous cells and normal cells. 
Metaplastic carcinoma: This type of breast cancer includes a range of cancers of mixed 
epithelial (cells lining the breast) and mesenchymal (connective tissue if the breast) cells, which 
then change into squamous (nonglandular) cells. This cancer does not have estrogen receptors 
(ERs), progesterone receptors (PRs), or HER2/neu protein. 
Mucinous (colloid) carcinoma: It is the cancer of the mucus-producing cells. They are 
usually estrogen receptor positive and HER2/neu negative. 
Tubular carcinoma: This is a rare type of invasive ductal carcinoma in which the cancer 
cells have a tubular microscopic appearance. Tumors are generally small, estrogen receptor 
positive and HER2/neu negative. 
Papillary carcinoma: It is a type of rare ductal carcinoma in situ in which the cells are 
arranged in small, finger-like projections (papilla) when viewed under the microscope. These are 
rarely invasive and are more prominent in older women. 
Adenoid cystic (adenocystic) carcinoma: These cancers have both glandular (adenoid) 
and cylinder-like (cystic) features under the microscope. They make up less than 1% of breast 
cancers and are rarely invasive. 
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Phyllodes (phylloids) tumor or cystosarcoma phyllodes: It is a rare sarcoma, cancer of the 
stroma (connective tissue), which is usually benign. 
Angiosarcoma breast tumor: A breast angiosarcoma is a rare type of breast cancer which 
starts in cells that line the blood vessels within the breasts. 
 Molecular genetics of breast cancer 
 Carcinogenesis is a multistep process which usually involves genetic alterations that 
influence important cellular pathways. About 10% of the breast cancer cases are shown to be 
hereditary, which results mainly due to genetic defects or mutations in the genome inherited 
from the parent. Women with these mutations have up to 80% risk of developing breast cancer 
during their lifetime. About 90% of breast cancers are due not to heredity, but mainly sporadic 
cancers, resulting from acquired somatic mutations or genetic abnormalities that happen as a 
result of aging process and life in general. More recently, using advanced technologies such as 
comparative genome hybridization (CGH), fluorescence in situ hybridization (FISH), 
chromosome painting and microsatellite marker analysis, the genome of the breast cancer cells 
have been shown to be highly unstable (Hedley, Rugg et al. 1987; Tirkkonen, Johannsson et al. 
1997; Ingvarsson, Geirsdottir et al. 1998; Lingle, Barrett et al. 2002). These are due to mutations 
or other alterations in the tumor suppressor genes and amplification of the oncogenes. Alterations 
in the tumor suppressor genes would cause loss-of-function effects, while oncogenes cause gain-
of-function effect that contribute to the malignant breast cancer phenotype. Table 1.1 gives the 
list of different oncogenes and tumor suppressor genes which usually undergo alterations in 
breast cancer. 
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Strategies for breast cancer treatment 
There are several treatment options available for the management of breast cancer. It can 
be treated either locally or systemically. Local treatment includes surgery (mastectomy or 
lumpectomy) and radiation therapy; while systemic treatment includes chemotherapy and 
hormone replacement therapy. There are several chemotherapeutic drugs used for the treatment 
of breast cancer (Table 1.2) that are usually used as an adjuvant therapy along with surgery.  In 
many cases, a combination of two or more medicines will be used as chemotherapy treatment for 
breast cancer (Table 1.3). However there are several side-effects associated with treatment with 
chemotherapeutic drugs, like anemia, hair loss, nausea, vomiting, diarrhea, etc . Hormonal 
therapy is also widely used for the management of breast cancers that are sensitive to hormones. 
These are usually estrogen and progesterone-receptors positive breast cancers. Table 1.4 gives 
the list of drugs used in hormone therapy. 
Recent advances in research and technology has seen the development of targeted drug 
therapies such as bevacizumab (Avastin – anti-angiogenesis drug designed to inhibit the 
signaling of cancer cells to new blood vessels); lapatinib (Tykerb – targets the protein HER2) 
and trastuzumab (Herceptin – targets the protein HER2), which are more specific for breast 
cancer treatment and are less likely to harm normal, healthy cells. More work is needed to 
improve chemotherapy for breast cancer and to develop new therapies to alleviate breast cancer 
and improve the general quality of living. 
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Chemotherapy and 5- Fluorouracil 
Several chemotherapeutic drugs are used for the treatment of breast cancer. 5-fluorouracil 
(5-fluoro-1H-pyrimidine-2,4-dione or 5-FU) is an important chemotherapeutic drug which is 
widely used for the treatment of different cancers, mainly breast (Fumoleau, Bonneterre et al. 
2003), colorectal (Wils, O'Dwyer et al. 2001) and head and neck cancers (Posner, Colevas et al. 
2000). It was first synthesized in 1957 by (Heidelberger, Chaudhuri et al. 1957). It has been in 
use for about 50 years and is available in market under different trade names – Adrucil®, 
Efudex®, Fluoroplex®, and Carac™. The drug can be administered as IV (intravenous) infusion 
or bolus, or applied topically, depending on the type of cancer treated. The patients are usually 
subjected to a continuous drug infusion at the constant rate of 450 – 966 mg/m2/day, causing 5-
FU plasma concentration to reach values of order of magnitude of 5µM or more (Petit, Milano et 
al. 1988). However, the daily dose of 5-FU is not to exceed 800 mg. 
5-FU is an antimetabolite drug. These drugs are cell-cycle specific, which affects cells 
only when they are in the S-phase or getting divided. Since the cancerous cells divide more 
rapidly compared to the normal cells, they take up these antimetabolites more rapidly than the 
normal cells, and hence are more toxic to them. 5-FU is a pyrimidine antagonist. It is an 
analogue of uracil, in which the hydrogen at C-5 position is substituted with a fluorine atom 
(Figure 1.1), hence called a Fluoropyrimidine. Its cytotoxicity has been ascribed to its inhibition 
of the thymidylate synthase (TS) and misincorporation into RNA and DNA, finally inducing 
cell-cycle arrest and apoptosis. 
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Mechanism of action 
Following administration, 5-FU enters the cell through the same facilitated transport 
mechanism as used by uracil (Wohlhueter, McIvor et al. 1980). It is then converted 
intracellularly into 3 different active metabolites: fluorodeoxyuridine monophosphate (FdUMP), 
fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP) (Figure 1.2).  
The first step in the activation on 5-FU is its conversion to fluorouridine monophosphate 
(FUMP). This conversion can occur in two ways: a) Direct conversion: by action of orotate 
phosphoribosyltransferase (OPRT) with co-factor phosphoribosyl pyrophosphate (PRPP); and b) 
Indirect conversion: through sequential conversion from 5-FU to fluorouridine (FUR) and then to 
FUMP by the action of enzymes uridine phosphorylase (UP) and uridine kinase (UK) 
respectively (Daher, Harris et al. 1990). FUMP can then be phosphorylated to fluorouridine 
diphosphate (FUDP), which can be converted to the active compound fluorouridine triphosphate 
(FUTP), causing the cytotoxic effects. FUDP can also be converted to fluorodeoxyuridine 
diphosphate (FdUDP) by ribonucleotide reductase (RR). FdUDP can then be phosphorylated or 
dephosphorylated to give the active compounds fluorodeoxyuridine triphosphate (FdUTP) or 
fluorodeoxyuridine monophosphate (FdUMP) respectively. Alternatively, 5-FU can also be 
converted to FdUMP by thymidine phosphorylase (TP) catalysed conversion of 5-FU to 
fluorodeoxyuridine (FUDR), which is then phosphorylated to FdUMP by thymidine kinase (TK). 
The three active metabolites, FdUMP, FdUTP and FUTP elicit the cytotoxicity of 5-FU in 
cancerous cells. 
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Inhibition of thymidylate synthase (TS) 
TS is a 36kDa dimeric protein which contains a nucleotide – binding site and a folate – 
binding site. It catalyses the conversion of deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP). dUMP undergoes reductive methylation to dTMP with 
N5,N10-methylenetetrahydrofolate (CH2THF) serving as the methyl donor. This reaction is a part 
of the de novo synthesis of thymidine and is the only source of thymidine, which is required for 
DNA replication and repair.  
FdUMP actively binds to the nucleotide-binding site of TS, which results in the formation 
of a stable ternary complex of TS, FdUMP and CH2THF (Figure 1.3). Binding of FdUMP to TS 
prevents the binding of the normal substrate dUMP to TS, resulting in inhibition of dTMP 
synthesis (Santi, McHenry et al. 1974; Sommer and Santi 1974). Reduction in the level of dTMP 
causes succesive reduction in dTTP levels, which in turn induces imbalances in the 
deoxynucleotide pool (dATP, dCTP and dGTP) and particularly dATP/dTTP ratio (Yoshioka, 
Tanaka et al. 1987; Houghton, Tillman et al. 1995). These imbalances result in inhibition of 
DNA synthesis and repair, and thus cause DNA damage. 
Misincorporation into DNA and RNA 
FdUTP gets misincorporated into the DNA strands in place of dTTP during DNA 
replication. Additionally, accumulation of dUMP results in allevated levels of dUTP inside the 
cells (Mitrovski, Pressacco et al. 1994; Aherne, Hardcastle et al. 1996). This causes 
misincorporation of dUTP in DNA strands. This misincorporation cannot be corrected / repaired 
by nucleotide excision due to the high dUTP/dTTP ratios, and this ultimately results in DNA 
strand breaks and cell death. 
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Further, FUTP is extensively misincorporated in RNA strands, which disrupts the normal 
RNA processing. This results in disruption of the further synthesis and processing of mRNAs 
(Doong and Dolnick 1988; Patton 1993), tRNAs (Randerath, Tseng et al. 1983; Santi and Hardy 
1987) and rRNAs (Kanamaru, Kakuta et al. 1986; Ghoshal and Jacob 1994) and in inhibition of 
post-transcriptional conversion of uridine to pseudouridine in these RNAs (Samuelsson 1991). 
This results in RNA toxicity and imbalances, causing variability in cellular metabolism and 
functioning. 
Inactivation of 5-FU 
5-FU is primarily catabolized in the liver, where the enzyme dihydropyrimidine 
dehydrogenase (DPD) is present in abundance. DPD catalyses the conversion of 5-FU to inactive 
compound dihydrofluorouracil (Diasio and Harris 1989) (DHFU, Figue 2). 
Dosage and clinical pharmacokinetics  
 5-FU is generally administered as an intravenous injection. The actual doses are 
dependent on the weight of the patient. Usually, 12 mg/kg of 5-FU are given intravenously once 
daily for 4 successive days. The daily dose should not exceed 800 mg. If no toxicity is observed, 
six mg/ml are given on the 6th, 8th, 10th and 12th days. Therapy is then discontinued at the end of 
12th day (Fluorouracil Injection, USP; Gensia Sicor Pharmaceuticals, Inc., Irvine, CA 92618). 
 Following intravenous injection, 5-FU gets distributed mainly into the tumors, bone 
marrow, liver, intestinal mucosa and other tissues in the body. It also diffuses readily across the 
blood brain barrier and gets distributed into the CSF (cerebrospinal fluid). Seven to 20% of the 
parent drug is excreted unchanged in the urine in about 6 hours (Diasio and Harris 1989), while 
60-90% of the administered dose is excreted in urine within 24 hours, primarily as α-fluoro-β-
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alanine (Heggie, Sommadossi et al. 1987). The mean half life of elimination from plasma is 
dose-dependent and in the range eight to 20 min (Heggie, Sommadossi et al. 1987; Diasio and 
Harris 1989). No intact drug can be detected in the plasma after three hours of intravenous 
injection (Heggie, Sommadossi et al. 1987; Diasio and Harris 1989). However, 5-FU active 
metabolites have prolonged elimination half lives (Heggie, Sommadossi et al. 1987). 
5-FU modulations / Improvements 
5-FU drug treatment is associated with varied side effects, ranging from mild to severe. 
Common side effects include nausea, vomiting, diarrhea, weakness, mouth sores, poor appetite, 
discoloration of the vein through which the medication is given, sensitivity to light 
(photophobia), reduced white and red blood cell and platelet counts which can cause increased 
risk of infections. More rare side effects include skin reactions like hyperpigmentation 
(darkening of skin), dryness or cracking of skin; discoloration of nails; thinning of hair and hand 
and foot syndrome. Several strategies have been adopted to improve the 5-FU therapy (Figure 
1.4). These include adjunct therapy of 5-FU with other chemotherapeutic drugs like Leucovorin, 
Methotrexate or Irinotecan. Oxaliplatin, 5-FU and Leucovorin adjunct therapy have also been 
used for advanced colorectal cancer. Various 5-FU pro-drugs have been synthesized, like 
Capecitabine and tegafur, which improves the targeted delivery of 5-FU and significantly 
reduces the associated side effects.  
Effect of 5-FU on gene expression 
5-FU has been shown to modify the expression of protein-coding genes. 5-FU may alter 
the gene expression levels of its target enzyme, TS and its metabolic enzymes, DPD, OPRT, TP 
and UP (Inokuchi, Uetake et al. 2004; Mauritz, van Groeningen et al. 2007). In a previous study, 
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five 5-FU-inducible transcriptional targets have been identified: SSAT (spermine / spermidine 
acetyl transferase), annexin II, thymosin β-10, chaperonin-10 and MAT-8 (Maxwell, Longley et 
al. 2003). Further, p53 have been shown to be a potential target of 5-FU (Hernandez-Vargas, 
Ballestar et al. 2006). 5-FU also upregulates FAS expression (Tillman, Petak et al. 1999). 
Another study reported differential expression of a set of genes between 5-FU sensitive and 5-FU 
resistant colon carcinoma cell line, including ornithine decarboxylase, spermine/spermidine 
synthases, spermine/spermidine acetyltransferase, p21/WAF1, mdm2, Fas, mic-1, EphA2, and 
ferredoxin reductase (Zhang, Ramdas et al. 2003). Most importantly, they reported role of p53 
and tumor necrosis factor (TNF) regulation in 5-FU treatment (Zhang, Ramdas et al. 2003). A 
study performed global gene expression pattern following 5-FU treatment on MCF7 cells 
(Hernandez-Vargas, Ballestar et al. 2006). A total of 300 genes were shown to be regulated at 
any time point following treatment at 10µM and 500µM of 5-FU (Hernandez-Vargas, Ballestar 
et al. 2006). Many of these genes were found to be related with the p53 transcription factor. A 
dose- and time-dependent pattern was observed in the gene expression, with gene expression 
changes correlated with cell cycle and cell death parameters (Hernandez-Vargas, Ballestar et al. 
2006). Thus, 5-FU modifies the expression levels of several protein–coding genes. However, the 
molecular mechanism of this effect is still unknown. 
 
MicroRNAs 
 MicroRNAs (miRNAs) are an important class of endogenous, non- protein-coding RNA 
molecules which play a regulatory role in gene expression. They are small RNA molecules, 
about19-25 nucleotides in length, which negatively regulate gene expression by binding to the 
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3’-Untranslated region (3’-UTR) of the target mRNAs, and causing mRNA degradation or 
translational repression. Most of the miRNAs are highly conserved interspecies. It has been 
predicted that miRNAs constitute more than 1% of the total protein coding gene, while they 
target more than 30% protein coding genes (Lewis, Shih et al. 2003). 
  The first miRNA, lineage-deficient-4 (lin-4), was discovered by Victor Ambros’s group 
in Caenorhabditis elegans in 1993 (Lee, Feinbaum et al. 1993). The lin-4 RNA showed near 
perfect antisense complementarity with the 3’ – UTR of mRNA of the lin-14 gene, which is 
important for regulation of developmental timing in C. elegans. Since its discovery, thousands of 
miRNAs have been discovered in animals, plants and several viruses. These miRNAs play an 
important role in multiple biological processes, including developmental timings, 
embryogenesis, cell differentiation, organogenesis, metabolism, apoptosis and various diseases, 
including cancers. 
Biogenesis of microRNAs 
MiRNAs are transcribed from miRNA genes, which can be transcribed as autonomous 
transcription units, or as clusters from a polycistronic transcription unit (Bartel 2004; Kim and 
Nam 2006). miRNA genes can be divided into three groups based on their genomic location: 
first, genes located in the exonic region of non-coding transcriptions units; second, genes located 
in the intronic regions of non-coding transcription units; and third, genes located in the intronic 
region of protein-coding transcription units (Kim 2005; Kim and Nam 2006). A majority of them 
are, however, located in the intronic region of a protein-coding gene. miRNA genes are generally 
transcribed by RNA polymerase II (pol II) (Cai, Hagedorn et al. 2004; Lee, Kim et al. 2004), or 
sometimes by RNA polymerase III (pol III) (Borchert, Lanier et al. 2006); to give primary 
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miRNA transcript, called pri-miRNA (Figure 1.5). These pri-miRNAs are usually several 
thousand bases long and consists of a local hairpin structure. They may also contain a 5’-cap and 
3’-poly(-A) tail (Cai, Hagedorn et al. 2004; Lee, Kim et al. 2004). This stem-loop structure is 
then cleaved by a Microprocessor complex to give precursors of microRNA, called pre-miRNAs 
(Denli, Tops et al. 2004; Gregory, Yan et al. 2004). The Microprocessor complex is composed of 
nuclear RNase III Drosha and double-stranded RNA binding domain protein DGCR8 (DiGeorge 
syndrome critical region 8). Drosha is a 160kDa protein consisting of two RNase III domains 
(RIIIDs) and a catalytic double-stranded RNA binding domain (dsRBD); whereas DGCR8 is a 
120kDa human protein which consists of two dsRBDs (Han, Lee et al. 2004). Drosha binds to 
the pri-miRNA and cleaves it at approximately two helical turns (about 22 nt) from the terminal 
loop, to give the pre-miRNAs (Zeng, Yi et al. 2005). The flanking regions are degraded in the 
nucleus. DGCR8 is supposed to aid substrate recognition by Drosha, by assisting in binding of 
microprocessor complex to RNA or orientating the complex to RNA (Denli, Tops et al. 2004; 
Gregory, Yan et al. 2004; Landthaler, Yalcin et al. 2004). These pre-miRNAs have a typical 
stem-loop secondary structure, comprising of a about 22bp stem, a terminal loop and a 3’-
overhang of around 2 nt (Lee, Ahn et al. 2003). The pre-miRNAs thus processed are then 
exported to the cytoplasm by the nuclear transport receptor, Exportin-5 (Yi, Qin et al. 2003; 
Lund, Guttinger et al. 2004).  
Exportin-5 binds cooperatively with the pre-miRNAs and its cofactor GTP-bound-Ran in 
the nucleus (Bohnsack, Czaplinski et al. 2004). This complex then transports the pre-miRNAs 
across the nuclear membrane through the nuclear pore complexes. Following export, the GTP is 
hydrolyzed to GDP and in the process, pre-miRNAs are released into the cytoplasm. The 
secondary stem-loop structure and short 3’-overhang of the pre-miRNAs are significant 
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structural requirements for their transport by Exportin-5 (Zeng and Cullen 2004). Following their 
export from the nucleus, these pre-miRNAs are further processed to about 22 nucleotide 
miRNA:miRNA* duplexes by the cytoplasmic RNase III enzyme Dicer, and its dsRBD TRBP 
(the human immunodeficiency virus transactivating response RNA-binding protein) (Hutvagner, 
McLachlan et al. 2001; Chendrimada, Gregory et al. 2005). Dicer is a about 160kDa protein, 
consisting of two RIIIDs, a dsRBD and a long N-terminal segment that contains a Dead-Box 
RNA helicase domain, a DUF283 domain and a PAZ domain. It cleaves the pre-miRNAs at 
approximately 2 helical turns (about 22 nucleotides) from the 3’-terminus to give the 
miRNA:miRNA* duplex. One strand of the duplex is then selected as the mature miRNA and the 
other strand is degraded in the cytoplasm by unknown mechanism. Studies on siRNA duplexes 
have shown that the relative thermodynamic stability of the two ends of the duplex plays a role 
in strand selection (Khvorova, Reynolds et al. 2003; Schwarz, Hutvagner et al. 2003). The strand 
with relatively unstable base pairs at the 5’-end is usually selected as mature miRNA, while the 
other miRNA* strand is degraded. The mature miRNA then gets incorporated into the 
ribonucleoprotein complexes (RNPs) called microRNA-RNPs (miRNPs) or into miRNA-induced 
silencing complexes (miRISCs), which bring about gene regulation. The Agronaute (Ago) 
proteins are an important protein constituent of these complexes.  
Mechanism of miRNA-mediated gene regulation 
MiRNAs interact with their target mRNAs by base pairing (Figure 1.6). In plants, a 
majority of miRNAs base pair with near perfect complementarity with the mRNAs, but in 
animals there is imperfect base pairing which follows certain rules in most miRNAs, as shown 
by experimental and bioinformatic analysis (Brennecke, Stark et al. 2005; Lewis, Burge et al. 
2005; Grimson, Farh et al. 2007) (Figure 1.7). The miRNAs bind perfectly with the mRNAs 
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between nucleotides 2 and 8, known as the “seed” region (Bartel 2004; Doench and Sharp 2004; 
Brennecke, Stark et al. 2005). The seed region is generally devoid of any mismatching base pairs 
or bulges. It is flanked by an A or U residue on positions 1 and 9, which may help in improving 
site efficiency (Lewis, Burge et al. 2005; Grimson, Farh et al. 2007). The bulges or mismatches 
may be present in the central region of the miRNA-mRNA duplex. Finally, the 3’-end of miRNA 
should bind complementarily with the mRNA to stabilize the interaction (Brennecke, Stark et al. 
2005; Grimson, Farh et al. 2007). The miRNA-mRNA duplex thus formed brings about the gene 
regulation. 
Eukaryotic translation 
The process of eukaryotic translation consists of three basic steps: initiation, elongation 
and termination. Initiation of translation involves recognition of the mRNA 5’-terminal 7-
methylguanosine (m7G) cap by eukaryotic initiation factor 4E (eIF4E) subunit of initiation factor 
eIF4F. Other important initiation factors are eIF4A, eIF4G, eIF3 and eIF6. Interaction of eIF4G 
with eIF3 results in recruitment of 40S ribosomal subunit, which identifies the start codon. 
Another important role of eIF4G is its ability to interact with the polyadenylate-binding protein 1 
(PABP1), which is associated with the poly(A) tail. Simultaneous interaction of eIF4G with 
eIF4E and PABP1 causes circularization of the mRNA, increasing the proximity of eIF4E and 
5’-m7G cap, and thus stimulating initiation of translation. Identification of start codon is 
followed by association of the large 60S ribosomal subunit and the start of elongation step. As 
translation proceeds, newly synthesized proteins (nascent polypeptides) emerge from the large 
ribosomal subunit. Several ribosomes can translate a single mRNA at the same time, resulting in 
formation of ‘Polysomes’ (ribosome clusters). Termination occurs when an elongating ribosome 
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encounters the stop codon; the ribosome dissociates from the mRNA, and the completed protein 
is released. 
Presently there are four proposed mechanisms of miRNA-mediated gene repression. 
mRNA cleavage 
MiRNAs that bind perfectly with their target mRNAs bring about direct cleavage of a 
phosphodiester bond in the mRNA (Figure 1.6). In plants, most miRNAs bind to target mRNAs 
with near perfect complementarity, and the mRNA is cleaved endonucleolytically in the middle 
of the miRNA-mRNA duplex (Jones-Rhoades, Bartel et al. 2006).  This cleavage occurs between 
the residues base paired to the 10 and 11 nucleotides of the miRNAs (counting from the 5’- end 
of miRNA) (Elbashir, Martinez et al. 2001). This cleavage is caused by the ‘slicer’ activity of the 
RISC. The Agronaute proteins (Ago) are an important constituent of this RISC. Ago are about 
100 kDa proteins which contain the PAZ and PIWI domains (Carmell, Xuan et al. 2002). The 
PAZ domain contains an oligonucleotide-binding fold which binds the single-stranded 3’- end of 
miRNAs (Lingel and Sattler 2005), while the PIWI domain has a conserved pocket for binding 
the 5’-phosphate of miRNAs (Parker, Roe et al. 2005). Thus, the miRNAs is lodged between the 
PAZ and PIWI domains of the Ago protein. In addition, the PIWI domain also shows the 
presence of a catalytic site which functions similar to RNase H enzyme, capable of cleaving the 
RNA strand. Thus, the ‘slicer’ activity of the RISC complex is associated with the Ago proteins. 
However, only Ago-2 protein complexes are capable of inducing mRNA cleavage (Meister, 
Landthaler et al. 2004). In human, mRNA cleavage is not the usual method of miRNA-induced 
gene silencing. miR-196 is the only miRNA which binds perfectly to 3’-UTR of the Hoxb8 
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mRNA, causing its cleavage (Yekta, Shih et al. 2004). All others miRNA induce gene silencing 
by imperfect binding.  
Translational repression 
Another mechanism of mRNA silencing by miRNA is by interfering with their 
translation (Elbashir, Lendeckel et al. 2001). This was first suggested by the observation that 
miRNA lin-4 reduced the amount of LIN-4 protein without significantly affecting the amount of 
lin-4 mRNA (Lee, Feinbaum et al. 1993). Presence of multiple miRNA binding sites on target 
mRNAs further supports this model. Translational repression generally occurs in the absence of 
perfect complementarity between miRNA and the target mRNA. Currently two main models of 
translational inhibition by miRNAs are available: repression at initiation step or at post-initiation 
step. Studies performed in various labs have provided support for both the mechanisms. It is still 
unclear as to which mechanism is more prevalent and what factors determine as to which 
mechanism will be followed. 
Translational repression at initiation step is proposed to be affected by two possible 
mechanisms. First mechanism is by suppression in recognition of 5’-m7G cap by the eIF4E 
(Humphreys, Westman et al. 2005; Pillai, Bhattacharyya et al. 2005) . It has also been reported 
that Ago2 can bind to the 7mGpppN cap via a motif resembling a cap-interacting sequence of the 
initiation factor eIF4E, preventing the cap–eIF4E interaction, and thus stopping the recruitment 
of the small ribosomal subunit to mRNA (Kiriakidou, Tan et al. 2007). Inefficient repression of 
mRNA containing IRES (Internal ribosome entry site) or a nonfunctional cap further supports 
this model. Briefly, miRNAs are supposed to prevent the synergy between the 5’-cap and the 3’-
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poly(A) tail. An alternative mechanism for translational repression is by obstructing the joining 
of 60S subunit, which is affected by eIF6 protein (Chendrimada, Finn et al. 2007) 
Translational repression has also been showed to occur post-initiation. The observation 
that lin-14 and lin-28 mRNAs, targets of lin-4 miRNA, remain associated with polysomes 
despite reduction in their protein products (Olsen and Ambros 1999; Seggerson, Tang et al. 
2002) supports this model. A ‘drop-off’ mechanism of post-initiation repression has been 
proposed by many researchers, which states that miRNAs cause ribosomes to become prone to 
premature termination of translation (Petersen, Bordeleau et al. 2006).  Another possible 
mechanism includes the slowing down of ribosome elongation (Mootz, Ho et al. 2004). 
The research does not unequivocally state the exact mechanism of translational 
repression. One possible reason for the ambiguity could be adoption of different experimental 
techniques for the study. Another possible explanation could be that miRNA function through 
multiple mechanisms. The complementary binding with the target mRNA, and the Ago and 
GW182 proteins may play a role in deciding the mechanism of miRNA silencing. Further, there 
isn’t enough evidence to support that initiation and post-initiation mechanisms are mutually 
exclusive. 
Cotranslational protein degradation by Proteolysis 
Another method of gene silencing by miRNA is at the protein production stage. Certain 
proteins can be found associated as polysomes after the binding of miRNA to its target mRNA 
(Olsen and Ambros 1999). These polysomes or nascent peptides are continuously synthesized 
from the mRNAs, but are not accumulated. They undergo rapid degradation by the proteases in 
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the cytosol (Nottrott, Simard et al. 2006). The association of miRISC or miRNP with the target 
mRNAs recruits the proteases and promotes its activity and affinity for the polysomes. 
Deadenylation and Decapping 
 mRNA destabilization is another possible mechanism of miRNA-induced gene silencing. 
The destabilization is a sequential process, with the initial step being shortening of the 3’-
Poly(A) tail (Giraldez, Mishima et al. 2006; Wu, Fan et al. 2006). This is followed by 
degradation step which can occur via two possible pathways: the mRNA can be progressively 
degraded in 3’-5’ direction by an exosome, or it can be first 5’-decapped , followed by 5’-3’ 
degradation by the exonuclease XRN1(Parker and Song 2004) .The degradation step usually 
occurs in the P bodies, cellular structure involved in mRNA catabolism and translational 
repression (Parker and Sheth 2007) . The GW182 protein and the Ago PIWI domain are 
important constituents for this mechanism. 
Thus miRNA-mediated gene silencing can be brought about by many different mechanisms 
(Figure 1.8).  
 
miRNAs, Breast cancer and 5-FU 
 Thousands of miRNAs have been detected and characterized in plants, animals and 
viruses (Zhang, Pan et al. 2006). miRNAs play a very important role in many biological 
processes, including developmental timing, organ development, stem cell maintenance and 
differentiation, disease, cell proliferation, apoptosis and response to different stresses (Ambros 
2001; Bartel 2004; Alvarez-Garcia and Miska 2005; Cheng, Tavazoie et al. 2005). miRNA has 
also been reported to play a role in cancer initiation and progression (Calin and Croce 2006) and 
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cancer metastasis (Cheng, Byrom et al. 2005). 50% of miRNA genes are localized in cancer-
associated genomic regions or in fragile sites (Calin, Sevignani et al. 2004). miRNA expression 
profiles have helped in classifying human cancers and development of a miRNA signature for 
different types of cancers (Lu, Getz et al. 2005). In most cancers, miRNAs show aberrant levels 
of expression. Those which are over-expressed in tumors are thought to be oncogenic in nature, 
called as ‘Oncomirs’, such as miR-17-92 cluster, which targets the E2F1 oncogenes in 
lymphoma, or miR-21, which targets PTEN tumor suppressors in hepatocellular carcinoma 
(O'Donnell, Wentzel et al. 2005; Meng, Henson et al. 2007). Those miRNAs whose expression is 
reduced in tumors are thought to be Tumor suppressors or ‘TSmirs’, such as in case of miR-15a 
and miR-16-1 which targets the BCL2 oncogene in Chronic Lymphocytic Leukemia (CLL) or 
let-7 family which target RAS oncogene in lung cancers (Johnson, Grosshans et al. 2005; Calin 
and Croce 2006).  
miRNAs also play an important role in breast cancer. miRNA signature pattern have been 
shown to predict estrogen, progesterone and HER2/neu receptor status in breast cancer (Lowery, 
Miller et al. 2009) (Ma, Teruya-Feldstein et al. 2007) showed that miR-10b initiates breast 
cancer invasion and metastasis. On the other hand, breast cancer metastasis is suppressed by 
miRNAs such as miR-335 and miR-126 (Tavazoie, Alarcon et al. 2008). Further, miR-373 and 
miR-520c stimulate cancer cell migration and invasion (Huang, Gumireddy et al. 2008). miRNA 
gene expression levels are also aberrantly altered in breast cancer. miR-21, miR-10b are over-
expressed (Ma, Teruya-Feldstein et al. 2007); whereas miR-125b and miR-145 are reduced in 
breast cancer (Iorio, Ferracin et al. 2005). These studies highlight the importance of miRNAs as 
both stimulators and inhibitors in breast cancer. Currently, a growing body of evidence has 
suggested the importance of miRNAs in modulating the chemosensitivity and chemoresistance 
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of tumor cells (Meng, Henson et al. 2006; Blower, Verducci et al. 2007; Blower, Chung et al. 
2008). (Si, Zhu et al. 2007) reported that suppression of miR-21 sensitized MCF7 cells to 
anticancer drug topotecan. Similar studies have been reported for the drugs gemcitabine, 
doxorubicin and tamoxifen (Kovalchuk, Filkowski et al. 2008; Miller, Ghoshal et al. 2008; Zhao, 
Lin et al. 2008) illustrating the importance of miRNAs in drug sensitivity and resistance. Further, 
miRNAs such as miR-15b and miR-16 have been shown to modulate multidrug resistance by 
targeting the anti-apoptotic bcl2 gene (Xia, Zhang et al. 2008). These studies reveal the intrinsic 
role of miRNAs in managing the efficiency of chemotherapy in several human cancers. 
 Currently, no work has been reported on the effect of 5-FU on miRNAs. 5-FU has been 
widely used for treatments of various types of cancer, including breast cancer. However, its exact 
mechanism of toxicity at the molecular level is still not clearly understood. Also, the mechanism 
of cancer cell resistance to drug is still eluded. 5-FU has been shown to modify the expression of 
protein-coding genes (Longley, Harkin et al. 2003; Maxwell, Longley et al. 2003; Hernandez-
Vargas, Ballestar et al. 2006; Rossi, Bonmassar et al. 2007), but the regulatory mechanism is 
unknown. Further, 5-FU was recently reported to modify the expression of several miRNAs in 
colon cancer cells (Rossi, Bonmassar et al. 2007), indicating the potential ability of 5-FU in 
altering miRNA expression. However, there is no report on the effect of 5-FU on miRNAs in 
human breast cancer. Considering the critical role of miRNAs in cancer and drug 
chemosensitivity, we hypothesized that the cytotoxicity of 5-FU in breast cancer may be partially 
elicited by regulation of miRNA expression levels.  Determination of the effects of 5-FU on 
expression of miRNAs can help to identify the miRNAs which play a role in chemosensitivity 
and resistance of 5-FU in particular, and other chemotherapeutic drugs in general. It may also 
help to improve the efficacy of 5-FU treatment, by reducing its side-effects or by decreasing the 
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incidence of 5-FU resistant cancers. Finally, the data can be extrapolated to other 
chemotherapeutic drugs, and targeted delivery systems, which can target these specific miRNAs, 
can be synthesized. 
 
Hypothesis 
5-FU induces its cytotoxicity partially by altering the expression levels of microRNAs 
associated with breast cancer, which accounts for the modification of the gene expression levels 
induced by 5-FU. 5-FU also modifies the expression of target mRNAs transcripts and proteins of 
associated miRNAs, which could play an important role in inducing 5-FU cytotoxicity. 
 
Research Objectives 
The goal of this proposed research project is to elucidate the molecular mechanism of 5-
FU and its effect on the global microRNA expression profile. A combined experimental and 
computational approach will be employed to achieve the following specific objectives: 
Specific Aim 1: To investigate the effects of 5-FU treatment on MCF7 breast cancer cells 
(Chapter 2) 
The sensitivity of MCF7 breast cancer cells to 5-FU treatment was analyzed using 
Trypan blue dye exclusion assay and MTT dye reduction assay. Modifications in the cell growth 
and proliferation after 5-FU exposure were studied by determining the inhibitory concentrations 
of 5-FU and the dose- and time-dependence of these responses. The effect on cell cycle and 
induction of apoptosis was also studied using Flow cytometry and Acridine Orange/Ethidium 
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Bromide (AO/EB) dye staining assay. This study helped us to classify the general effect of 5-FU 
treatment on MCF7 breast cancer cells. 
Specific Aim 2: To identify the miRNAs which are differentially expressed after 5-FU 
treatment (Chapter 3) 
In this objective, a comparative analysis of the expression pattern of miRNAs in normal 
and 5-FU treated MCF7 cells was performed using miRNA microarray technology. Six potential 
miRNAs, miR-575, miR-671-5p, miR-483-5p, miR-574-3p, miR-365 and miR-374b, which 
showed maximum differential expression after 5-FU treatment, were selected based on fold – 
change and statistical analysis. The differential expression levels of these miRNAs post – 5-FU 
treatment will be validated by qRT-PCR technique. 
Specific Aim 3: To determine the dose-dependence and time-dependence of the miRNA 
expression response to 5-FU treatment (Chapter 4) 
The dose and time dependence of the expression levels of the miRNAs selected in 
Objective 2 after 5-FU treatment were analyzed at different concentrations and for varying time 
periods using the qRT-PCR analysis. This study helped to identify any significant pattern in the 
expression levels of miRNA following 5-FU treatment.  
 
Experimental model 
The model for my experiment is the MCF7 human breast adenocarcinoma cell line. 
MCF7 cell line was originally isolated in 1970 from the pleural effusion of a 69-year old 
Caucasian woman with metastatic mammary carcinoma (Soule, Vazguez et al. 1973).  These 
cells are positive for estrogen receptor, progesterone receptor, epidermal growth factor receptor 
and E-cadherin expression. They lack expression of apoptotic enzyme caspase-3 and basic 
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fibroblast growth factor. It is an adherent cell line which grows in monolayer. MCF7 breast 
cancer cells are widely used as an in vitro model of breast cancer, mainly to study the role of 
estrogen in breast cancer due to the presence of well-characterized estrogen receptors. They are 
easy to culture and maintain, and show many genetic and morphological similarities to the breast 
cancer cells. 
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Table 1.1: Oncogenes and tumor suppressor genes and their functions in breast cancer (modified 
from (Osborne, Wilson et al. 2004)) 
Gene Classification Function 
HER2 Oncogene Tyrosine kinase receptor; involved in signal 
transduction pathways of cell growth and 
differentiation 
Ras Oncogene G Protein involved in cellular signal transduction 
important in cell growth, differentiation and survival 
PI3K Oncogene Kinase involved in cellular functions such as cell 
growth, proliferation, differentiation, motility, survival 
and intracellular trafficking 
Akt Oncogene Kinase regulating cell-cycle, cell survival, metabolism 
and in angiogenesis 
eIF-4E Oncogene Initiator of protein translation 
Cyclin D1 Oncogene Cell-cycle mediator required for cell cycle G1/S 
transition; interacts with tumor suppressor gene Rb 
Cyclin E Oncogene Cell-cycle mediator required for cell cycle G1/S 
transition 
c-myc Oncogene Transcription factor which binds with Enhancer box 
sequence (E-boxes) and recruits Histone 
acetyltransferases (HATs) 
c-fos Oncogene Transcription factor 
p53 Tumor suppressor 
gene 
Transcription factor; response to DNA damage and 
stress; induces cell-cycle arrest; cell-cycle checkpoint 
activation; triggers/facilitates apoptosis 
p27 Tumor suppressor 
gene 
Inhibit cyclin-dependent protein kinases; arrest cell 
cycle in G1 phase;  
BRCA1 Tumor suppressor 
gene 
Regulates DNA transcription; acts in DNA repair; 
interacts with Rad 51 protein; involved in cell cycle 
control and apoptosis 
BRCA2 Tumor suppressor 
gene 
Acts in DNA repair; interacts with Rad 51 protein; also 
involved in transcriptional regulation 
CHK2 Tumor suppressor 
gene 
Cell cycle checkpoint kinase; activates p53 after DNA 
damage 
ATM Tumor suppressor 
gene 
Checkpoint kinase; acts in DNA repair; activates 
CHK2; induction of p53; phosphorylation of BRCA1 
PTEN Tumor suppressor 
gene 
Phosphatase; negative regulator of Akt kinase; controls 
PIP3 pathway in cell growth 
Rb Tumor suppressor 
gene 
Retinoblastoma gene, repressor of cell cycle and 
protein translation 
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Table 1.2: Common chemotherapeutic drugs used for the treatment of breast cancer 
Chemical 
name 
Brand names Class Mechanism 
Capecitabine Xeloda Antimetabolite Pro-drug for 5-fluorouracil, an 
antimetabolite 
Carboplatin Paraplatin Alkylating 
agents 
Forms DNA intrastrand 
crosslinks, inhibits replication 
Cyclophospha
mide 
Cytoxan, 
Neosar 
Alkylating 
agents 
Forms DNA intrastrand 
crosslinks, inhibits replication 
Daunorubicin Cerubidine, 
DaunoXome 
Anthracyclins Prevents cell division by disrupting the 
structure of the DNA in two ways: 
intercalate into the base pairs in the DNA 
minor grooves; and cause free radical 
damage of the ribose in the DNA. 
Docetaxel Taxotere Taxanes 
(Mitotic 
inhibitor) 
Disrupts microtubules, arrests 
mitosis in metaphase 
Doxorubicin Adriamycin, 
Doxil, Rubex 
Anthracyclins Prevents cell division by disrupting the 
structure of the DNA in two ways: 
intercalate into the base pairs in the DNA 
minor grooves; and cause free radical 
damage of the ribose in the DNA. 
Epirubicin Ellence, 
Pharmorubicin 
Anthracyclins Prevents cell division by disrupting the 
structure of the DNA in two ways: 
intercalate into the base pairs in the DNA 
minor grooves; and cause free radical 
damage of the ribose in the DNA. 
Fluorouracil 
or 5-
fluorouracil 
Adrucil; 
Efudex; 
Fluoroplex; 
Carac 
Antimetabolite Pyrimidine analog, interferes with DNA 
synthesis 
Gemcitabine Gemzar Antimetabolite Pyrimidine analog, interferes with DNA 
synthesis 
Idarubicin Idamycin Anthracyclins Prevents cell division by disrupting the 
structure of the DNA in two ways: 
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intercalate into the base pairs in the DNA 
minor grooves; and cause free radical 
damage of the ribose in the DNA. 
Ixabepilone Ixempra Epothilones 
(microtubule 
inhibitor)  
Disrupts microtubules 
Methotrexate Amethopterin, 
Mexate, Folex 
Antimetabolite Inhibits folate metabolism, 
blocks nucleoside synthesis 
Mitoxantrone Novantrone Type II 
topoisomerase 
inhibitor 
Intercalates with DNA; disrupts DNA 
synthesis and DNA repair 
Mitomycin Mutamycin Cell-cycle 
inhibitors 
Inhibits DNA synthesis by inhibiting cell-
cycle transition 
Paclitaxel Abraxane, 
Taxol 
Taxanes 
(Mitotic 
inhibitor) 
Disrupts microtubules, arrests 
mitosis in metaphase 
Thiotepa Thioplex Alkylating 
agents 
Forms DNA intrastrand 
crosslinks, inhibits replication 
Vincristine Oncovin, 
Vincasar PES, 
Vincrex 
Mitotic 
inhibitor 
Disrupts microtubules, arrests 
mitosis in metaphase 
Vinorelbine Navelbine Mitotic 
inhibitor 
Disrupts microtubules, arrests 
mitosis in metaphase 
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Table 1.3: Standard chemotherapy drug combination regimens used for the treatment of breast 
cancer (American cancer Society, Inc.) 
• AT: Adriamycin and Taxotere 
• AC ± T: Adriamycin and Cytoxan, with or without Taxol or Taxotere 
• CMF: Cytoxan, methotrexate, and fluorouracil 
• CEF: Cytoxan, Ellence, and fluorouracil 
• FAC: fluorouracil, Adriamycin, and Cytoxan 
• CAF: Cytoxan, Adriamycin, and fluorouracil  
(The FAC and CAF regimens use the same medicines but use different doses and frequencies) 
• TAC: Taxotere, Adriamycin, and Cytoxan 
• GET: Gemzar, Ellence, and Taxol 
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Table 1.4: Hormone therapy treatment used for the treatment of breast cancer 
Drug class Mechanism Examples 
Selective Estrogen-
Receptor Modulators 
(SERMs) 
Binds to the estrogen receptors in breast 
cancer cells, thus blocking the effects of 
estrogen on breast cancer cells 
Nolvadex (Tamoxifen) 
Evista (Raloxifene) 
Fareston (Toremifene) 
Aromatase Inhibitors Inhibits the enzyme aromatase, which 
prevents the production of estrogen in 
adrenal glands 
Aromasin (Exemestane) 
Femara (Letrozole) 
Arimidex (Anastrozole) 
Megace (Megestrol) 
Hormone agonists Causes an initial increase in the production 
of hormones by the body, which is then 
subsequently suppressed due to negative 
feedback loop mechanism of the body. 
Zoladex (Goserelin) 
Lupron (Leuprolide) 
Estrogen receptor 
antagonist 
Binds to the ER and prevents ER 
dimerization, which leads to the rapid 
degradation of the fulvestrant-ER complex, 
producing the loss of cellular ER 
Faslodex (Fulvestrant) 
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Figure 1.1: Structure of 5-fluorouracil, a fluoropyrimidine, in which the hydrogen atom at the 5th 
carbon is replaced by a fluorine atom. 
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Figure 1.2: Metabolism of 5-FU to active products FdUMP, FdUTP and FUTP (Longley, Harkin 
et al. 2003). 
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Figure 1.3: Inhibition of TS by 5-FU metabolite FdUMP (Longley, Harkin et al. 2003). 
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Figure 1.4: Summary of some of the strategies investigated for improving the efficiency of 5-FU 
treatment: Leucovorin (LV), Eniluracil, Uracil, Methotrexate (MTX), Interferones (IFNs), 
Capecitabine (Longley, Harkin et al. 2003). 
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Figure 1.5: Biogenesis of miRNAs (modified from (Filipowicz, Bhattacharyya et al. 2008). 
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Figure 1.6: Mechanism of miRNA-induced gene silencing based on complementarity with target 
mRNAs (modified from (Bartel 2004). 
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Figure 1.7: Imperfect base-pairing of miRNA and its target mRNA in animals 
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Figure 1.8: Mechanism of gene regulation by miRNA in animals (modified from (Filipowicz, 
Bhattacharyya et al. 2008). 
  
Chapter 2: Effects of 5-fluorouracil on Growth, Cell Cycle Progression and Apoptosis of 
MCF7 Breast Cancer Cells 
Abstract 
Breast cancer is one of the leading causes of deaths in women worldwide. 5-flourouracil 
(5-FU) is an important chemotherapeutic drug used in the treatment of breast cancer patients. In 
this study, using several biochemical techniques, we studied the global effects of 5-FU treatment 
on MCF7 breast cancer cells. The dose-response curve obtained after the treatment of MCF7 
cells with 23 different 5-FU concentrations for 48 hours showed a dose-dependent decrease in 
cell proliferation. However, an atypical bimodal or biphasic curve was obtained, with two 
distinct curves observed between 0.001-0.1µM and 0.7-2000µM, thus indicating that 5-FU might 
act via a dual mechanism. Two different IC50 (Inhibitory concentration 50 %) values were 
calculated to be 0.007 and 2.8µM. A similar bimodal inhibition of the cellular metabolism of 
MCF7 cells was also observed after 48 hours of treatment using the MTT assay. The acridine 
orange/ethidium bromide nuclei staining assay determined that the mechanism of cell death 
induced was mainly by apoptosis after 48 hours. The morphology of the cells also showed a 
distinct reduction in the cell size, with compromised anchorage ability. The cell cycle 
progression however remained unaffected even after treatment with high 5-FU doses after 48 
hours of exposure. These findings provide evidence of the global inhibitory effects of 5-FU on 
human breast cancer cells in vitro and warrant further evaluation to study the molecular basis of 
its cytotoxicity. 
Keywords: 5-fluorouracil, breast cancer, MCF7, bimodal, viability, apoptosis, cell cycle 
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Introduction 
Chemotherapy with antineoplastic (or cytotoxic) drugs has been extensively used in the 
palliative treatment and management of breast cancer. Chemotherapeutic drugs having varying 
mechanisms of action are used for the treatment of breast cancer. Of the several classes of drugs, 
antimetabolites are one of the most effective first-line drugs. They are used as monotherapy as 
well as in combination regimens with other drugs. Fluoropyrimidines, mainly 5-fluorouracil (5-
fluoro-2,4(1H,3H)-pyrimidinedione or 5-FU) is one such antimetabolite which is widely used 
mainly for the treatment of breast (Fumoleau, Bonneterre et al. 2003), colorectal (Wils, O'Dwyer 
et al. 2001) and head and neck cancers (Posner, Colevas et al. 2000). It is mainly used to treat 
more aggressive forms of breast cancer, but can be used to treat any stage of breast cancer as a 
part of the combination therapy of CAF (Cyclophosphamide, Adriamycin and 5-fluorouracil); 
CMF (Cyclophosphamide, Methotrexate and 5-fluorouracil) and CEF (Cytoxan, Ellence, and 
fluorouracil) (Smalley, Lefante et al. 1983; Falkson, Falkson et al. 1992). Extensive research has 
been performed to improve the effectiveness of these combination strategies for the treatment of 
breast cancer. The combination of 5-FU with other newly developed anticancer drugs such as 
irinotecan, tomudex (TDX), and oxaliplatin has also help improve the response rates for breast 
cancer (Longley, Harkin et al. 2003). 
At the cellular level, 5-FU is a pyrimidine antagonist which is rapidly taken inside 
actively dividing cancerous cells by facilitated transport similar to uracil (Wohlhueter, McIvor et 
al. 1980). Once inside the cancer cells, 5-FU is converted intracellularly into three cytotoxic 
metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate 
(FdUTP) and fluorouridine triphosphate (FUTP) by the sequential action of different enzymes, 
orotate phosphoribosyltransferase (OPRT), uridine phosphorylase (UP), uridine kinase (UK), 
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ribonucleotide reductase (RR) and thymidine kinase (TK) (Daher, Harris et al. 1990). These 
three metabolites account for all the cytotoxic effects of 5-FU. The primary mechanism of 
cytotoxicity of 5-FU is the inhibition of enzyme thymidylate synthase (TS) activity by FdUMP, 
resulting in inhibition of dTMP de novo synthesis (Santi, McHenry et al. 1974; Sommer and 
Santi 1974) and subsequent imbalances in the deoxynucleotide pool, particularly dATP/dTTP 
ratio (Yoshioka, Tanaka et al. 1987; Houghton, Tillman et al. 1995). This in turn inhibits DNA 
synthesis and repair, and thus causes DNA damage. In addition, FdUTP and FUTP gets 
misincorporated into the DNA strands in place of dTTP during DNA replication, resulting in 
allevated levels of dUTP inside the cells (Mitrovski, Pressacco et al. 1994; Aherne, Hardcastle et 
al. 1996). Further, FUTP is extensively misincorporated in RNA strands, which disrupts the 
normal RNA processing. This results in disruption of the further synthesis and processing of 
mRNAs (Doong and Dolnick 1988; Patton 1993), tRNAs (Randerath, Tseng et al. 1983; Santi 
and Hardy 1987) and rRNAs (Kanamaru, Kakuta et al. 1986; Ghoshal and Jacob 1994) and in 
inhibition of post-transcriptional conversion of uridine to pseudouridine in these RNAs 
(Samuelsson 1991). This results in RNA toxicity and imbalances, causing variability in cellular 
metabolism and functioning. 
Cell cycle arrest and induction of apoptosis are the primary mechanisms of inhibition of 
cell growth by most of the anti-cancer drugs (Barry, Behnke et al. 1990; Hickman 1992; 
Lundberg and Weinberg 1999; Shapiro, Koestner et al. 1999; Qin and Ng 2002). Previous 
studies have demostrated the ability of 5-FU to arrest the cell cycle pregression of human breast 
cancer and colorectal cancer cells. It mainly causes a G1/S phase arrest in the cancer cells (Grem, 
Nguyen et al. 1999; Tokunaga, Oda et al. 2000; Mirjolet, Didelot et al. 2002; Hernandez-Vargas, 
Ballestar et al. 2006). Further, previous studies have attributed the cellular effects of 5-FU as 
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well as 5-FU in combination with other drugs to changes in p53 and p53 target molecules (Lowe, 
Ruley et al. 1993; Lowe, Bodis et al. 1994; Grem, Nguyen et al. 1999; Petak, Tillman et al. 2000; 
Tokunaga, Oda et al. 2000; Backus, Dukers et al. 2001; Yoshikawa, Kusunoki et al. 2001; 
Yukimoto, Nakata et al. 2001; Mirjolet, Didelot et al. 2002; Zhang, Ramdas et al. 2003; 
Hernandez-Vargas, Ballestar et al. 2006). Another study has reported that the induction of 
apoptosis by 5-FU has been linked with FAS regulation, a member of the Tumor-necrosis factor 
(TNF) receptor superfamily (Maxwell, Longley et al. 2003). It has also been shown to induce 
overexpression of several p53 target genes involved in apoptosis and cell cycle regulation, like 
APAF1, BCL2, BAK1; and repression of the c-Myc gene (Hernandez-Vargas, Ballestar et al. 
2006). 
Unfortunately, 5-FU is rarely used as a monotherapy now-a-days, and is mainly used in 
combination with other drug regimens. Recent research has been focussed on improving the 
efficacy of therapeutic drugs with fewer side effects and more specific action in cancer cells 
only. In this process, several prodrugs have been synthesized which have a lower hydrophobicity 
and more specific action in cancer cells to improve 5-FU therapy. These include Tegafur, S1, 
Capecitabine, Eniluracil, and several other compounds (Miwa, Ura et al. 1998; Cunningham and 
James 2001; O'Shaughnessy, Twelves et al. 2002; Dominguez, Marchal et al. 2003; Marchal, 
Rodriguez-Serrano et al. 2007). Studying the molecular effects of 5-FU on breast cancer cells 
will help better understand the mechanism of 5-FU cytotoxicity, which in turn would help to 
improve the efficacy of 5-FU treatment.  
The aim of this study was to investigate the global effects of 5-FU on MCF7 breast 
cancer. The MCF7 breast cancer cell line has been shown to be an excellent experimental model 
to study breast cancer (Horwitz, Costlow et al. 1975; Engel and Young 1978; Gioanni, Le 
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Francois et al. 1990; Levenson and Jordan 1997; Simstein, Burow et al. 2003). Hematocytometer 
cell counts, microscopy, flow cytometry and staining assays were performed to determine the 
effect of 5-FU on cell proliferation, morphology, cell cycle progression and induction of 
apoptosis. The results of our study illustrated that 5-FU inhibits cell proliferation and induces 
apoptosis in a dose-dependent manner. However, no significant effect was observed on the cell 
cycle clock of the cells. Thus, the data helps to better appreciate the biological effects of 5-FU 
and confirms its efficiency in treatment of breast cancer. 
 
Materials and Methods 
Cell line and cell culture 
All cell culture reagents were purchased from Invitrogen, Inc, Carlsbad, CA.  The human 
breast adenocarcinoma cell line MCF7 (HTB-22™) was obtained from the American Type 
Culture Collection (ATCC, Rockville, MD). They were cultured in RPMI 1640 media containing 
L-Glutamine and 25 mM HEPES, and supplemented with 10% Fetal Bovine Serum (FBS), 10 
µg/ml gentamicin and 4 µg/ml insulin and sterilized using a 0.22µM polyethersulfone filter 
(Corning Inc., Corning, NY). The cells were maintained at 37˚C in a humidified incubator with 
5% CO2. The media was replaced every 48 hours, and the cells were passaged once a week by 
trypsinization using 0.05% trypsin/0.02% EDTA (Sigma, St. Louis, MO). 
Growth Curve Analysis 
The growth curve and the doubling time of MCF7 cells were determined by monitoring 
the growth of the cells for 5 days. For this purpose, cells were seeded at 1.5x104 cells/cm2 
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(9.6x104 cells/well) in flat-bottom 6-well plates in 2ml of RPMI 1640 complete media. After 
every 24 hours interval thereafter, the cells were harvested using 0.05% trypsin/0.02% EDTA 
and counted by the Trypan blue dye exclusion assay as described below. The media was replaced 
every 48 hours. The experiment was performed in triplicates on four separate occasions. 
5-fluorouracil Drug treatment 
5-fluorouracil (5-FU) was purchased from Sigma-Aldrich (St. Louis, MO) and stored at 
4˚C, away from light and moisture. For cell treatments, a 10 mM stock solution of 5-FU was 
prepared in RPMI complete media and stored at 4˚C for not more than two weeks. The stock was 
filtered through a 0.22µM polyethersulfone filter prior to further dilution. The effect of 5-FU on 
the growth curve of MCF7 cells was assessed every 24 hours using the MTT dye reduction assay 
as described below. In the preliminary experiment, we determined that the trypan blue dye 
exclusion assay for cell viability correlates well with the MTT dye reduction assay. Briefly, the 
cells were seeded at 1.5x104 cells/cm2 (4800 cells/well) in flat-bottom 96-well plates in 100µl of 
complete media without phenol red; and after 24 hours, treated with four different concentrations 
of 5-FU (0.01µM, 1µM, 10µM and 50µM) as described below. In order to determine the cell 
number in each sample following the 5-FU treatments, the cells were treated with MTT (as 
described below) and the Optical Density (OD) was measured directly at a wavelength of 540nm 
using a microplate reader (Multiscan MCC/340, Fisher Scientific, Pittsburg, PA). The OD was 
measured before treating the cells (control), and at 24 and 48 hours. The OD of each sample was 
then compared with a standard curve, in which the OD was directly proportional to the actual 
cell numbers. The experiment was performed in triplicates in five separate trials. 
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Cell morphology analysis 
Briefly, 5x105 cells were seeded in a 25cm2 cell culture flask (2.0x104 cells/cm2) in 5ml 
of complete media.  After 24 hours, the fresh media was replaced in control flasks and media 
with 5-FU was replaced in the treatment flasks. The control MCF7 cells and cells treated with 
different concentrations of 5-FU (1µM and 50µM) for 48 hours were observed using a light 
microscope with a CCD camera.  
Cell proliferation assays 
The different inhibitory concentrations of 5-FU were then determined by generating 
dose-response curves after treating the cells with increasing concentration of 5-FU and analyzing 
the cell sensitivity using the Trypan blue dye exclusion and the MTT [3-(4,5-dimethylthiazolyl-
2)-2,5-diphenyltetrazolium bromide] dye reduction assays.  
For the trypan blue dye exclusion assay, the cells were seeded at 2.5x104 cells/cm2 
(9.5x104 cells/well) in flat-bottom 12-well plates in 1ml of complete media. After 24 hours, the 
media was replaced with fresh media containing different 5-FU concentrations (0-2000µM); a 
negative control (containing cells and only media but no drug) was also included. After 48 hours, 
the cells were detached by trypsinization, appropriately diluted with 0.4% trypan blue dye 
(Sigma-Aldrich, St. Louis, MO) and 10µl of this mixture was loaded on the counting chambers 
of the Hematocytometer. The viable cells were then visually counted using a microscope and the 
percentage of unstained treated cells compared to the unstained control cells was calculated. The 
cells were counted in three individual experiments in triplicates. The following formula was used 
to determine the number of viable cells/well: 
Number of viable cells/ml = (Total number of viable cells counted/4) * Dilution factor * 10,000 
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The dose-response for 5-FU was confirmed using the MTT dye reduction assay. The 
technique originally developed by (Mosmann 1983) was followed. Briefly, cells were seeded at 
1.5x104 cells/cm2 (4800 cells/well) in flat-bottom 96-well plates in 100µl of complete media 
without phenol red. After 24 hours, they were treated with various concentrations of 5-FU for 48 
hours. Negative controls (containing cells and only media but no drug) and blank controls 
(containing only media and no cells) were also included. After 48 hours of drug treatment, 20µl 
of 5 mg/ml MTT (Sigma-Aldrich, St. Louis, MO) in Phosphate-Buffered Saline (PBS) (12mM) 
was added to each well and incubated for 4 h at 37˚C with 5% CO2. The drug and MTT 
containing media was then removed and 100µl of dimethyl sulfoxide (DMSO) was added to each 
well to dissolve the formazan crystals. The absorbance of the plates was measured at 540nm 
using a microplate reader (Multiscan MCC/340, Fisher Scientific, Pittsburg, PA) and the % cell 
viability was calculated compared to the negative control. All experiments were performed five 
separate times in triplicates.  
% Cell viability = [(OD of treated group – OD of blank) / (OD of control group – OD of blank)] * 100 
OD = Optical density obtained using the Microplate reader. 
Detection of Apoptosis and Necrosis 
 The induction of apoptosis and necrosis in MCF7 cells by 5-FU was determined 
morphologically using a Fluorescent microscope after labeling the cells with acridine orange and 
ethidium bromide dyes to detect nuclear changes characteristic of apoptosis in the cells as 
described by (Duke 1992). Briefly, cells were treated with 0.01µM, 0.3µM, 2µM and 50µM 5-
FU solutions for 48 hours, floating and attached cells were then collected by trypsinization, 
washed in PBS and resuspended in 25µl of complete media. 100µg each of acridine orange and 
ethidium bromide was dissolved in 1ml of PBS and 5µl of this dye mixture was mixed with 25µ 
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of the cell suspension. Ten µl of this mixture was loaded on a microscopic glass slide and 
examined under the 20X dry objective of the Fluorescent microscope using the epillumination 
and a filter combination suitable for observing fluorescein. A minimum of 300 cells were scored 
for each sample preparation and each concentration was treated in triplicates.  
Acridine orange intercalates into the DNA staining it green, and binds to the RNA 
making it appear red.  Ethidium bromide is taken up only by dead (nonviable) cells and stains 
them orange-red (Duke 1992). Cells were scored as live normal (bright green nuclei with intact 
structure), live apoptotic (bright green nuclei with condensed chromatin), dead apoptotic 
(red/orange nuclei with condensed chromatin) and dead necrotic (red/orange nuclei with intact 
structure). 
Flow cytometric analysis of cell cycle progression 
5-FU induced changes in the cell cycle of MCF7 cells were determined by using BD 
FACScan™ Flow Cytometer (Becton-Dickinson, Franklin Lakes, NJ). Briefly, 5x105 cells were 
seeded in a 25cm2 cell culture flask (2.0x104 cells/cm2) in 5ml of complete media.  After 24 
hours, the media was discarded and fresh media without serum (FBS) was added. Cells were 
synchronized by serum starvation for 5 days (120 hours), after which they were treated with 
0.01µM, 2µM and 50µM 5-FU solutions in complete media (different ICs of 5-FU) or with fresh 
complete media (control) for 48 hours. After 48 hours, the cells were detached by trypsinization, 
centrifuged, washed with PBS and fixed by passing through a 23G needle into cold 70% ethanol, 
followed by incubating at -20˚C for 30 mins. The cells were then resuspended in 1 ml PBS 
containing 10µg/ml RNase (Sigma-Aldrich, St. Louis, MO) and 10µg/ml Propidium iodide (PI) 
(Sigma-Aldrich, St. Louis, MO) and incubated in dark for 30 mins at room temperature (RT), 
after which they were refrigerated until analyzed on a FACScan Flow cytometer. Ten thousand 
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events were captured and the data was analyzed using the CellQuest software. Each 
concentration was repeated five times. 
Statistical Analysis 
All data are expressed as mean ± S.E.M. (Standard error of the mean). Statistical 
significance of the differences between the control and treated groups was determined by one-
way analysis of variance (ANOVA) using the PASW (Predictive Analytics SoftWare) Statistics 
17.0 (SPSS Inc., Chicago, IL). Differences were considered significant if P < 0.05. 
 
Results 
MCF7 growth curves 
The MCF7 breast cancer cell line is a moderately aggressive adherent cell line which 
grows in monolayer. The normal growth curve of the cells was determined over a time period of 
5 days using the Trypan blue dye exclusion assay. The cells were counted every 24 hours and the 
cells/well was calculated. Figure 2.1 shows the summarized growth curve for four independent 
experiments. As shown in the figure, the MCF7 cells entered log growth phase ~ 24 hours after 
plating and continued to grow exponentially even after 5 days. Our data showed that the 
doubling time of the cells was approximately 31 hours. Our data concurs with the ATCC 
guidelines, which state that the doubling time for MCF7 cells is about 29 hours. 
Growth inhibitory effect of 5-FU on MCF7 cells 
The effect of 5-FU on the growth of MCF7 cells was determined using the MTT dye 
reduction assay. For this purpose, the cells were treated with different 5-FU concentrations, the 
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optical density was measured at times 0, 24 and 48 hours (Figure 2.2a), and the actual cells/well 
was calculated by comparing the optical density to a standard curve (Figure 2.2b). Figures 2.2a 
and c show the dose-response curves of MCF7 cells at 24 and 48 hours. These figures illustrates 
that cells treated with 5-FU exhibit a dose- and time-dependent reduction in their proliferation 
rate. A reduction in cell growth compared to control untreated cells was observed at 24 hours 
itself. However, a significant reduction in the cell number was observed following 48 hours of 
exposure to 5-FU (p < 0.05). Concentration as low as 0.01µM of 5-FU was shown to be 
sufficient to inhibit cell growth. Further, a higher inhibition of cell growth was observed with 
increasing 5-FU concentrations. The growth inhibitory rate of 50µM 5-FU amounted to around 
50% inhibition compared to control cells at 48 hours. Thus, the data suggest an increase in drug 
effect with higher drug concentrations and longer exposure. 
Changes in cell morphology following 5-FU treatment 
The changes in morphology of the MCF7 cells after 5-FU exposure was analyzed using 
phase contrast microscopy. The cells were treated with 1µM and 50µM 5-FU for 48 hours and 
observed directly using a light microscope. Figure 2.3a shows the control untreated adherent 
MCF7 cells and Figure 2.3b shows the control cells that have been detached by trypsinization. 
The untreated MCF7 cells are circular when unattached, and variously shaped when attached to 
the culture plate. Figures 2.3c and 2.3d show MCF7 cells treated with 1µM and 50µM 
respectively. As shown in the figures (arrow marks), cells exposed to 5-FU exhibited an obvious 
change in their morphological characteristics. Cells were shrunken and rounded which increased 
in a dose-dependent manner. Further, it was observed that 5-FU treated MCF7 cells exhibited 
compromised anchorage to the culture plate, and increased amount of floating cells were 
observed with higher 5-FU concentrations. 
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Dose-response curve of MCF7 cells after 5-FU treatment 
 To further study the anti-proliferative effects of 5-FU on MCF7 cells, the cells were 
treated with different 5-FU concentrations over a broad range (0-2000µM) for 48 hours and the 
cell viability was measured using the Trypan blue dye exclusion and the MTT dye reduction 
assays. The trypan blue dye exclusion assay distinguishes between live, viable cells with intact 
cell membrane which exclude the trypan blue dye, and the non-viable cells which will take up 
the dye. Alternatively, the MTT dye reduction assay considers the ability of the viable cells to 
metabolically reduce the MTT dye to an insoluble colored compound, which can then be 
measured spectrophotometrically. The viable cell counts were calculated compared to the control 
untreated MCF7 cells as described under Methods and Materials and the data were plotted vs. 
log drug concentrations to give the dose-response curves from which the Inhibitory 
concentrations (ICs) values for 5-FU were determined. The IC50 was defined as the drug 
concentration required to reduce the cell number by 50% as compared to the control untreated 
cells; the other ICs for 5-FU were defined similarly. 
 Figure 2.4 shows the dose-response curve of 5-FU treatment in MCF7 cells. As shown in 
the figure, treatment of MCF7 cells with increasing concentrations of 5-FU for 48 hours gave an 
atypical dose-dependent decrease in cell number (p < 0.001). It was observed that with 
increasing 5-FU concentrations, the cell numbers decreased initially (0-0.5µM), followed by an 
increase (0.7µM) and then again a decrease in the cell numbers (1-2000µM). Concentrations as 
low as 0.005µM and 0.01µM 5-FU induced a significant reduction in MCF7 cell numbers, ~ 
35% and 72% inhibition respectively compared to the control cells (p < 0.001). 0.01-0.5µM 5-
FU caused a significant decrease in MCF7 cell number (~ 75% inhibition), but little difference 
was observed among these treatments, thus creating a plateau phase in the curve. However, 
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treatment with 0.7µM 5-FU showed a significant increase in the cell counts, with only 30% cells 
inhibited compared to the control MCF7 cells (p < 0.001). This rise in the cell numbers was 
followed again by a decline in a dose-dependent manner with increasing 5-FU concentrations. 
The MCF7 cells were almost completed inhibited at concentrations greater than 50µM 5-FU. As 
a result of the bimodal dose-response curve, two separate IC50s of 5-FU were calculated, 
0.007µM and 2.8µM respectively. The results suggest that 5-FU is potent to inhibit growth of 
MCF7 cells even at an extremely low concentration. Table 2.1 gives the different ICs of 5-FU in 
MCF7 cells after 48 hours of treatment. 
In parallel with this assay, the effects of 5-FU on MCF7 cells were also examined by the 
MTT dye reduction assay. The results obtained with the MTT dye reduction assay were strongly 
correlated with those obtained by the Trypan blue dye reduction assay (n = 24, r = 0.779, p < 
0.001). Figure 2.5 shows the dose-response curve of 5-FU in MCF7 cells at 48 hours by the MTT 
dye reduction assay. The MCF7 cells exhibit a similar growth inhibition pattern as observed by 
the Trypan blue dye exclusion assay. 0-0.5µM 5-FU causes a partial reduction in the optical 
density of the cells, with highest inhibition of 25% at 0.5µM. A similar increase in the optical 
density of the cells was observed at 0.7µM, followed by a decline in a dose-dependent manner. 
This demonstrates that 5-FU significantly interferes with the metabolic activity of the MCF7 
cells. The data is consistent with that from the Trypan blue dye exclusion assay. However, even 
very high 5-FU concentrations failed to completely inhibit the cellular metabolism. 
Induction of apoptosis by 5-FU treatment 
 To determine if 5-FU induced apoptosis in MCF7 cells, the cells were exposed to varying 
concentrations of 5-FU (0-50µM) and evaluated for morphological changes characteristic of 
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apoptosis by AO/EB staining for fluorescence microscopy. Acridine orange (AO) enters live 
cells and stains them green, while Ethidium bromide (EB), a DNA-binding fluorescent dye, is 
taken up by only non-viable, dead cells and stains its DNA red. As shown in Figure 2.6, 
treatment of MCF7 cells with 5-FU led to four morphologically distinct populations of cells on 
AO/EB stained samples: uniformly green cells with normal nuclei (Live normal cells, Figure 
2.6a), Live apoptotic cells (Figure 2.6b), Dead apoptotic cells (Figure 2.6c) and Dead necrotic 
cells (Figure 2.6d), as described in the Materials and Methods section. Figure 2.7 gives the 
response of MCF7 cells to different 5-FU concentrations. Live, normal cells were observed 
mainly in control cells and their numbers decreased significantly following 5-FU treatment. 
Presence of live and dead apoptotic cells was evaluated to indicate induction of apoptosis in 
MCF7 cells. At 48 hours, 5-FU induced significant numbers of apoptotic cells in a concentration-
dependent manner. Early apoptotic cells were observed at concentrations as low as 0.002µM, 
and reaching 82% at 50µM (Figure 2.8). Alternatively, dead necrotic cells were not shown to be 
significantly increased following 5-FU treatment. Thus, both light microscopy and AO/EB 
staining assay together suggest that 5-FU is able to induce apoptosis in MCF7 cells even at low 
concentrations. 
Effect of 5-FU on cell cycle of MCF7 cells 
To determine the effect of 5-FU on the cell cycle of MCF7 cells, flow cytometric analysis 
was performed. Synchronized MCF7 cells were incubated with or without increasing 
concentrations of 5-FU for after 48 hours, and relative DNA content was analyzed by propidium 
iodide staining followed by flow cytometry. As shown in figures 2.9 and 2.10, no significant 
differences in cell cycle distribution were found after exposure to 5-FU (p = 0.166; p = 0.290; p 
= 0.160 for G1, S and G2 phases respectively). The data showed that control untreated sample 
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had a higher percentage of cells in the G0/G1 phase of the cell cycle. After treatment with 
increasing concentrations of 5-FU, the cells were still present in the G0/G1 phase of the cell 
cycle. All results were virtually indistinguishable from the control untreated cells. Further, no 
significant apoptosis was detected even at 50µM 5-FU. 
 
Discussion 
 The fluoropyrimidine 5-FU has been used in clinical practice for almost 50 yrs, and it has 
been shown that a good correlation exists between 5-FU plasma levels and the biological effects 
of 5-FU treatment. Presently, the standard approach for calculating the 5-FU drug dosage has 
been to use body surface area (mg/m2), which results in considerable variability in 5-FU plasma 
concentrations. 5-FU yields a 20% response rate in patients with metastatic breast cancer when 
given as a single drug by bolus i.v. injection (Ansfield, Klotz et al. 1977). (Finch, Bending et al. 
1979) reported that i.v. administration of a single dose of 5-FU (370 to 560 mg/m2) gives a peak 
plasma concentration of 13 to 130 µg/ml. Another study by (Muller, Mader et al. 1997) have 
demonstrated that administration of a single i.v. dose of 600 mg/m2 5-FU for 5 mins in breast 
cancer patients achieved a tumor concentration of 16.4 ( ± 6.7) µg/ml and plasma concentration 
of 27.3 ( ± 4.1) µg/ml. The plasma half-life is approximately 6 to 20 min and varies significantly 
among patients. Within 6 hours of administration, plasma concentrations fall below 0.13 µg/ml. 
Further, the major urinary metabolite, α–fluoro-ß-alanine (FBAL), has a plasma elimination half-
life of approximately 33 hours (Huan, Pazdur et al. 1989; Porter, Chestnut et al. 1992). However, 
single-agent bolus 5-FU does not seem to have much of a role in the treatment of breast cancer 
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(Rubens 1991), and this is partly related to the low response rates, about 29% (Cameron, Gabra 
et al. 1994). 
The short half life and S phase-specificity (Pinedo and Peters 1988) of 5-FU makes it 
pharmacokinetically suitable for administration as a continuous infusion which ensures 
prolonged cancer cell exposure and thereby enhances 5-FU cytotoxicity. Continuous infusion of 
5-FU is very well tolerated, as demonstrated by various studies. It is possible to administer doses 
of 1-1.4 g/m2/day up to 5 days; 500 mg/m2/day up to 30 days (Lokich, Bothe et al. 1981; 
McDermott, van den Berg et al. 1982; Hansen, Quebbeman et al. 1987; Chang, Most et al. 1989; 
Hatfield AK 1989; Huan, Pazdur et al. 1989; Jabboury, Holmes et al. 1989; J Berlie 1990; 
Lokich, Ahlgren et al. 1991; Cameron, Gabra et al. 1994; Ng, Cameron et al. 1994); and 250 
mg/m2/day for up to 3 weeks (Regazzoni, Pesce et al. 1996). (Petit, Milano et al. 1988) have 
reported a circadian rhythm-varying pattern in the plasma concentrations of 5-FU following a 
five-day continuous venous infusion. Some authors have reported that plasma peak levels of up 
to 584 ng/ml 5-FU were achieved by the continuous infusion of 450-955 mg/m2/day (Petit, 
Milano et al. 1988); while others have reported that maximum dose of only 300 mg/m2/day can 
be administered for a prolonged period of time without any side effects (Lokich, Ahlgren et al. 
1991), and this results in 5-FU plasma concentration of only 27 ng/ml (Harris, Song et al. 1990). 
Thus, a large variability have been shown to exist in the plasma levels of 5-FU following i.v. 
infusions. However, an optimal therapeutic window has been recommended by several 
pharmacokinetic clinical studies to obtain improved clinical outcomes and reduced toxicity. A 
consistent target range of AUC (area under the concentration range) of 20-25 mg.h/L or a plasma 
concentration of 450-550 µg/L have been established as most optimal despite different 
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administration modes (bolus/ infusion i.v. or oral) and time schedules (Gamelin, Delva et al. 
2008). 
 In the present study, we confirmed the anti-tumor properties of 5-FU in vitro and have 
shown that 5-FU inhibits the growth of MCF7 cells in a dose- and time-dependent manner. 
Treatment with different concentrations of 5-FU for 48 hours was observed to significantly 
inhibit MCF7 cell proliferation. A wide 5-FU concentration range, ranging from 0-2000µM, with 
small interval groups was selected to determine the minimum effective and maximum effective 
concentrations of 5-FU exposure. A unique dose-response curve was obtained following 5-FU 
treatment. The MCF7 cells displayed a bimodal dose-response curve after treatment with 5-FU 
for 48 hours. A significant decline in the cell number was observed at very low doses of 5-FU, 
followed by an increase in the cell number and further subsequent decrease as very high 5-FU 
concentrations were used. Thus two separate dose-response curves were obtained between 0-
0.5µM and 0.7-2000µM 5-FU. Doses as low as 0.005µM and 0.01µM were capable of inhibiting 
35% and 72% of MCF7 cell numbers respectively. A plateau stage was then observed between 
0.01 – 0.5µM 5-FU doses, indicating that these doses were equally capable of inhibiting MCF7 
growth (~ 75% inhibition). 
Two separate sets of ICs of 5-FU were calculated because of the bimodal response curve. 
The IC50s of 5-FU in MCF7 cells following 48 hours of exposure were calculated to be 
approximately 0.007 and 2.8µM. Several studies have been performed to determine the 
inhibitory concentrations of 5-FU on the MCF7 cells. (Wang, Cassidy et al. 2004) reported an 
IC50 of 1.2µM following exposure of MCF7 cells to 5-FU for 48 hours. Other studies have 
reported IC50 values of 10µM (Hernandez-Vargas, Ballestar et al. 2006) and 23µM (Raymond, 
Buquet-Fagot et al. 1997) following treatment for 48 hours. Different 5-FU IC50 have been 
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reported after treatment of MCF7 cells with 5-FU for longer period of time: 0.7µM after 3 days 
treatment (Akbulut, Tang et al. 2004); 13µM after 4 days treatment (Miwa, Ura et al. 1998); 
6.3µM after 5 days treatment (Etienne, Ilc et al. 2004); and 1.03µM after 7 days treatment 
(Patterson, Zhang et al. 1995). It is easy to understand that the IC50 is decreased as the time of 
treatment increased, however the variations in the IC50 values of 5-FU might be caused by cell 
culture maintenance conditions, cell passage number or treatment conditions. 
 A bimodal response has not been previously reported for 5-FU. The reason for this could 
be because the effects of 5-FU has not been studied over a very large concentration range, and 
over small concentration intervals. In this study, 23 different 5-FU concentrations were analyzed 
covering the range of 0-2000µM, which helped get a detailed dose-response curve for 48 hours 
time point. Gurevich (Gurevich 2001) discussed that low doses of certain biologically active 
substances sometimes function with a different mechanism of action as compared with the 
clinically relevant doses. A similar low-dose response curve was obtained between 0-0.5µM, 
suggesting that a low-dose treatment with 5-FU might function with a different mechanism 
compared to the clinical doses. A similar bimodal response has been reported for some other 
compounds. The alkaloid sanguinarine was shown to act via a bimodal cell death, apoptosis and 
oncosis, in human cervical cancer cells (Ding, Tang et al. 2002). 5-FU might act with a dual 
mechanism of action, which is dose-dependent; low doses elicit a different response than the 
higher doses. Further work needs to be performed in order to support this hypothesis. 
 The MTT dye reduction assay was also used to determine the effect of 5-FU on MCF7 
cell viability and proliferation. It is a spectrophotometric assay which helps to distinguish 
between metabolically active cells from the non-active cells depending on their ability to 
metabolically convert MTT. Thus, although there is an obvious difference in the MCF7 growth 
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curves obtained by Trypan blue dye exclusion assay and MTT assay, the MTT assay mainly 
demonstrates the effect of 5-FU on cell metabolism. The curves obtained by both the methods 
show the same trend in the growth curve and a bimodal response for 5-FU. Further, the results 
obtained with the MTT dye reduction assay show a strong correlation with those obtained by the 
Trypan blue dye reduction assay (n = 24, r = 0.779, p < 0.001). The results obtained from the 
morphological examination and AO/EB assay further confirm with these results. Higher 
concentrations of 5-FU are able to induce morphological changes and damage the ability of the 
cells to adhere. The results from the AO/EB assay look at the different stages of cell death 
induced after 5-FU exposure. A significant increase in the number of both live and dead 
apoptotic cells was observed following treatment with higher 5-FU concentrations. The study 
together confirms the ability of 5-FU to inhibit proliferation and induce apoptosis in MCF7 
breast cancer cells. 
 Flow cytometry was used to analyze the effect of 5-FU treatment on the cell cycle 
progression of MCF7 cells. The results obtained in this study suggested that 5-FU does not have 
an influence on cell cycle progression in MCF7 cells. Contrasting results have been previously 
reported by other studies. (Grem, Nguyen et al. 1999) demonstrated that 5-FU caused an 
accumulation of MCF7 cells in S-phase, along with induction of p53 and p21 proteins and DNA 
strand breaks. (Hernandez-Vargas, Ballestar et al. 2006) also reported a G1 phase block 
following 5-FU treatment. Similar effects of 5-FU have also been described in other cancer cell 
line (Tokunaga, Oda et al. 2000). However, no significant accumulation of cells in G1-S phase 
was observed after 5-FU treatment as compared to the control MCF7 cells. The reason for this 
inconsistency could be because of the technique used for cell synchronization prior to flow 
cytometric analysis. Cell synchronization by serum starvation results in accumulation of cells in 
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the G1 phase. As a result, the control cells also showed cells accumulated in the G1 phase, and 
no significant difference could be observed in 5-FU treated samples compared to the control. The 
data represented here thus cannot conclude anything about the effect of 5-FU on the cell cycle 
progression of MCF7 cells.  
 In summary, this study confirmed the anti-tumor activity of 5-FU in human breast cancer 
cell in vitro. Our results indicated that 5-FU significantly inhibited cell proliferation of MCF7 
cells in a dose-dependent manner, and with a plausible dual mechanism of action. Further work 
needs to be carried out to show this. Induction of apoptosis was shown to be one of the major 
mechanisms of cytotoxicity, as significant apoptosis was seen even at low doses of 5-FU. 
However, any effects on the cell cycle progression were not shown by our results. These 
experimental findings provide evidence of the global effects of 5-FU on human breast cancer 
cells in vitro and warrant further evaluation to study the molecular basis of its cytotoxicity. 
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Table 2.1: Different inhibitory concentrations (ICs) of 5-FU in MCF7 breast cancer cells 
IC values at 48hours 5-FU Concentrations (µM) 
LEC 0.005 
IC5 0.001 
IC10 0.002 
IC25 0.004 
IC50 0.007, 2.8 
IC75 0.15, 0.5, 6 
IC90 50 
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Figure 2.1: Growth curve of MCF7 cells. Cells were seeded in RPMI complete media, followed 
by harvesting them every 24 hours for 5 days and counted using a hematocytometer. The 
cells/well was calculated for each day and plotted against time to determine the growth curve of 
MCF7 cells. Results are mean ± SEM of four independent experiments. 
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Figure 2.2 Effect of 5-FU on the growth and proliferation of MCF7 cells at 24 and 48 hours. a) 
OD vs. incubation time for different 5-FU concentration. The OD of each treatment was 
compared with the OD of control cells and plotted against time. The results are mean ± SEM for 
five different experiments. b) The cells/well vs. different 5-FU concentrations (µM). The 
cells/well for each treatment was determined and plotted against different 5-FU concentrations to 
investigate the effect of 5-FU on proliferation rate of MCF7 cells following 24 and 48 hours. 
Results are mean ± SEM for five separate trials. p values are 0.848, 0.589, 0.003 for 0, 24 and 48 
hours of treatment with 5-FU respectively. 
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Figure 2.3: Morphological changes induced in MCF7 cells by 5-FU after 48 h treatment. Cells 
were seeded in a 5 cm2 flask and treated with 5-FU (0, 1 and 50µM) for 48 hours. Cells were 
then observed using a light microscope and photographed after 48 hours. a) Control (untreated) 
MCF7 cells after 48 hours. Attached cells grow in monolayer and appear big and variously 
shaped. b) Control (untreated) MCF7 cells when unattached by trypsinization and observed using 
a glass slide. c) MCF7 cells treated with 1µM of 5-FU for 48 hours. The cells appeared shrunken 
and more were found detached following 5-FU treatment. Affected cells are marked with arrows. 
d) MCF7 cells treated with 50µM of 5-FU for 48 hours. The number of detached and shrunken 
increased, in a dose-dependent manner. Affected cells are marked with arrows. 
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Figure 2.4: Dose-dependent effect of 5-FU on the growth of MCF7 breast cancer cells 
represented in a logarithmic graph. The cells were treated with different concentrations of 5-FU 
for 48 hours and IC values were calculated by using the Trypan blue dye exclusion assay. 
Percent inhibition was calculated compared to the control MCF7 cells. IC50 values have been 
shown in red in the graph. The results are mean ± SEM for triplicates in three different 
experiments (p < 0.001). Points with the same letter are not statistically different. 
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Figure 2.5: Dose-response curve for 5-FU in MCF7 breast cancer cells obtained from the MTT 
dye reduction assay and represented in a logarithmic graph. The cells were treated with different 
concentrations of 5-FU for 48 hours and the OD of each treated sample was compared to the 
control MCF7 cells to obtain the percent cell viability. The results are mean ± SEM for 
triplicates in five separate experiments (p < 0.001). Points with the same letter are not 
statistically different. 
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Figure 2.6: Morphological analysis of induction of apoptosis in MCF7 cells after treatment with 
5-FU for 48 hours using the Acridine orange / Ethidium bromide (AO/EB) nuclei staining assay. 
a) Live normal cells - bright green with an intact nucleus; b) Live apoptotic cells - bright green 
nuclei with condensed chromatin; c) Dead apoptotic cells - red/orange nuclei with condensed 
chromatin; d) Dead normal cells - red/orange nuclei with intact structure. 
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Figure 2.7: Acridine Orange/Ethidium Bromide Apoptosis analysis of MCF7 cells treated with 5-
FU for 48 hours. LN= live normal, LA= live apoptotic, DA= dead apoptotic, DN = Dead 
necrotic. The results are represented as mean ± SEM. Statistically significant differences in 5-FU 
concentration are represented by single letters on the error bars (p < 0.001). Values that share a 
letter are not statistically significantly different. 
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Figure 2.8: Total apoptosis induced following treatment of MCF7 cells with 5-FU for 48 hours. 
Both live apoptotic and dead apoptotic cells were included to estimate the total % apoptosis 
induced by 5-FU. The results are represented as mean ± SEM (p < 0.001). Values that share a 
letter are not statistically significantly different. 
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Figure 2.9: Flow cytometry analysis showing the DNA histogram and scatter plots for MCF7 
cells following treatment with four different 5-FU concentrations for 48 hours: a) Control MCF7 
cells; b) 10nM 5-FU; c) 2µM 5-FU; d) 50µM 5-FU 
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Figure 2.10: Cell cycle analysis of MCF7 cells treated with 5-FU for 48 hours. Cells were 
synchronized prior to 5-FU treatment using serum deprivation. Treated cells were then analyzed 
using the FACScan Flow cytometer. The results are represented as mean ± SEM of five 
individual experiments. (p = 0.166 for change in G1 phase; p = 0.290 for change in S phase; p = 
0.160 for G2 phase respectively). 
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Chapter 3: Effects of 5-fluorouracil Drug Treatment on MicroRNA Expression Profile in 
MCF7 Breast Cancer Cells 
Abstract 
5-fluorouracil (5-FU) is a classic chemotherapeutic drug that has been widely used for 
breast cancer treatment. Although aberrant expression of protein-coding genes was observed 
after 5-FU treatment, the regulatory mechanism is unknown. In this study, by using a combined 
advanced microarray and quantitative real time PCR (qRT-PCR) technology, we found for the 
first time that 5-FU significantly alter the global expression profile of miRNAs, one class of 
recently identified small regulatory RNAs, in human breast cancer cells. After 48 hours of 
treatment with a low dosage (0.01µM), we observed that 42 miRNAs were differentially 
expressed in MCF7 cells. Of these, 23 miRNAs were up-regulated with up to a 4.59-fold change, 
while 19 were down-regulated with up to a 1.89-fold change. The most up-regulated miRNAs 
are miR-575 (4.59-fold change), miR-671-5p (3.25-fold change), miR-483-5p (3.07-fold 
change), miR-574-3p (2.52-fold change); the most down-regulated miRNAs are miR-365 (1.89-
fold change) and miR-374b (1.62-fold change). A majority of miRNAs with differential 
expression are associated with cancer development, including breast cancer. Target prediction 
and GO analysis suggest that these differentially expressed miRNAs potentially targeted many 
oncogenes and tumor suppressor genes as well as protein-coding genes which are related to 
programmed cell death, activation of immune response and cellular catabolic process. 
Key words: 5-fluorouracil, microRNA, human breast cancer, gene regulation, microarray, 
MCF7 
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Introduction 
Chemotherapy with antineoplastic (or cytotoxic) drugs is the most extensively adopted 
practice for managing cancers. 5-fluorouracil (5-Fluoro-2,4(1H,3H)-pyrimidinedione or 5-FU) is 
one such chemotherapeutic drug which is widely used mainly for the treatment of breast 
(Fumoleau, Bonneterre et al. 2003), colorectal (Wils, O'Dwyer et al. 2001) and head and neck 
cancers (Posner, Colevas et al. 2000). 5-FU is a pyrimidine antagonist which is rapidly taken 
inside actively by dividing cancerous cells through facilitated transport similar to uracil 
(Wohlhueter, McIvor et al. 1980); in cancer cells, 5-FU is converted intracellularly into three 
cytotoxic metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine 
triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). The cytotoxicity of 5-FU has been 
primarily attributed to the inhibition of enzyme thymidylate synthase (TS) activity by FdUMP, 
resulting in inhibition of dTMP de novo synthesis (Santi, McHenry et al. 1974; Sommer and 
Santi 1974) and subsequent imbalances in the deoxynucleotide pool, particularly dATP/dTTP 
ratio (Houghton, Tillman et al. 1995). This in turn inhibits DNA synthesis and repair, and thus 
causes DNA damage. In addition, 5-FU toxicity was also caused by misincorporation of FdUTP 
and FUTP into DNA (Aherne, Hardcastle et al. 1996) and RNA (Ghoshal and Jacob 1994) 
strands. 
Despite the widespread clinical use of 5-FU for over 40 years, its molecular mechanism 
of cytotoxicity in cancer cells has only been recently understood. Recent evidence suggests that 
additional mechanisms could be involved in the cytotoxic activity of 5-FU, including gene 
regulation. 5-FU has been recently shown to modify the expression levels of protein-coding 
genes (Lowe, Bodis et al. 1994; Petak, Tillman et al. 2000; Hwang, Bunz et al. 2001; Longley, 
Harkin et al. 2003; Maxwell, Longley et al. 2003; Inokuchi, Uetake et al. 2004; Hernandez-
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Vargas, Ballestar et al. 2006; Mauritz, van Groeningen et al. 2007; Rossi, Bonmassar et al. 
2007), but the underlying regulatory mechanisms of these protein-coding genes are still 
unknown. The recently identified class of post-transcriptional gene regulators, microRNAs 
(miRNAs), may play an important role in 5-FU induced alteration of gene expression. miRNAs 
are a group of small (20-22 nt) endogenous non-protein-coding RNA molecules that negatively 
regulate gene expression (Ambros 2004). These miRNAs usually bind to the 3’-untranslated 
region (3’-UTR) of the target mRNAs for mRNA cleavage or translation inhibition (Ambros 
2001; Zhang, Wang et al. 2007). It has been predicted that miRNAs may target more than 30% 
of protein coding genes (Lewis, Shih et al. 2003). 
  Extensive studies have indicated the significance of miRNAs in various biological 
processes, including developmental timing, organ development, stem cell maintenance and 
differentiation, disease, cell proliferation, apoptosis and response to different stresses (Ambros 
2001; Alvarez-Garcia and Miska 2005; Hatfield, Shcherbata et al. 2005; Hwang and Mendell 
2006; Zhang, Pan et al. 2006). miRNAs have also been reported to play a role in cancer initiation 
and progression (Calin and Croce 2006) and metastasis (Cheng, Byrom et al. 2005), with many 
miRNA genes being localized in cancer-associated genomic regions or in fragile sites (Calin, 
Sevignani et al. 2004). Aberrant miRNA expression levels have been reported in almost all 
human cancers (Iorio, Ferracin et al. 2005; Lu, Getz et al. 2005; Calin and Croce 2006; 
Blenkiron, Goldstein et al. 2007; Zhang, Pan et al. 2007). Many miRNAs targeting protein-
coding genes are oncogenes and tumor suppressor genes, which are involved in tumorigenesis 
(Calin, Dumitru et al. 2002).  Certain miRNAs have also displayed unique expression profiles in 
specific types of cancers (Lu, Getz et al. 2005), suggesting that miRNAs may be considered as a 
new biomarker for cancer diagnosis (Zhang and Farwell 2008). miRNA gene expression levels 
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are also aberrantly altered in breast cancer, miR-21, miR-10b are over-expressed (Ma, Teruya-
Feldstein et al. 2007); whereas miR-125b and miR-145 are down-regulated (Iorio, Ferracin et al. 
2005). Further, miRNAs also modulate breast cancer initiation, invasion and metastasis (Ma, 
Teruya-Feldstein et al. 2007; Huang, Gumireddy et al. 2008; Tavazoie, Alarcon et al. 2008). 
These studies highlight the importance of miRNAs as both stimulators and inhibitors in breast 
cancer. 
Currently, a growing body of evidence has suggested the importance of miRNAs in 
modulating the chemosensitivity and chemoresistance of tumor cells (Meng, Henson et al. 2006; 
Blower, Verducci et al. 2007; Blower, Chung et al. 2008). It is reported that suppression of miR-
21 sensitized MCF7 cells to anticancer drug topotecan (Si, Zhu et al. 2007). Similar studies have 
been reported for the drugs gemcitabine, doxorubicin and tamoxifen (Kovalchuk, Filkowski et al. 
2008; Miller, Ghoshal et al. 2008; Zhao, Lin et al. 2008) illustrating the importance of miRNAs 
in drug sensitivity and resistance. Further, miRNAs such as miR-15b and miR-16 have been 
shown to modulate multidrug resistance by targeting the anti-apoptotic bcl2 gene (Xia, Zhang et 
al. 2008). These studies reveal the intrinsic role of miRNAs in managing the efficiency of 
chemotherapy in several human cancers. 
In a recent study, 5-FU was reported to modify the expression of several miRNAs in 
colon cancer cells (Rossi, Bonmassar et al. 2007), indicating the potential role of 5-FU in altering 
miRNA expression. However, there is no report on the effect of 5-FU on miRNAs in human 
breast cancer. Considering the critical role of miRNAs in cancer and drug chemosensitivity, we 
hypothesized that the cytotoxicity of 5-FU in breast cancer may be partially elicited by regulation 
of miRNA expression levels. In this study, we have used miRNA microarray technology and 
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quantitative real time PCR (qRT-PCR) to investigate the effect of 5-FU exposure on the global 
expression profile of miRNAs in human breast cancer cell line MCF7.  
 
Materials and Methods 
Cell line and cell culture 
All cell culture reagents were purchased from Invitrogen Inc (Carlsbad, CA).  The human 
breast adenocarcinoma cell line MCF7 was obtained from the American Type Culture Collection 
(ATCC). They were cultured in RPMI 1640 media containing L-glutamine and 25 mM HEPES, 
and supplemented with 10% fetal bovine serum (FBS), 10 µg/ml gentamicin and 4 µg/ml insulin. 
The cells were maintained at 37˚C in a humidified incubator with 5% CO2. 
Drug treatment and cell viability assay 
5-fluorouracil (5-FU) was purchased from Sigma-Aldrich (St. Louis, MO) and stored at 
4˚C, away from light and moisture. For cell treatments, a 10 mM stock solution of 5-FU was 
prepared in RPMI complete media and stored at 4˚C for not more than two weeks. The different 
inhibitory concentrations of 5-FU were determined by generating dose-response curves after 
treating the cells with increasing concentrations of 5-FU and analyzing the cell sensitivity using 
trypan blue dye exclusion assays. Briefly, the cell suspension was appropriately diluted with 
0.4% trypan blue dye (Sigma-Aldrich, St. Louis, MO) and a hematocytometer was used to 
estimate the percentage of unstained treated cells compared to the control cells. The IC10 
(concentration of 5-FU to produce 10% cell inhibition) was determined and used for further 
analysis. All experiments were carried in triplicate. 
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RNA isolation 
Cells were seeded at 50,000 cells/cm2 (480,000 cells/well) in flat-bottom 6-well plates in 
2 ml of complete media. After 24 h, media was replaced with fresh media (control group) or with 
0.01µM 5-FU in complete media (treatment group) and cells were incubated for 48 hours, a 
traditional time points for most drug treatment. Total RNA was extracted from both groups with 
the mirVana™ miRNA Isolation Kit (Ambion, Austin, TX) according to manufacturer’s 
instructions. Briefly, the cells were detached from the wells by trypsinization and washed in cold 
PBS (phosphate buffer saline – 1X, pH-7.4, without Calcium chloride and magnesium chloride). 
Cells were lysed by adding 500 µl of Lysis/Binding Solution, followed by vortexing. 50 µl of 
miRNA Homogenate Additive was then added, mixed by vortexing and cells were incubated on 
ice for 10 min. The RNA was extracted by adding 500 µl of Acid-Phenol: Chloroform, vortexing 
for 60 sec and centrifuging for 5 min at 10,000 X g to separate the aqueous and organic phases. 
The upper (aqueous) phase (400 µl) was transferred to another 2ml micro-centrifuge tube and 
500 µl (1.25 volumes) of 100% ethanol at room temperature was added to precipitate the RNA. 
The total RNA was then filtered onto a filter cartridge by centrifugation, followed by multiple 
washings with Wash solutions 1 and 2/3. Finally, the total RNA was eluted with 50 µl of pre-
heated (95˚C) nuclease-free water. All the steps were performed on ice. RNA quantity and 
quality was analyzed using NanoDrop ND1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE) and immediately stored at -80˚C. The experiment was performed a minimum 
of three times. 
MicroRNA microarray expression analysis 
The miRNA Microarray Expression Analysis was performed by LC Sciences (Houston, 
Texas). The assay was performed on approximately 5 µg of total RNA sample. T
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was size fractionated using a YM-100 Microcon centrifugal filter (Millipore, Billerica, MA) and 
RNA sequences with <30 nt were isolated. These small RNA were then extended at 3’-end with 
a poly(A) tail using poly(A) polymerase, followed by ligation of an oligonucleotide tag to the 
poly(A) tail for later fluorescent staining. Two different tags (Cy3 and Cy5) were used for the 
two different RNA samples (control and 5-FU treated RNA samples). The two RNA samples 
were then hybridized overnight on a µParaflo™ microfluidic chip using a microcirculation pump 
(Atactic Technologies Inc., Houston, TX). Each microfluidic chip contained detection probes, 
positive control probes and negative control probes. The detection probes were made in situ by 
photogenerated reagent (PGR) chemistry. These probes consisted of chemically – modified 
nucleotide coding sequences complementary to the target miRNAs (all 871 human miRNAs 
listed in the Sanger’s miRNA miRBase, Release 13.0 http://microrna.sanger.ac.uk/sequences/ ) 
and a spacer segment of polyethylene glycol to extend the coding sequence away from the 
substrate. A total of 50 positive and negative control probes were included to ensure uniformity 
of assay conditions and sample labeling. Chemical modifications of the probes were done to 
balance the melting temperatures of hybridization. RNA Hybridization was performed using 
100µl of 6X SSPE buffer (0.9 M NaCl, 6 mM EDTA, 60 mM Na2HPO4 , pH 6.8) containing 
25% formamide at 34 ˚C. After hybridization, control and 5-FU treated cells were dye-stained 
using tag – conjugating dyes Cy3 and Cy5 respectively. An Axon GenePix 4000B Microarray 
Scanner (Molecular Device, Union City, CA) was used to collect the fluorescent images, which 
were then digitized using the Array-Pro image Analysis software (Media Cybernetics, Bethesda, 
MD). Dye switching between control and treated RNA samples was performed in order to avoid 
dye bias. Each miRNA was analyzed four times and the controls were repeated four to sixteen 
times. 
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Statistical Analysis of miRNA microarray data 
The statistical analysis of the microarray data was also performed at LC Sciences. The 
microarray data was analyzed by subtracting the background and then the signals were 
normalized using a locally – weighed regression (LOWESS) filter as reported by Bolstad et al., 
2003. Detectable miRNAs were selected based on the following criteria: signal intensity higher 
than 3X (background standard deviation); spot CV < 0.5 (where CV = standard deviation/signal 
intensity); and signals from at least two out of the four replicates are above the detection level. 
To identify miRNAs whose expression differs between control and 5-FU treated MCF7 cells, 
statistic analysis was performed. The ratio of the two sets of detected signals (control and 
treated) was calculated and expressed in log2 scale (balanced) for each miRNA. The miRNAs 
were then sorted according to their differential ratios. The p-values of the t – test were also 
calculated. miRNAs with p-values < 0.01 and log2 ratio > 0.5 were considered to be significantly 
differentially expressed. 
Quantitative Real Time PCR (qRT-PCR) of miRNA expression 
The data obtained from miRNA microarray was confirmed by performing qRT-PCR on 
selected differentially expressed miRNAs. Total RNA was isolated using the mirVana™ miRNA 
Isolation Kit (Ambion, Austin, TX) as previously described. Detection and quantification of the 
miRNAs was performed using TaqMan® MiRNA Assays (Applied Biosystems, Foster City, 
CA). A single-stranded cDNA for a specific miRNA was generated by reverse transcription of 
500 ng of total RNA using a miRNA-specific stem-looped RT primer and the Applied 
Biosystems TaqMan® miRNA Reverse Transcription Kit. A Reverse transcription reaction 
mixture contains 500ng of total RNAs, 1.5µL 10X TR Buffer, 1mM of each dNTPs, 0.188µL 
RNase Inhibitor, 3µL 5X Taqman® miRNA RT primer for a specific miRNA and 1µL 
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MultiScribe™ Reverse Transcriptase (50U/µL). An Eppendorf Mastercycler Personal PCR 
(Westbury, NY) was used to conduct the reverse transcription reaction at the following 
temperature conditions: 16°C for 30 min, 42°C for 30 min followed by 85°C for 5 min and 
finally held at 4°C.   
Following reverse transcription reaction, quantitative RT-PCR was performed with 
Applied Biosystems 7300 Real-Time PCR system using the Taqman® MiRNA Assay kit. A total 
of 20µL qRT-PCR reaction mixture contains 3µL RT PCR product (diluted 1:7 times), 10µL 
Taqman® 2X Universal PCR Master Mix (No AmpErase® UNG), 2µL Taqman® MiRNA 
Assays 20X Taqman® Assay (qRT-PCR primers). Nuclease free water was used to adjust the 
final volume to 20µL. The reactions were incubated in a 96-well optical plate at 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec. RNU 48 was used as an 
endogenous reference gene for normalizing the results. The relative abundance of each miRNA 
was calculated using the comparative cycle threshold (2-∆∆Ct) method. The results are presented 
as fold change of each miRNA in 5-FU treated cells relative to the control MCF7 cells. 
Individual samples were assayed in triplicate with five independent biological replicates. 
Target prediction and function analysis 
The miRNAs which showed most dysregulation after 5-FU exposure were selected for 
target prediction. Two different computational programs, TargetScan (Lewis, Shih et al. 2003; 
Lewis, Burge et al. 2005); (Release 5.1, http://www.targetscan.org/) and MicroCosm Targets 
(Griffiths-Jones, Saini et al. 2008) (Version 5, http://www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/) were used to predict the targets. The reason for selecting two 
computational programs is that all current programs over-predict potential miRNA targets and 
two different computational programs would reduce the potential false positives and increase the 
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accuracy of prediction (Zhang and Pan 2009). During target prediction, we first generated two 
potential target lists using both computational programs. Second, the top 200 targets predicted by 
each program were compared and the common targets were selected. Third, top 50 targets of 
each list were compared to the entire list of the other program and the common targets were 
selected. Finally, the top 10 targets of each list that were not already included were added to the 
final list. The targets were sorted according to their total score obtained after adding up the 
individual scores from each program. The higher the total score a predicted gene has, more likely 
it is to be the actual target of the specific miRNA. 
The list of potential gene targets for each selected miRNA was compiled as explained 
above and the genes were then classified according to their biological function determined using 
the Gene Ontology system (http://www.geneontology.org/). To determine the possible 
overlapping of biological functions among these miRNAs, significantly overrepresented GO 
terms among all predicted gene targets for each individual miRNA were searched using the 
GOstat software (http://gostat.wehi.edu.au/cgi-bin/goStat.pl) (Falcon and Gentleman 2007). The 
program determines all the annotated GO terms associated with the target genes, and then counts 
the number of appearances of each GO term for these genes; a Fischer’s exact test is then 
performed to give the p-value for each GO term, representing the probability that the observed 
counts could have been due to chance. In addition, Pathway analysis of the target genes was 
performed using the DAVID Bioinformatics Resources 2008 (http://david.abcc.ncifcrf.gov/) 
(Dennis, Sherman et al. 2003; Huang da, Sherman et al. 2009). The program groups together 
related annotations (GO terms) for a similar set of genes, compares the GO processes if they 
might be related in a biological network and compiles a list of potential pathways for the effects 
of the target genes. 
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Results 
miRNA expression profile of MCF7 breast cancer cells 
The MCF7 breast cancer cells were analyzed for the expression of 871 human miRNAs 
listed in the Sanger’s miRNA miRBase, Release 13.0. A unique miRNA expression profile was 
observed in the cells. Of the 871 human miRNAs, only 223 (25.6%) miRNAs were detected 
(Figure 3.2, Table 3.1). Of these, majority of the miRNAs were expressed at low signal 
intensities. 148 (66%) miRNAs showed a signal intensity of less than 500. However, 11 miRNAs 
were highly expressed in human MCF7 breast cancer cells with signal intensities greater than 
10,000; these include miR-21, let-7f, let-7a, miR-1826, let-7d, miR-1979, miR-200c, let-7c, 
miR-191, miR-342-3p, and miR-26a. Among all 871 analyzed miRNAs, miR-21, let-7f and let-
7a showed the highest expression levels with signal intensities of 57,600, 21,201 and 20,206, 
respectively. The variation in the expression levels of miRNAs indicates that the abundance of 
these miRNAs varies significantly in MCF7 cells. Some miRNAs are expressed in many copies, 
while others are expressed only in few copies, thus exhibiting a distinct miRNA expression 
signature pattern in MCF7 breast cancer cells. 
Effect of 5-FU on human breast cancer cell MCF7 
To determine the sensitivity of MCF7 cells to anticancer drug 5-FU, we performed cell 
viability assays and generated a dose-response curve. From the data obtained, the concentration 
of 0.01µM of 5-FU was selected for determining the effect of 5-FU on the global expression 
levels of miRNAs in MCF7 cells. Since genetic changes are more sensitive as compared to 
cellular changes, a low concentration of 5-FU was selected to avoid the possibility of observing 
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alterations in miRNA expression levels due to cellular changes such as apoptosis or necrosis, 
which are generally induced at high 5-FU doses.  
Alteration of miRNA expression profiles in MCF7 cells after 5-FU treatment 
5-FU treatment significantly altered the miRNA expression profile in human breast 
cancer cell line MCF7. Of the 871 human miRNAs analyzed, a total of 309 miRNAs were 
detected (either in control or treated cells). The control cells expressed 223 miRNAs, while the 
treated cells expressed 289 miRNAs. This result shows that 5-FU exposure resulted in the 
expression of higher number of miRNAs as compared to the control. Among these, 193 miRNAs 
were expressed in both the control and treated cells, while 20 miRNAs were detected only in 
control cells, and 96 miRNAs were detected only in the treated cells (Table 3.2). Of the total 309 
miRNAs that were detected (either in control or treated cells), 55 were miRNA* sequences. 
miRNA* are usually degraded during miRNA biogenesis. The reason for detection of these 
miRNA* sequences after 5-FU exposure is unclear. 
 For most of the detected miRNAs, the expression levels were low, which is evident by 
their low signal intensities (less than 1000) during microarray analysis (Figures 3.3 and 3.4). Of 
the 223 miRNAs detected in control cells, 144 miRNAs emitted signals less than 1000, and only 
19 miRNAs gave signal more than 10,000. On the other hand, of the 289 miRNAs detected in 
treated cells, 219 gave signals below 1000, while 19 gave signals higher than 10,000. The signal 
intensities of the 20 miRNAs expressed only in control cells and the 96 miRNAs expressed only 
in treated cells were not high enough to consider them as being differentially expressed between 
control and treated cells, and hence will not be considered for further analysis. 
Along with the difference in number of detectable miRNAs, the expression levels of 
these miRNAs were also significantly altered after 5-FU exposure. Of the total 193 miRNAs that 
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were differentially expressed between the control and treatment groups, 115 were up-regulated, 
while 78 were down-regulated (Table 3.2). Statistical analysis of these differentially expressed 
miRNAs showed that 42 of these miRNAs (22%) were significantly dysregulated with p < 0.01 
and with more than one fold change, while the remaining 151 miRNAs were not significantly 
different (Figure 3.4). Fold-change comparisons of the significantly altered miRNAs are shown 
in Figure 3.5. Among these 42 miRNAs, 23 (55%) miRNAs were up-regulated and 19 (45%) 
miRNAs were down-regulated (Table 3.4). miRNAs showing at least two-fold difference (i.e. 
log2-fold change ≥ 1) in their expression levels between control and treated groups were selected 
for further analysis using qRT-PCR technique. For the up-regulated miRNAs, only four showed 
a more than two-fold increase: miR-575 (4.6 fold), miR-671-5p (3.25 fold), miR-483-5p (3.00 
fold) and miR-574-3p (2.5 fold). Since all the down-regulated miRNAs showed a less than two-
fold decrease in their expression, we selected miRNAs with at least a 1.5 fold decrease in their 
expression (i.e. log2-fold change ≥ 0.56) for further analysis.  These include following two 
miRNAs: miR-365 (1.9 fold) and miR-374b (1.6 fold). 
Validation of miRNA expression levels by qRT-PCR 
To validate the data obtained from miRNA microarray, qRT-PCR was performed on five 
differentially expressed miRNAs (two up-regulated: miR-575 and miR-574-3p; and three down-
regulated: miR-374b, miR-15a, miR-27a) and the results from microarray and qRT-PCR were 
compared. As shown in Figure 3.6, miR-15a, miR-27a and miR-374b were down-regulated, 
while miR-575 and miR-574-3p were up-regulated according to the qRT-PCR data. Our qRT-
PCR data is comparable with the microarray data and thus validated the results for these 
miRNAs obtained from miRNA microarray. 
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Prediction of target genes of differentially expressed miRNAs 
In order to determine the probable biological function of the differentially expressed 
miRNAs, we predicted the potential miRNA targets of six most 5-FU-regulated miRNAs (miR-
575, miR-671-5p, miR-483-5p, miR-574-3p, miR-365 and miR-374b) by using two different 
computational programs, TargetScan and miRBase Targets. After prediction by these programs 
as described, a total of 318 potential targets were identified for the five miRNAs with most 
differential expression after 5-FU treatment; about 50-60 protein-coding targets were predicted 
for each miRNA (Table 3.4). Generally speaking, 5-FU-up-regulated miRNAs targets many 
oncogenes, such as HMGA2, KRAS and MYC while 5-FU-down-regulated miRNAs targets many 
tumor suppressor genes. This suggests the role of 5-FU treatment in chemotherapy by targeting 
miRNA-mediated gene regulation. 
The basic biological function of each gene was also classified using the Gene Ontology 
system. Since a single gene is associated with many GO terms, the overrepresented GO terms for 
each miRNA were identified by GOstat software. Table 3.5 gives a few representative biological 
processes associated with each miRNA as predicted by the GOstat software. The targets of these 
miRNAs were further used for pathway analysis by DAVID Bioinformatics Resources. The 
program provides potential pathways of function for the target genes of the 5-FU responsive 
miRNAs. Based on the target analysis, we found that several important biological processes, 
such as programmed cell death, activation of the immune response, neurotransmitter metabolic 
process and cellular catabolic process were included as putative biological functions of the 
predicted potential genes. This result suggests an important role of these miRNAs in human 
health and disease regulation. Further, a pathway analysis suggests an important regulatory role 
of these miRNAs in different biological processes (Tables 3.5 and 3.6).  
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Discussion 
 miRNAs are an important class of gene regulators which have the potential to function as 
a diagnostic and prognostic tool for a variety of human cancers (Blenkiron and Miska 2007; 
Tricoli and Jacobson 2007; Lowery, Miller et al. 2008; Zhang and Farwell 2008). They 
constitute a novel target system for cancer treatment as each miRNA has the ability to regulate 
the expression of several hundred target genes, including several important oncogenes or tumor 
suppressor genes. Extensive research is currently being focused on identifying differential 
expressed miRNAs that play primary roles in cancer development and therapy. Thus, a study of 
the possible effects of chemotherapeutic drug treatment on the expression profile of miRNAs is 
of prime importance for cancer therapy and resistance. 
In this study, the effect of chemotherapeutic drug 5-FU on miRNA expression profile was 
investigated for the first time in human breast cancer cells. In this study, we found that 23 
miRNAs were up-regulated while 19 were down-regulated. Among the differentially expressed 
miRNAs, several miRNAs were well characterized and have been previously implicated in 
different cancers (Table 3.7). Of particular interest are the miRNAs that showed maximum 
dysregulation in their expression levels. Of the 42 differentially expressed miRNAs after 5-FU 
treatment, 26 miRNAs (62%) have been previously confirmed to be linked with different human 
cancers, most of them being differentially expressed between tumors and normal cells. 
Identification of such a high proportion of cancer-related miRNAs may suggest that these 
miRNAs may be involved in anti-cancer treatment.  
Many up-regulated miRNAs function as tumor suppressor genes by targeting oncogenes 
or genes involved in cell cycle and apoptosis. After 5-FU treatment, both miR-15 and miR-16 
96 
 
were overexpressed. Pervious study shows that miR15/16 induces apoptosis by targeting the bcl2 
gene (Cimmino, Calin et al. 2005), and also cause cell cycle arrest by regulating multiple cell 
cycle genes (Xia, Qi et al. 2009). miR-15b and miR-16 also modulate multidrug resistance by 
targeting the bcl2 gene (Xia, Zhang et al. 2008). Further, miR-200c regulates the expression of 
ZEB1 and ZEB2, which play an important function in breast cancer progression (Gregory, Bert 
et al. 2008). miRNA-23a and -23b on the other hand modulate the expression of proto-oncogene 
c-Met (Salvi, Sabelli et al. 2009). Additionally, miRNA let-7a has been found to be a tumor 
suppressor gene by targeting the oncogenes HMGA2 (High mobility group AT-hook 2), KRAS 
and Myc (Johnson, Grosshans et al. 2005; Lee and Dutta 2007; Sampson, Rong et al. 2007).  
In our study, 5-FU also reduced the expression of several important cancer-associated 
miRNAs, such as miR-21, miR-203, miR-24, miR-25 and miR-27a. All of these miRNAs target 
different tumor suppressor genes; for example, miR-21 targets PTEN (Phosphatase and tensin 
homolog) (Meng, Henson et al. 2007), TPM1 (Tropomyosin-1) (Zhu, Si et al. 2007) and PDCD4 
(Programmed cell death protein 4) (Asangani, Rasheed et al. 2008) while as p16 and p57 have 
been found to be modulated by miRNAs miR -24 (Lal, Kim et al. 2008) and miR -25 (Kim, Yu 
et al. 2009) respectively. Additionally, miR-27a is reported to be an oncogene targeting 
specificity transcription protein in breast cancer cells (Mertens-Talcott, Chintharlapalli et al. 
2007). The down-regulation of these miRNAs after 5-FU treatment aids the function of the 
tumor suppressor genes, and thus helps control cancer progression and metastasis. Further, 
several miRNAs are reported to be differentially expressed in breast cancer cells in comparison 
with normal breast cells. Our data identified 13 such miRNAs that are usually dysregulated in 
breast cancer. These include miR-16, let-7a, let-7d, let-7f and miR-200b, which are usually 
down-regulated; and miR-23a, miR-23b, miR-203, miR-21, miR-24, miR-27a, miR-30a and 
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miR-365, which are usually up-regulated. Most of these miRNAs, except miR-23a, miR-23b and 
miR-200b, have been shown to be inversely expressed in 5-FU treated cells compared to 
untreated breast cancer cells (Table 3.7).  
Previous studies have reported p53 to be an important molecular effector in 5-FU 
cytotoxicity. p53-mutated cells have demonstrated higher resistance to 5-FU treatment 
suggesting its role in 5-FU sensitivity (Lowe, Bodis et al. 1994). Further, p53 has been suggested 
to induce apoptosis and cause Fas upregulation after 5-FU treatment (Petak, Tillman et al. 2000). 
Moreover, several p53 regulated genes have been shown to be modified by 5-FU. Thus, there is 
evidence for the importance of the p53 regulatory process in 5-FU toxicity, but the molecular 
mechanism is still unclear. In this study, we found that 5-FU induced differential expression of 
several miRNAs that putatively target several p53-regulated genes. These genes include CASP8, 
SERPINB5, CASP9, CCND2, CCND3, CASP3, PTEN, CDK6, CCNE1 and CCND1 (Table 3.7). 
This observation suggests that miRNAs might be involved in the p53-5-FU interaction. Further 
investigations of the regulatory mechanism of miRNAs on these p53 -regulated genes are 
required to better understand the 5-FU regulated p53 pathway. 
The widespread deregulation of the miRNAome global expression profiles and the 
identification of several cancer-related deregulated miRNAs after low dose 5-FU treatment 
indicates that the cytotoxicity of 5-FU may be partially due to alteration in the miRNA 
expression levels. The observation that an antimetabolite drug is able to increase the expression 
of certain miRNAs is inconsistent with its DNA-synthesis-inhibiting mechanism. However, it 
has been previously suggested that incorporation of 5-FU into RNA is a major mechanism of 
cytotoxicity in MCF7 breast cancer cells (Kufe and Major 1981). Further, it is established that 
the 5-FU active metabolites, FdUTP and FUTP, get actively incorporated into growing DNA and 
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RNA molecules. Incorporation into RNA results in disruption of the further synthesis and 
processing of mRNAs, tRNAs and rRNAs (Randerath, Tseng et al. 1983; Kanamaru, Kakuta et 
al. 1986). Additionally, 5-FU has also been shown to be incorporated into the uridine-rich U2 
snRNA at pseudouridylation sites, thus inhibiting post-transcriptional conversion of uridine to 
pseudouridine in these RNAs (Samuelsson 1991), and greatly affecting the splicing mechanism. 
Assimilating together this knowledge of 5-FU activity, it can be hypothesized that the drug might 
be incorporated into the miRNA gene transcript (as FdUTP) or produce fluorinated mature 
miRNA, thus causing misexpression of miRNAs and altering their primary function. However, 
further work is needed to test this hypothesis and to elucidate the exact molecular mechanism. 
Determination of the effects of 5-FU on the expression profile of miRNAs in the human 
breast cancer cell can help to identify miRNAs that play a role in chemosensitivity and resistance 
of 5-FU in breast cancer cells in particular, and other chemotherapeutic drugs in general. This 
information might be helpful in improving the efficacy of 5-FU treatment, by reducing its side-
effects or by decreasing the incidence of 5-FU resistant cancers. The data also could be 
extrapolated to other chemotherapeutic drugs which could target these specific miRNAs. The 
research could be extended to predict the protein targets of the miRNAs whose expression levels 
are mainly altered by 5-FU treatment. On a broad consideration, the data could also be used to 
determine the oncogenic miRNAs or Oncomirs associated with breast cancer after 5-FU 
treatment. Specific targeted deliveries, such as artificial miRNAs or siRNAs that target these 
miRNAs and alter their expression levels in tumor cells can be synthesized, thus down-regulating 
the expression of these oncomirs and prevent breast cancer initiation and metastasis. Examples of 
such delivery systems that are currently under development include antisense oligonucleotide 
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(ASOs), siRNAs, miRNA mimics and antagomirs. Thus, our data demonstrates the potential of 
miRNAs as novel targets for cancer therapy. 
In summary, a low dosage of 5-FU induced the differential expression of a set of 
miRNAs, which in turn regulated the expression of oncogenes and tumor suppressor genes, 
potentially by multiple mechanisms. A proposed model showing the functional mechanism of 
action of 5-FU involving miRNA activity is shown in Figure 3.7. Although the mechanism of 
how 5-FU regulates miRNA expression is unclear, our results provide some interesting clues for 
chemotherapeutic drugs and their effects on miRNAs. Further investigation on the regulation 
mechanism of miRNAs on gene expression in breast cancer cells will provide new insights into 
cancer chemotherapy and designing new anti-cancer drugs. 
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Table 3.1: miRNA expression profile in MCF7 breast cancer cells 
 
Microarray 
signal 
intensity 
Number miRNAs 
> 10,000 11 miR-21, let-7f, let-7a, miR-1826, let-7d, miR-1979, miR-200c, let-7c, 
miR-191, miR-342-3p, miR-26a 
5,000-10,000 14 let-7e, miR-1977, miR-15b, miR-23a, miR-23b, miR-16, miR-1308, let-7b, miR-125a-5p, let-7i, miR-638, miR-1974, miR-25, miR-182 
1,000-5,000 34 
miR-26b, miR-200b, miR-92a, let-7g, miR-361-5p, miR-1975, miR-
151-5p, miR-103, miR-203, miR-320a, miR-99b, miR-107, miR-24, 
miR-1978, miR-93, miR-320c, miR-1280, miR-454, miR-27a, miR-
27b, miR-183, miR-106b, miR-320b, miR-7, miR-1915, miR-375, 
miR-425, miR-423-5p, miR-30b, miR-185, miR-320d, miR-98, miR-
30d, miR-92b 
< 1,000 164 
miR-20a, miR-1275, miR-30c, miR-17, miR-151-3p, miR-128, miR-
195, miR-197, miR-663, miR-15a, miR-106a, miR-720, miR-149*, 
miR-193a-5p, miR-374b, miR-125b, miR-365, miR-424, miR-130b, 
miR-1246, miR-342-5p, let-7d*, miR-1469, miR-181a, miR-877, miR-
625, miR-30a, miR-421, miR-574-5p, miR-29a, miR-200a, miR-1180, 
miR-503, miR-34a, miR-324-5p, miR-192, miR-378, miR-484, miR-
301a, miR-1268, miR-498, miR-489, miR-340, miR-652, miR-548m, 
miR-574-3p, miR-148a, miR-20b, miR-744, miR-222, miR-126, miR-
28-5p, miR-99a, miR-141, miR-193b*, miR-132, miR-532-5p, miR-
148b, miR-22, miR-345, miR-429, miR-625*, miR-29c, miR-140-3p, 
miR-1281, miR-18a, miR-486-5p, miR-505*, miR-149, miR-424*, 
miR-940, miR-194, miR-1307, miR-331-3p, miR-362-5p, miR-152, 
miR-629, miR-7-1*, miR-101, miR-125a-3p, miR-1277, miR-575, 
miR-16-2*, miR-27b*, miR-103-2*, miR-25*, miR-200b*, miR-671-
5p, miR-548d-3p, miR-1259, miR-548h, miR-30b*, miR-23a*, miR-
210, miR-181b, miR-605, miR-483-5p, miR-933, miR-455-3p, miR-
30e, miR-765, miR-15b*, miR-302f, miR-938, miR-500*, miR-106b*, 
let-7b*, miR-1289, miR-1825, miR-425*, miR-30e*, miR-32*, miR-
708, miR-138-1*, miR-30a*, miR-616*, miR-1973, miR-32, miR-19b, 
miR-760, miR-451, miR-296-5p, miR-501-5p, miR-191*, miR-183*, 
miR-550*, miR-361-3p, miR-193a-3p, miR-589*, miR-24-2*, miR-
133a, miR-29c*, miR-1249, miR-208a, miR-30c-2*, miR-200a*, miR-
330-3p, miR-30c-1*, miR-936, let-7f-1*, miR-30d*, miR-221, miR-
374a, miR-31*, miR-31, miR-2052, miR-629*, miR-28-3p, miR-1247, 
miR-302e, miR-365*, miR-2054, miR-150*, miR-1913, miR-302d, 
miR-302c, miR-146b-5p, miR-105, miR-376a, miR-29b-2*, miR-
302b, miR-513a-3p, miR-202, miR-1470 
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Table 3.2: Comparison of miRNA expression profiles between control and 5-FU treated groups 
 
miRNA 
category 
Number miRNAs 
Up-regulated 
miRNAs 
115 miR-181b, miR-151-5p, miR-421, miR-7-1*, miR-720, miR-
320b, let-7i, let-7b, miR-107, miR-484, miR-361-5p, miR-1975, 
miR-486-5p, miR-125b, miR-17, miR-425, miR-26a, let-7d, 
miR-106b, miR-1978, miR-148b, miR-1308, miR-744, miR-
1977, miR-183, miR-1979, let-7f, miR-28-5p, miR-149, miR-
148a, let-7a, miR-625, miR-130b, miR-342-3p, miR-532-5p, 
miR-15b, miR-28-3p, miR-126, miR-16, miR-1180, miR-99a, 
miR-708, miR-200c, miR-22, miR-23b, miR-192, miR-191, 
miR-365*, miR-342-5p, miR-141, miR-200b*, miR-18a, miR-
222, miR-1275, let-7b*, miR-23a, miR-16-2*, miR-362-5p, miR-
652, miR-503, miR-425*, miR-1307, miR-1826, miR-132, miR-
625*, miR-30e, miR-125a-3p, miR-302f, miR-106b*, miR-498, 
miR-345, miR-1246, miR-505*, miR-489, miR-1259, miR-194, 
miR-629, miR-140-3p, miR-936, miR-19b, miR-25*, miR-1915, 
miR-1281, miR-548m, miR-1268, miR-1469, miR-638, miR-
331-3p, miR-193a-3p, miR-940, miR-221, miR-24-2*, miR-574-
5p, miR-550*, miR-500*, miR-27b*, miR-501-5p, miR-23a*, 
miR-424*, miR-210, miR-149*, miR-152, miR-663, miR-200a*, 
miR-183*, miR-1277, miR-330-3p, miR-629*, miR-455-3p, 
miR-548h, miR-574-3p, miR-1289, miR-671-5p, miR-483-5p, 
miR-575 
Down-regulated 
miRNAs 
78 miR-30a*, miR-374a, miR-1249, miR-365, miR-374b, miR-361-
3p, miR-1913, miR-30b*, miR-589*, miR-1825, miR-150*, 
miR-146b-5p, miR-27a, miR-15a, miR-30a, miR-296-5p, miR-
29b-2*, miR-877,miR-21, miR-197 , miR-26b, miR-765, miR-
29c*, miR-15b*, miR-1247, miR-101, miR-98, miR-200b, let-7e, 
miR-7, miR-454, let-7g, miR-27b, miR-760, let-7d*, miR-203, 
miR-29c, miR-30b, miR-30c, miR-20b, miR-1280, miR-423-5p, 
miR-103-2*, let-7f-1*, miR-1974, miR-25, miR-193a-5p, miR-
181a, miR-200a, miR-193b*, miR-24, miR-93, miR-424, miR-
378, miR-340, miR-106a, miR-125a-5p, miR-99b, miR-301a, 
miR-29a, miR-92a, miR-92b, miR-195, miR-375, miR-182, let-
7c, miR-30d, miR-320a, miR-128, miR-320d, miR-103, miR-
20a, miR-185, miR-324-5p, miR-34a, miR-429, miR-320c, miR-
151-3p 
miRNAs 20 miR-105, miR-1470, miR-202, miR-2052, miR-2054, miR-208a, 
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expressed only 
in control group 
miR-302b, miR-302c, miR-302d, miR-302e, miR-30c-1*, miR-
30c-2*, miR-30d*, miR-30e*, miR-31, miR-31*, miR-32, miR-
32*, miR-376a, miR-513a-3p 
miRNAs 
expressed only 
in treatment 
group 
96 hsa-let-7a-2*, hsa-let-7c*, hsa-let-7g*, hsa-miR-100, hsa-miR-
1181,, hsa-miR-1200, hsa-miR-1207-5p, hsa-miR-1224-3p, hsa-
miR-1224-5p, hsa-miR-1226, hsa-miR-1227, hsa-miR-1228, hsa-
miR-1228*, hsa-miR-1229, hsa-miR-1231, hsa-miR-1233, hsa-
miR-1234, hsa-miR-1237, hsa-miR-1238, hsa-miR-1260, hsa-
miR-1267, hsa-miR-1271, hsa-miR-1285, hsa-miR-1287, hsa-
miR-1292, hsa-miR-1293, hsa-miR-129-3p, hsa-miR-1300, hsa-
miR-1301, hsa-miR-1303, hsa-miR-130a, hsa-miR-130b*, hsa-
miR-133a, hsa-miR-138-2*, hsa-miR-17*, hsa-miR-184, hsa-
miR-18b, hsa-miR-1908, hsa-miR-191*, hsa-miR-1910, hsa-
miR-1911*, hsa-miR-1973, hsa-miR-2110, hsa-miR-212, hsa-
miR-215, hsa-miR-23b*, hsa-miR-299-3p, hsa-miR-299-5p, hsa-
miR-323-5p, hsa-miR-324-3p, hsa-miR-328, hsa-miR-329, hsa-
miR-331-5p, hsa-miR-335, hsa-miR-339-3p, hsa-miR-339-5p, 
hsa-miR-33b*, hsa-miR-340*, hsa-miR-34a*, hsa-miR-34b*, 
hsa-miR-34c-5p, hsa-miR-362-3p, hsa-miR-371-5p, hsa-miR-
378*, hsa-miR-380*, hsa-miR-409-3p, hsa-miR-448, hsa-miR-
450a, hsa-miR-485-3p, hsa-miR-497, hsa-miR-500, hsa-miR-
502-3p, hsa-miR-502-5p, hsa-miR-517b, hsa-miR-548f, hsa-
miR-550, hsa-miR-553, hsa-miR-584, hsa-miR-605, hsa-miR-
627, hsa-miR-628-3p, hsa-miR-654-5p, hsa-miR-658, hsa-miR-
659, hsa-miR-660, hsa-miR-664*, hsa-miR-665, hsa-miR-671-
3p, hsa-miR-766, hsa-miR-769-3p, hsa-miR-769-5p, hsa-miR-
93*, hsa-miR-933, hsa-miR-935, hsa-miR-943, hsa-miR-96 
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Table 3.3: Significantly dysregulated miRNAs after 5-FU exposure 
 
Probe_ID Control 
Signal 
Treatment 
Signal 
Log2 
(Treatmen
t/ 
Control) 
Fold 
Change 
p-value 
Up-regulated (n=23) 
hsa-miR-575 31.68 145.42 2.22 4.59 4.11E-03 
hsa-miR-671-5p 42.18 136.96 1.70 3.25 3.60E-03 
hsa-miR-483-5p 43.41 133.14 1.62 3.07 2.14E-03 
hsa-miR-574-3p 190.02 479.10 1.40 2.52 3.94E-05 
hsa-miR-149* 761.77 1,380.01 0.78 1.81 4.72E-05 
hsa-miR-663 750.55 1,290.55 0.81 1.72 6.87E-07 
hsa-miR-1268 167.69 280.34 0.76 1.67 4.95E-03 
hsa-miR-1915 891.28 1,359.02 0.59 1.52 1.02E-04 
hsa-miR-574-5p 351.25 532.08 0.61 1.51 4.99E-03 
hsa-miR-638 5,497.66 8,256.06 0.56 1.50 5.55E-17 
hsa-miR-1246 770.27 1,043.87 0.45 1.36 4.28E-03 
hsa-miR-1826 22,510.52 27,941.79 0.33 1.24 2.07E-12 
hsa-miR-23a 10,898.44 13,085.57 0.23 1.20 1.32E-05 
hsa-miR-191 14,586.74 16,888.33 0.21 1.16 1.72E-05 
hsa-let-7a 24,215.14 27,545.79 0.19 1.14 1.91E-07 
hsa-miR-342-3p 15,599.63 17,665.54 0.18 1.13 1.01E-08 
hsa-miR-23b 10,734.11 12,153.14 0.15 1.13 1.06E-03 
hsa-miR-16 12,622.24 14,011.40 0.15 1.11 1.18E-04 
hsa-miR-1979 12,024.04 13,317.24 0.15 1.11 1.48E-04 
hsa-miR-15b 12,855.28 14,081.31 0.14 1.10 2.85E-03 
hsa-miR-200c 16,146.22 17,485.41 0.16 1.08 6.66E-04 
hsa-let-7d 19,259.32 20,608.62 0.10 1.07 2.37E-03 
hsa-let-7f 24,515.34 25,713.03 0.07 1.05 9.87E-04 
Down-regulated (n=19) 
hsa-miR-365 394.04 208.43 -0.83 -1.89 2.06E-03 
hsa-miR-374b 1,116.20 688.88 -0.76 -1.62 1.21E-04 
hsa-miR-30a 626.23 421.31 -0.57 -1.49 2.93E-04 
hsa-miR-15a 1,433.70 1,018.10 -0.50 -1.41 1.06E-03 
hsa-miR-197 1,231.67 906.19 -0.44 -1.36 1.46E-03 
hsa-miR-27a 4,197.58 3,093.67 -0.44 -1.36 1.43E-08 
hsa-miR-21 57,202.28 44,077.27 -0.38 -1.30 0.00E+00 
hsa-miR-26b 8,444.64 6,784.69 -0.33 -1.24 3.51E-06 
hsa-miR-203 5,749.60 4,644.42 -0.27 -1.24 1.78E-03 
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hsa-miR-1280 3,838.92 3,152.21 -0.21 -1.22 4.02E-04 
hsa-miR-454 4,618.90 3,860.29 -0.25 -1.20 7.08E-04 
hsa-miR-200b 8,059.98 6,745.94 -0.24 -1.19 7.45E-05 
hsa-miR-7 3,475.24 2,930.62 -0.25 -1.19 2.78E-03 
hsa-miR-27b 4,034.72 3,443.66 -0.21 -1.17 1.81E-03 
hsa-let-7g 7,585.57 6,538.32 -0.23 -1.16 2.50E-04 
hsa-let-7e 13,719.05 12,008.35 -0.25 -1.14 1.57E-04 
hsa-miR-25 8,505.37 7,512.26 -0.18 -1.13 1.03E-03 
hsa-miR-24 4,427.72 3,926.62 -0.17 -1.13 1.31E-03 
hsa-miR-125a-5p 11,138.55 10,205.68 -0.13 -1.09 4.05E-03 
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Table 3.4: Predicted targets of the selected miRNAs 
Gene 
name 
Description Gene 
name 
Description 
miR-575   miR-671-5p   
DENND1C DENN/MADD domain containing 1C CD79A B-cell antigen receptor complex-associated protein alpha-chain precursor (Ig-alpha) 
SLC7A7 
solute carrier family 7 [Y+L amino 
acid transporter 1 (y(+)L-type amino 
acid transporter 1)] 
CPNE2 Copine-2 (Copine II). 
FBXO15 F-box only protein 15 ZNF668 Zinc finger protein 668 
TMEM81 transmembrane protein 81 (TMEM81) POLR3D 
DNA-directed RNA polymerase III subunit 
D 
NENF Neudesin precursor (Neuron-derived 
neurotrophic factor). FES 
Proto-oncogene tyrosine-protein kinase 
Fes/Fps 
CPNE2 Copine-2 (Copine II) LGALS3BP 
Galectin-3-binding protein precursor 
(Lectin galactoside-binding soluble 3-
binding protein) 
GPX3 Glutathione peroxidase 3 precursor CHCHD2 Coiled-coil-helix-coiled-coil-helix domain-
containing protein 2 
MASP2 Mannan-binding lectin serine protease 2 precursor MS4A8B 
Membrane-spanning 4-domains subfamily 
A member 8B 
FAM22G Protein FAM22G precursor CA7 Carbonic anhydrase 7 
KIR2DL4 
Killer cell immunoglobulin-like 
receptor 2DL4 precursor (MHC class 
I NK cell receptor KIR103AS) 
VPS25 Vacuolar protein sorting-associated protein 25 
HAGH Hydroxyacylglutathione hydrolase DGKZ Diacylglycerol kinase zeta  
DPH5 Probable diphthine synthase PITX3 Pituitary homeobox 3 (Homeobox protein PITX3). 
DDT D-dopachrome decarboxylase C1QA Complement C1q subcomponent subunit A precursor. 
VEGFB Vascular endothelial growth factor B precursor SIPA1L1 
Signal-induced proliferation-associated 1-
like protein 1 
KIR2DL1 
Killer cell immunoglobulin-like 
receptor 3DL2 precursor (MHC class 
I NK cell receptor) 
HOOK2 Hook homolog 2 
IARS2 Isoleucyl-tRNA synthetase, 
mitochondrial precursor KRT9 Keratin, type I cytoskeletal 9 
NEU4 Sialidase-4 HTR3E 5-hydroxytryptamine receptor 3 subunit E 
IL3RA Interleukin-3 receptor alpha chain precursor HOXB1 Homeobox protein Hox-B1 (Hox-2I). 
CDC45L CDC45 cell division cycle 45-like (S. 
cerevisiae) ACO2 
Aconitate hydratase, mitochondrial 
precursor 
DPP8 Dipeptidyl peptidase 8 CCDC114 coiled-coil domain containing 114 
FMO1 flavin-containing monooxygenase 1 SLC46A3 solute carrier family 46, member 3 
CSTA Cystatin-A ADCK2 Uncharacterized aarF domain-containing 
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protein kinase 2 
HSPBAP1 
HSPB1-associated protein 1 (27 KdA 
heat shock protein-associated protein 
1) 
C14orf124 UPF0105 protein C14orf124. 
RDH12 Retinol dehydrogenase SPTBN2 Spectrin beta chain, brain 2 (Spectrin, non-
erythroid beta chain 2) 
KIR3DL1 
Killer cell immunoglobulin-like 
receptor 3DL1 precursor (MHC class 
I NK cell receptor) 
HYAL1 Hyaluronidase-1 precursor 
RAB25 Ras-related protein Rab-25 C2orf16 Uncharacterized protein C2orf16 
ACTL6A Actin-like protein 6A PCBP4 Poly (rC)-binding protein 4 (Alpha-CP4). 
TPT1 Translationally-controlled tumor protein (TCTP) DVL3 
Segment polarity protein disheveled 
homolog DVL-3 (Dishevelled-3) (DSH 
homolog 3). 
PMM1 Phosphomannomutase 1 SIRT3 NAD-dependent deacetylase sirtuin-3, 
mitochondrial precursor  
MRPL12 39S ribosomal protein L12, 
mitochondrial precursor KCNA6 
Potassium voltage-gated channel subfamily 
A member 6 
SPAG11A sperm associated antigen 11B isoform H precursor USP36 Ubiquitin carboxyl-terminal hydrolase 36 
FOXRED1 FAD-dependent oxidoreductase domain-containing protein 1 SSBP1 
Single-stranded DNA-binding protein, 
mitochondrial precursor 
ALS2CR4 
Amyotrophic lateral sclerosis 2 
chromosomal region candidate gene 4 
protein 
C6orf129 OTTHUMP00000016329 (Chromosome 6 
open reading frame 129). 
TFPI Tissue factor pathway inhibitor precursor C10orf25 
Uncharacterized protein C10orf25 
precursor. 
BID BH3-interacting domain death agonist BCAP31 B-cell receptor-associated protein 31 (BCR-associated protein Bap31) 
CCDC74A Coiled-coil domain-containing protein 74A SPTB 
Spectrin beta chain, erythrocyte (Beta-I 
spectrin). 
WDR57 WD repeat protein 57 (Prp8-binding protein) RAB32 Ras-related protein Rab-32. 
GALR1 Galanin receptor type 1 TRIM47 Tripartite motif-containing protein 47 
RB1CC1 RB1-inducible coiled-coil protein 1 CRTC3 transducer of regulated CREB protein 3 isoform a 
ST8SIA1 ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 1 MYOM3 myomesin family, member 3 
RAB6IP1 RAB6 interacting protein 1 ST8SIA5 Alpha-2,8-sialyltransferase 8E 
EPB41L5 erythrocyte membrane protein band 4.1 like 5 SYPL2 Synaptophysin-like protein 2. 
UBAP2 ubiquitin associated protein 2 ACBD6 Acyl-CoA-binding domain-containing protein 6. 
PCDH19 protocadherin 19 SATB2 DNA-binding protein SATB2 (Special AT-
rich sequence-binding protein 2). 
TRAF3IP1 TNF receptor-associated factor 3 SLC30A6 solute carrier family 30 (zinc transporter), 
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interacting protein 1 member 6 
ZNF142 zinc finger protein 142 AAK1 AP2-associated protein kinase 1 (Adaptor-
associated kinase 1). 
POLR3B polymerase (RNA) III (DNA directed) polypeptide B CFL2 Cofilin-2 (Cofilin, muscle isoform). 
STIL SCL/TAL1 interrupting locus TGOLN2 Trans-Golgi network integral membrane protein 2 precursor  
GCLC GRIP and coiled-coil domain 
containing 2 LIN9 
Lin-9 homolog (huLin-9) (hLin-9) (Beta-
subunit associated regulator of apoptosis) 
GCM2 glial cells missing homolog 2 (Drosophila) BCR Breakpoint cluster region protein 
IGSF6 immunoglobulin superfamily, 
member 6 SH3TC2 
SH3 domain and tetratricopeptide repeats-
containing protein 2. 
P2RY14 purinergic receptor P2Y, G-protein 
coupled, 14 ANKRD33 
Ankyrin repeat domain-containing protein 
33. 
NCAPH Condensin complex subunit 2 (Non-SMC condensin I complex subunit H) PIK4CB Phosphatidylinositol 4-kinase beta 
ST7L suppression of tumorigenicity 7-like isoform 3 
NP_00101
7927.1 hypothetical protein LOC447937 
ZYG11B zyg-11 homolog B (C. elegans) MAT1A S-adenosylmethionine synthetase isoform type-1  
BLID BH3-like motif containing, cell death inducer    
FLJ40296 FLJ40296 protein miR-574-3p   
MICA MHC class I polypeptide-related 
sequence A C9orf19 chromosome 9 open reading frame 19 
C20orf57 Dual specificity protein phosphatase 15 COL7A1 
collagen, type VII, alpha 1 (epidermolysis 
bullosa, dystrophic, dominant and 
recessive) 
    LAT linker for activation of T cells 
miR-483-
5p   CSE1L 
CSE1 chromosome segregation 1-like 
(yeast) 
    CBX8 chromobox homolog 8 (Pc class homolog, Drosophila) 
ACBD6 Acyl-CoA-binding domain-
containing protein 6. MAPK11 mitogen-activated protein kinase 11 
RUSC1 RUN and SH3 domain-containing protein 1 MADD MAP-kinase activating death domain 
BACE2 Beta-secretase 2 precursor TRPC4AP transient receptor potential cation channel, 
subfamily C, member 4 associated protein 
TACC3 Transforming acidic coiled-coil-
containing protein 3 (ERIC-1). 
ADAMTS
17 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 17 
ACO2 Aconitate hydratase, mitochondrial precursor DEAF1 
deformed epidermal autoregulatory factor 
1 (Drosophila) 
SLC7A3 Cationic amino acid transporter 3 EXOC3 exocyst complex component 3 
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(CAT-3) (Solute carrier family 7 
member 3) 
CBS Cystathionine beta-synthase LRRC23 Leucine-rich repeat-containing protein 23 
IL1R1 Interleukin-1 receptor type I precursor GABBR1 gamma-aminobutyric acid (GABA) B 
receptor, 1 
CYP2F1 Cytochrome P450 2F1 MAGEA6 melanoma antigen family A, 6 
LAIR2 
Leukocyte-associated 
immunoglobulin-like receptor 2 
precursor (LAIR-2) (CD306 antigen). 
MAGEA3 melanoma antigen family A, 3 
CCDC9 Coiled-coil domain-containing protein 9. CSDC2 
cold shock domain containing C2, RNA 
binding 
PHOX2A Paired mesoderm homeobox protein 2A (Paired-like homeobox 2A) MUM1 melanoma associated antigen (mutated) 1 
MEA1 Male-enhanced antigen 1 (MEA-1). IL6 interleukin 6 (interferon, beta 2) 
PARL Presenilins-associated rhomboid-like protein, mitochondrial precursor ELL2 elongation factor, RNA polymerase II, 2 
RSU1 Ras suppressor protein 1 (Rsu-1) (RSP-1). NKG7 natural killer cell group 7 sequence 
CUTA 
Protein CutA precursor (Brain 
acetylcholinesterase putative 
membrane anchor) 
CLRN3 clarin 3 
MLLT1 Protein ENL (YEATS domain-
containing protein 1). MMP3 
matrix metallopeptidase 3 (stromelysin 1, 
progelatinase) 
C19orf52 Uncharacterized protein C19orf52 SOHLH1 spermatogenesis and oogenesis specific basic helix-loop-helix 1 
KLHDC3 
Kelch domain-containing protein 3 
(Protein Peas) (Testis intracellular 
mediator protein). 
ZDHHC18 zinc finger, DHHC-type containing 18 
PIP5K1A Phosphatidylinositol-4-phosphate 5-kinase type-1 alpha CUL2 cullin 2 
NXF1 Nuclear RNA export factor 1 (Tip-
associating protein) SLC2A11 
solute carrier family 2 (facilitated glucose 
transporter), member 11 
KIFC3 Kinesin-like protein KIFC3. TPRX1 tetra-peptide repeat homeobox 1 
ACAD9 Acyl-CoA dehydrogenase family 
member 9, mitochondrial precursor C15orf27 chromosome 15 open reading frame 27 
CRTAP Cartilage-associated protein precursor. SLC41A3 solute carrier family 41, member 3 
MYOM2 Myomesin-2 (M-protein)  EPHB3 EPH receptor B3 
IQSEC2 IQ motif and Sec7 domain-containing protein 2. DAK 
dihydroxyacetone kinase 2 homolog (S. 
cerevisiae) 
SHROOM
2 Apical-like protein (Protein APXL). TMEM49 transmembrane protein 49 
TMEM143 transmembrane protein 143 (TMEM143), mRNA MIZF MBD2-interacting zinc finger 
TNN Tenascin-N precursor (TN-N). SSX3 synovial sarcoma, X breakpoint 3 
ACHE Acetylcholinesterase precursor STRN3 striatin, calmodulin binding protein 3 
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PDGFD Platelet-derived growth factor D precursor  NAP1L4 nucleosome assembly protein 1-like 4 
UGT3A1 UDP glycosyltransferase 3 family, polypeptide A1 DKK3 dickkopf homolog 3 (Xenopus laevis) 
ICAM4 Intercellular adhesion molecule 4 precursor. SSX1 synovial sarcoma, X breakpoint 1 
ADRBK1 Beta-adrenergic receptor kinase 1  PMP22 peripheral myelin protein 22 
MAPK3 Mitogen-activated protein kinase 3  SSX4B synovial sarcoma, X breakpoint 4B 
ALCAM 
CD166 antigen precursor (Activated 
leukocyte-cell adhesion molecule) 
(ALCAM). 
SSX4 synovial sarcoma, X breakpoint 4 
GPT2 Alanine aminotransferase 2 SSX6 synovial sarcoma, X breakpoint 6 
PLA2G5 Calcium-dependent phospholipase A2 precursor  ZSWIM5 zinc finger, SWIM-type containing 5 
IQCE IQ domain-containing protein E. FBXO34 F-box protein 34 
WDR92 WD repeat domain 92 MTM1 myotubularin 1 
CLCN3 Chloride channel protein 3 (ClC-3). CCDC39 coiled-coil domain containing 39 
SPAG11B 
Sperm-associated antigen 11 
precursor (EP2 protein) (Sperm 
antigen HE2). 
TMCC1 transmembrane and coiled-coil domain family 1 
SPAG11A sperm associated antigen 11B isoform H precursor 
TMPRSS1
1D transmembrane protease, serine 11D 
AMICA1 Junctional adhesion molecule-like precursor CLTC clathrin, heavy chain (Hc) 
    DCP1A DCP1 decapping enzyme homolog A (S. 
cerevisiae) 
miR-365   B4GALT5 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5 
COL7A1 Collagen alpha-1(VII) chain precursor EP300 E1A binding protein p300 
BEST3 bestrophin 3 TCF25 Transcription factor 25 (Nuclear localized protein 1) 
TBCEL Tubulin-specific chaperone cofactor E-like protein (EL) 
Q5JVI1_H
UMAN 
Novel protein (Fragment). 
[Source:Uniprot/SPTREMBL;Acc:Q5JVI1
] 
PSMD8 26S proteasome non-ATPase 
regulatory subunit 8 AIFM1 
Apoptosis-inducing factor 1, mitochondrial 
precursor 
SETX senataxin ESR2 Estrogen receptor beta (ER-beta) 
PTCRA pre T-cell antigen receptor alpha NP_945352.1 RIKEN cDNA 2310002J15 gene 
ITGAD 
Integrin alpha-D precursor 
(Leukointegrin alpha D) (ADB2) 
(CD11d antigen) 
PLEKHG3 pleckstrin homology domain containing, family G, member 3 
CPT2 carnitine palmitoyltransferase II SLC22A7 solute carrier family 22 member 7 isoform 
a 
MUS81 Crossover junction endonuclease XR_01778 annexin A2 pseudogene 2 (ANXA2P2), 
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MUS81 4.1 misc RNA 
UBAC2 UBA domain containing 2    
MGA MAX gene associated miR-374b   
NUDT1 7,8-dihydro-8-oxoguanine triphosphatase    
KIAA0391 Uncharacterized protein KIAA0391 MYC Myc proto-oncogene protein (c-Myc) (Transcription factor p64) 
DYNLL1 Dynein light chain 1, cytoplasmic GNL3 Guanine nucleotide-binding protein-like 3 (Nucleolar GTP-binding protein 3) 
HAPLN2 Hyaluronan and proteoglycan link protein 2 precursor NETO1 neuropilin (NRP) and tolloid (TLL)-like 1 
FCRL1 Fc receptor-like 1 ACTR10 Actin-related protein 10 (hARP11) 
STYXL1 Serine/threonine/tyrosine-interacting-like protein 1 SMPDL3A 
Acid sphingomyelinase-like 
phosphodiesterase 3a precursor  
TMEM106
C transmembrane protein 106C PSMC3IP TBP-1 interacting protein isoform 1 
PRPF40A PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae) MEP1B Meprin A subunit beta precursor 
CYP2C9 cytochrome P450, family 2, 
subfamily C, polypeptide 9 TIGD4 
Tigger transposable element-derived 
protein 4 
KCNQ1 potassium voltage-gated channel, KQT-like subfamily, member 1 
GRAMD1
A GRAM domain containing 1A 
NLRP1 NLR family, pyrin domain containing 1 CCL18 
Small inducible cytokine A18 precursor 
(CCL18) 
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 CCL11 chemokine (C-C motif) ligand 11 
RHEBL1 Ras homolog enriched in brain like 1 COPB2 Coatomer subunit beta 
CYP24A1 cytochrome P450, family 24, 
subfamily A, polypeptide 1 NOG Noggin precursor 
USP22 ubiquitin specific peptidase 22 C11orf71 Uncharacterized protein C11orf71 
DLAT dihydrolipoamide S-acetyltransferase NSUN3 NOL1/NOP2/Sun domain family, member 3 
ADD3 adducin 3 (gamma) TRMT11 tRNA guanosine-2'-O-methyltransferase TRM11 homolog 
CCDC55 coiled-coil domain containing 55 BPNT1 3'(2'), 5'-bisphosphate nucleotidase 1 
MAK male germ cell-associated kinase ANKRD32 Ankyrin repeat domain-containing protein 32 
IHPK2 inositol hexaphosphate kinase 2 PCNX pecanex homolog (Drosophila) 
USP48 ubiquitin specific peptidase 48 SFRS15 Splicing factor, arginine/serine-rich 15 (CTD-binding SR-like protein RA4) 
ZNF680 zinc finger protein 680 PAXIP1 PAX interacting protein 1 
NUFIP2 nuclear fragile X mental retardation protein interacting protein 2 OCIAD1 OCIA domain containing 1 isoform 1 
C14orf142 chromosome 14 open reading frame 142 ADD3 adducin 3 (gamma) 
DCP2 DCP2 decapping enzyme homolog NCK1 NCK adaptor protein 1 
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(S. cerevisiae) 
USP33 ubiquitin specific peptidase 33 DBR1 debranching enzyme homolog 1 (S. 
cerevisiae) 
NSL1 NSL1, MIND kinetochore complex 
component, homolog (S. cerevisiae) STK38L serine/threonine kinase 38 like 
LUC7L2 LUC7-like 2 (S. cerevisiae) RANBP6 RAN binding protein 6 
TRAM1 translocation associated membrane protein 1 DPY19L4 dpy-19-like 4 (C. elegans) 
TMOD3 tropomodulin 3 (ubiquitous) 7A5 putative binding protein 7a5 
MTMR2 myotubularin related protein 2 ACVR2B activin A receptor, type IIB 
TBK1 TANK-binding kinase 1 KIAA0999 KIAA0999 protein 
RBM11 RNA binding motif protein 11 VGLL3 vestigial like 3 (Drosophila) 
ACVR1 activin A receptor, type I SYT14L synaptotagmin XIV-like 
LPAR5 lysophosphatidic acid receptor 5 AHI1 Abelson helper integration site 1 
SGTB small glutamine-rich tetratricopeptide 
repeat (TPR)-containing, beta DCDC2 doublecortin domain containing 2 
MGC1305
7 hypothetical protein MGC13057 
TMPRSS1
1B transmembrane protease, serine 11B 
PRUNE2 prune homolog 2 (Drosophila) DNAJC12 DnaJ homolog subfamily C member 12 (J domain-containing protein 1) 
NFIB nuclear factor I SLC25A5 ADP/ATP translocase 2 (Adenine 
nucleotide translocator 2) 
MYCBP c-myc binding protein VPS36 Vacuolar protein sorting-associated protein 36  
UBOX5 U-box domain containing 5 SLC26A5 Prestin (Solute carrier family 26 member 5) 
NP_05721
8.1 plasma glutamate carboxypeptidase 
Q7Z2R7_
HUMAN MSTP131 
THBS3 Thrombospondin-3 precursor ATF2 Cyclic AMP-dependent transcription factor ATF-2 
XR_01589
3.1 
similar to zinc finger protein 611 
(LOC731301), mRNA CYorf15A Putative testis protein CYorf15A 
NP_001006
948.1 RIKEN cDNA E030041M21 gene C4orf20 Ufm1-specific protease 2 
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Table 3.5: Analysis of biological processes of the predicted miRNAs targets by GOstat 
miRN
As GO process Target genes 
Cou
nt 
Tota
l 
p-
value 
miR-
575 
GO:0065008: Regulation 
of biological quality 
vegfb rdh12 rb1cc1 tpt1 actl6a gclc 
tfpi gcm2 
8 953 0.028
1 
  GO:0048518: Positive 
regulation of biological 
process 
nenf masp2 vegfb bid rb1cc1 gclc 
mrpl12 
7 1062 0.056 
  GO:0012501: Programmed 
cell death 
bid rb1cc1 tpt1 gclc blid gcm2 6 862 0.056 
  GO:0009308: Amine 
metabolic process 
ddt iars2 rb1cc1 gclc slc7a7 5 636 0.056 
miR-
671-
5p 
GO:0051129: Negative 
regulation of cellular 
component organization 
and biogenesis 
sptbn2 sptb 2 52 0.061
1 
  GO:0002253 Activation of 
immune response 
c1qa cd79a 2 71 0.079 
miR-
483-
5p 
GO:0042133: 
Neurotransmitter 
metabolic process 
ache phox2a 2 32 0.029
6 
  GO:0009306: Protein 
secretion 
bace2 ache 2 57 0.034
5 
miR-
574-
3p 
GO:0050789: Regulation 
of biological process 
lat deaf1 csdc2 il6 cul2 tcf25 plekhg3 
ell2 ssx4 ep300 cbx8 tprx1 aifm1 
esr2 ssx1 dkk3 ssx3 mizf madd ssx6 
pmp22 gabbr1 sohlh1 
23 6731 0.018
5 
  GO:0010468: Regulation 
of gene expression 
deaf1 csdc2 ssx1 il6 mizf ssx3 ssx6 
tcf25 ell2 ssx4 ep300 tprx1 cbx8 esr2 
sohlh1 
15 3833 0.021
1 
  GO:0048468: Cell 
development 
deaf1 madd il6 cul2 ephb3 ep300 
aifm1 cse1l 
8 1242 0.030
6 
  GO:0048856: Anatomical 
structure development 
deaf1 col7a1 il6 dkk3 ephb3 mtm1 
tcf25 ep300 pmp22 esr2 
10 2005 0.045 
  GO:0012501: Programmed 
cell death 
ep300 madd il6 cul2 aifm1 cse1l 6 862 0.054
1 
miR-
365 
GO:0043687: Post-
translational protein 
modification 
acvr1 usp48 tbcel usp33 ubox5 
mtmr2 mak rapgef4 styxl1 tbk1 
usp22 
11 2815 0.067
8 
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  GO:0044248: Cellular 
catabolic process 
dlat dcp2 usp33 usp48 usp22 5 809 0.091
2 
  GO:0043067: Regulation 
of programmed cell death 
acvr1 ihpk2 nlrp1 prune2 4 576 0.091
2 
  GO:0006512: Ubiquitin 
cycle 
usp33 ubox5 usp48 usp22 4 549 0.091
2 
  GO:0048522: Positive 
regulation of cellular 
process 
acvr1 ihpk2 nlrp1 tbk1 prune2 5 954 0.095
1 
miR-
374b 
GO:0000287: Magnesium 
ion binding 
acvr2b stk38l kiaa0999 bpnt1 4 447 0.101 
  GO:0006968: Cellular 
defense response 
dcdc2 ccl11 2 72 0.101 
  GO:0042379: Chemokine 
receptor binding 
ccl18 ccl11 2 77 0.101 
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Table 3.6: Pathway analysis of the selected miRNAs using DAVID Bioinformatics software 
Category Term Count % PValue Genes 
miR-575           
KEGG_ 
PATHWAY 
hsa04650:Natural killer cell 
mediated cytotoxicity 5 8.47% 2.77E-03 
KIR2DL4, MICA, 
KIR2DL1, KIR3DL1, 
BID 
KEGG_ 
PATHWAY 
hsa04612:Antigen 
processing and presentation 3 5.08% 5.42E-02 
KIR2DL4, KIR2DL1, 
KIR3DL1 
miR-483-5p           
KEGG_ 
PATHWAY hsa04510:Focal adhesion 3 6.67% 1.23E-01 
PDGFD, TNN, 
MAPK3 
miR-574-3p           
KEGG_ 
PATHWAY 
hsa05040:Huntington's 
disease 2 3.77% 6.68E-02 EP300, CLTC 
KEGG_ 
PATHWAY 
hsa05211:Renal cell 
carcinoma 2 3.77% 1.48E-01 CUL2, EP300 
miR-374b           
KEGG_ 
PATHWAY 
hsa04350:TGF-beta 
signaling pathway 3 6.98% 1.47E-02 ACVR2B, NOG, MYC 
KEGG_ 
PATHWAY 
hsa04060:Cytokine-cytokine 
receptor interaction 3 6.98% 9.98E-02 
ACVR2B, CCL11, 
CCL18 
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Table 3.7: Significantly dysregulated miRNAs and the associated human cancers 
 
miRNAs 
(up / down 
regulation) 
Associated cancers Chromosome 
Location 
Validated Gene targets 
 Down regulation Up regulation   
miR-125a-
5p↓ 
Lung cancer (Wang, 
Mao et al. 2009) 
 19q13.41  
miR-15a↓ Chronic Lymphocytic 
Leukemia (CLL) 
(Calin, Liu et al. 2004; 
Calin, Pekarsky et al. 
2007; Calin, Cimmino 
et al. 2008)  
Pituitary adenoma 
(Bottoni, Piccin et al. 
2005) 
HCC (Budhu, Jia et al. 
2008) 
Prostate cancer 
(Bonci, Coppola et al. 
2008) 
Kidney cancer (Chow, 
Youssef et al. 2009) 
13q14.2 BCL2 (Cimmino, Calin 
et al. 2005; Calin, 
Pekarsky et al. 2007),  
CDC25A (Lee, Masyuk 
et al. 2008),  
CCND1(Bandi, 
Zbinden et al. 2009),  
CCND2(Bandi, 
Zbinden et al. 2009),  
CCNE1(Bandi, Zbinden 
et al. 2009),  
WNT3A(Bonci, 
Coppola et al. 2008),  
RARS(Calin, Dumitru 
et al. 2002; Bottoni, 
Piccin et al. 2005) 
miR-15b↑ CLL (Calin, Liu et al. 
2004; Calin, Pekarsky 
et al. 2007) 
Gastric cancer (Xia, 
Zhang et al. 2008) 
Colorectal cancer 
(Volinia, Calin et al. 
2006) 
3q25.33 BCL2 (Xia, Zhang et al. 
2008), 
CCNE1 (Xia, Qi et al. 
2009),  
eIF-4A (Xi, Shalgi et al. 
2006) 
miR-16↑ Breast cancer (Iorio, 
Ferracin et al. 2005) 
CLL (Calin, Pekarsky 
et al. 2007) 
Gastric cancer (Xia, 
Zhang et al. 2008) 
Pituitary adenoma 
(Bottoni, Piccin et al. 
2005) 
Prostate cancer 
(Porkka, Pfeiffer et al. 
2007; Schaefer, Jung 
et al. 2009) 
Lung cancer (Yanaihara, 
Caplen et al. 2006) 
miR-16-1: 
13q14.2; 
miR-16-2: 
3q25.33 
BCL2 (Cimmino, Calin 
et al. 2005; Xia, Zhang 
et al. 2008), 
Caprin-1 (Kaddar, 
Rouault et al. 2009), 
CGI-38 (Kiriakidou, 
Nelson et al. 2004),   
CCND1 (Liu, Fu et al. 
2008; Bandi, Zbinden et 
al. 2009), 
CCND3 (Liu, Fu et al. 
2008),  
CCNE1 (Liu, Fu et al. 
2008), 
CDK6 (Liu, Fu et al. 
2008),  
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HMGA1 (Kaddar, 
Rouault et al. 2009),  
WNT3A(Bonci, 
Coppola et al. 2008),  
RARS(Calin, Dumitru 
et al. 2002) 
miR-191↑ 
 
Kidney cancer (Chow, 
Youssef et al. 2009) 
Colorectal cancer 
(Volinia, Calin et al. 
2006; Xi, Formentini et 
al. 2006; Xi, Shalgi et al. 
2006) 
Gastric cancer (Volinia, 
Calin et al. 2006) 
Lung cancer (Volinia, 
Calin et al. 2006; 
Yanaihara, Caplen et al. 
2006) 
Pancreatic cancer 
(Volinia, Calin et al. 
2006) 
Pituitary adenoma 
(Bottoni, Piccin et al. 
2005) 
Prostate cancer (Volinia, 
Calin et al. 2006; Prueitt, 
Yi et al. 2008)  
Glioblastoma (Ciafre, 
Galardi et al. 2005) 
3p21.31  
miR-197↓ Glioblastoma (Ciafre, 
Galardi et al. 2005) 
OSCC (Kozaki, Imoto 
et al. 2008) 
Uterine leiomyeomas 
(Wang, Zhang et al. 
2007) 
Lung cancer (Yanaihara, 
Caplen et al. 2006) 
Pituitary adenoma 
(Bottoni, Piccin et al. 
2005; Bottoni, Zatelli et 
al. 2007) 
1p13.3 FUS1 (Du, Schageman 
et al. 2009),  
ACVR1(Weber, Teresi 
et al. 2006),  
TSPAN3(Weber, Teresi 
et al. 2006) 
miR-
200b↓ 
 
Breast cancer 
(Gregory, Bert et al. 
2008) 
CLL (Calin, Liu et al. 
2004) 
HCC (Murakami, 
Yasuda et al. 2006) 
Kidney cancer (Chow, 
Youssef et al. 2009) 
OSCC (Kozaki, Imoto 
et al. 2008) 
Colorectal cancer 
(Bandres, Cubedo et al. 
2006) 
Ovarian cancer (Iorio, 
Visone et al. 2007) 
Cholangiocarcinoma 
(Meng, Henson et al. 
2006) 
1p36.33 SIP1 (ZEB2) (Korpal, 
Lee et al. 2008),  
ZEB1(Korpal, Lee et al. 
2008), 
 ZFHX1B 
(Christoffersen, 
Silahtaroglu et al. 
2007),  
PDGFD (Kong, Li et al. 
2009),  
PTPN12 (Meng, 
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Henson et al. 2006) 
miR-
200c↑ 
Breast cancer 
(Hurteau, Carlson et 
al. 2007; Korpal, Lee 
et al. 2008) 
Lung cancer (Hurteau, 
Carlson et al. 2007) 
OSCC (Kozaki, Imoto 
et al. 2008) 
Ovarian cancer (Iorio, 
Visone et al. 2007) 
12p13.31 SIP1 (ZEB2) (Korpal, 
Lee et al. 2008),  
ZEB1 (Korpal, Lee et 
al. 2008),  
TUBB3 (Cochrane, 
Spoelstra et al. 2009) 
miR-203↓ Acute Lymphoblastic 
Leukemia (Bueno, 
Perez de Castro et al. 
2008) 
Chronic Myeloid 
Leukemia (Bueno, 
Perez de Castro et al. 
2008) 
Esophageal cancer 
(Feber, Xi et al. 2008) 
OSCC (Kozaki, Imoto 
et al. 2008) 
uterine leiomyoma 
(Wang, Zhang et al. 
2007) 
Bladder cancer (Gottardo, 
Liu et al. 2007) 
Breast cancer (Iorio, 
Ferracin et al. 2005) 
Colorectal cancer 
(Schetter, Leung et al. 
2008) 
Lung cancer (Yanaihara, 
Caplen et al. 2006) 
Pancreatic cancer 
(Greither, Grochola et al. 
2009) 
14q32.33 ABL1 (Bueno, Perez de 
Castro et al. 2008),  
SOCS3 (Sonkoly, Wei 
et al. 2007),  
p63 (TP63) (Yi, Poy et 
al. 2008) 
miR-21↓  Breast cancer (Iorio, 
Ferracin et al. 2005; Yan, 
Huang et al. 2008) 
Cervical cancer (Lui, 
Pourmand et al. 2007) 
Cholangiocarcinoma 
(Meng, Henson et al. 
2006) 
CLL (Marton, Garcia et 
al. 2008) 
Colorectal cancer 
(Volinia, Calin et al. 
2006) 
Diffuse large B cell 
lymphoma 
(DLBCL)(Lawrie, Gal et 
al. 2008) 
Esophageal cancer (Feber, 
Xi et al. 2008) 
Glioblastoma (Chan, 
Krichevsky et al. 2005; 
Ciafre, Galardi et al. 
17q23.2 BTG2 (Liu, Wu et al. 
2009),  
MARCKS (Li, Li et al. 
2009), 
SERPINB5 (Zhu, Wu et 
al. 2008), 
PDCD4 (Asangani, 
Rasheed et al. 2008; 
Chen, Liu et al. 2008; 
Yao, Xu et al. 2009), 
PTEN (Meng, Henson 
et al. 2007),  
TPM1 (Zhu, Si et al. 
2007; Zhu, Wu et al. 
2008),  
HNRPK 
(Papagiannakopoulos, 
Shapiro et al. 2008), 
TAp63 
(Papagiannakopoulos, 
Shapiro et al. 2008), 
LRRFIP1 (Li, Li et al. 
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2005; Chen, Liu et al. 
2008) 
Head & Neck cancer 
(Tran, McLean et al. 
2007; Chang, Jiang et al. 
2008) 
HCC (Meng, Henson et 
al. 2007) 
Kidney cancer (Chow, 
Youssef et al. 2009) 
Lung cancer (Yanaihara, 
Caplen et al. 2006) 
OSCC (Kozaki, Imoto et 
al. 2008) 
Ovarian cancer (Iorio, 
Visone et al. 2007) 
Pancreatic cancer 
(Bloomston, Frankel et al. 
2007) 
Prostate cancer (Volinia, 
Calin et al. 2006; Prueitt, 
Yi et al. 2008) 
Stomach cancer (Volinia, 
Calin et al. 2006) 
Uterine leiomyomas 
(Wang, Zhang et al. 2007) 
2009) 
JAG1 (Hashimi, 
Fulcher et al. 2009), 
WNT1 (Hashimi, 
Fulcher et al. 2009) 
miR-23a↑ CLL (Calin, Liu et al. 
2004) 
Prostate cancer 
(Volinia, Calin et al. 
2006; Porkka, Pfeiffer 
et al. 2007)  
OSCC (Kozaki, Imoto 
et al. 2008) 
 
 
Bladder cancer (Gottardo, 
Liu et al. 2007) 
Breast cancer (Iorio, 
Ferracin et al. 2005) 
Glioblastoma (Ciafre, 
Galardi et al. 2005) 
Head & Neck cancer 
(Tran, McLean et al. 
2007) 
Pancreatic cancer 
(Bloomston, Frankel et al. 
2007) 
Stomach cancer (Volinia, 
Calin et al. 2006)  
19p13.12 RING1 (Lin, Murtaza et 
al. 2009),  
CXCL12 (Lewis, Shih 
et al. 2003), 
FLJ13158 (Kiriakidou, 
Nelson et al. 2004) 
miR-23b↑ 
 
Prostate cancer 
(Porkka, Pfeiffer et al. 
2007) 
Renal cancer 
(O'Rourke, Swanson 
et al. 2006) 
Bladder cancer (Gottardo, 
Liu et al. 2007) 
Breast cancer (Iorio, 
Ferracin et al. 2005) 
CLL (Calin, Ferracin et 
al. 2005) 
9q22.32 uPA (Salvi, Sabelli et 
al. 2009), 
 c-met/MET (Salvi, 
Sabelli et al. 2009), 
 MOR1 (Wu, Law et al. 
2008) 
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OSCC (Kozaki, Imoto 
et al. 2008) 
Cervical cancer (Lui, 
Pourmand et al. 2007) 
Colon cancer (Volinia, 
Calin et al. 2006) 
Glioblastoma (Ciafre, 
Galardi et al. 2005) 
Head & Neck cancer 
(Tran, McLean et al. 
2007) 
Pancreatic cancer 
(Volinia, Calin et al. 
2006; Bloomston, Frankel 
et al. 2007) 
Stomach cancer (Volinia, 
Calin et al. 2006) 
Uterine leiomyomas 
(Wang, Zhang et al. 2007) 
miR-24↓ 
 
 Breast cancer (Iorio, 
Ferracin et al. 2005) 
miR-42-1: 
9q22.32;  
miR-24-2: 
19p13.13 
DHFR (Mishra, 
Humeniuk et al. 2007),  
E2F2, MYC, AURKB, 
CCNA2, CDC2, CDK4 
(Lal, Navarro et al. 
2009), 
 p16 (Lal, Kim et al. 
2008) 
miR-25↓ 
 
CLL (Calin, Liu et al. 
2004) 
Pancreatic cancer 
(Volinia, Calin et al. 
2006) 
Prostate cancer (Volinia, 
Calin et al. 2006) 
Stomach cancer (Volinia, 
Calin et al. 2006) 
Glioblastoma (Ciafre, 
Galardi et al. 2005) 
HCC (Li, Tan et al. 2009) 
7q22.1 p57 (Kim, Yu et al. 
2009),  
BIM (Li, Tan et al. 
2009) 
miR-26b↓ CLL (Calin, Pekarsky 
et al. 2007) 
OSCC (Kozaki, Imoto 
et al. 2008) 
Prostate cancer 
(Porkka, Pfeiffer et al. 
2007) 
Bladder cancer (Gottardo, 
Liu et al. 2007) 
Pituitary adenoma 
(Bottoni, Zatelli et al. 
2007) 
2q35  
miR-27a↓ OSCC (Kozaki, Imoto 
et al. 2008) 
Breast cancer (Mertens-
Talcott, Chintharlapalli et 
al. 2007; Guttilla and 
White 2009) 
19p13.12 Myt1 (Mertens-Talcott, 
Chintharlapalli et al. 
2007),  
MDR1(Zhu, Wu et al. 
131 
 
Kidney cancer (Chow, 
Youssef et al. 2009) 
Gastric cancer (Liu, Tang 
et al. 2009) 
Prostate cancer (Porkka, 
Pfeiffer et al. 2007) 
Uterine leiomyomas 
(Wang, Zhang et al. 2007) 
2008) , 
FOXO1 (Guttilla and 
White 2009),  
PHB (prohibitin) 
(Schaar, Medina et al. 
2009), 
ZBTB10 (Mertens-
Talcott, Chintharlapalli 
et al. 2007) 
miR-27b↓ 
 
Lung cancer 
(Yanaihara, Caplen et 
al. 2006) 
OSCC (Kozaki, Imoto 
et al. 2008) 
Prostate cancer 
(Porkka, Pfeiffer et al. 
2007; Prueitt, Yi et al. 
2008) 
 9q22.32 CYP1B1 (Tsuchiya, 
Nakajima et al. 2006) 
miR-30a↓ HCC (Budhu, Jia et al. 
2008) 
Uterine leiomyomas 
(Wang, Zhang et al. 2007) 
6q13  
miR-342-
3p↑ 
 Kidney cancer (Chow, 
Youssef et al. 2009) 
14q32.2  
miR-365↓  Breast cancer (Yan, 
Huang et al. 2008) 
miR-365-1: 
16p13.12; 
miR-365-2: 
17q11.2 
 
miR-7↓ Glioblastoma (Kefas, 
Godlewski et al. 2008) 
Bladder cancer (Veerla, 
Lindgren et al. 2009) 
Lung cancer (Crawford, 
Batte et al. 2009) 
miR-7-1: 
9q21.32; 
miR-7-2: 
15q26.1; 
miR-7-3: 
19p13.3 
PAK1 (Reddy, Ohshiro 
et al. 2008),  
EGFR (Kefas, 
Godlewski et al. 2008),  
SNCA (Junn, Lee et al. 
2009) 
let-7a↑ Breast cancer (Iorio, 
Ferracin et al. 2005) 
CLL (Marton, Garcia 
et al. 2008) 
Lung cancer  
(Takamizawa, Konishi 
et al. 2004) 
Prostate cancer 
(Porkka, Pfeiffer et al. 
2007) 
Burkitt’s Lymphoma 
(Sampson, Rong et al. 
2007) 
Cholangiocarcinoma 
(Meng, Henson et al. 
2007) 
let-7a-1:  
9q22.32;  
let-7a-2: 
11q24.1; 
 let-7a-3: 
22q13.31 
MYC (Sampson, Rong 
et al. 2007),  
caspase 3 (CASP3) 
(Tsang and Kwok 
2008), 
Integrinβ3 (Muller and 
Bosserhoff 2008), 
NIRF (UHRF2), NF2 
(He, Duan et al. 2009),  
HMGA2 (Motoyama, 
Inoue et al. 2008), 
PRDM1 (Blimp-1) 
(Nie, Gomez et al. 
2008) 
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let-7d↑ Breast cancer (Iorio, 
Ferracin et al. 2005) 
Head & Neck  
  Squamous Cell   
  Carcinoma (Childs, 
Fazzari et al. 2009) 
OSCC (Kozaki, Imoto 
et al. 2008) 
Prostate cancer (Porkka, 
Pfeiffer et al. 2007) 
9q22.32  
Let-7e↓ OSCC (Kozaki, Imoto 
et al. 2008) 
Ovarian cancer 
(Dahiya, Sherman-
Baust et al. 2008) 
Pituitary adenoma 
(Bottoni, Zatelli et al. 
2007) 
Acute myeloid leukemia 
(Dixon-McIver, East et al. 
2008) 
DLBCL (Roehle, Hoefig 
et al. 2008) 
19q13.33 SMC1L1 (SMC1A) 
(Kiriakidou, Nelson et 
al. 2004) 
let-7f↑ Breast cancer (Yan, 
Huang et al. 2008) 
Ovarian cancer 
(Dahiya, Sherman-
Baust et al. 2008) 
Prostate cancer 
(Porkka, Pfeiffer et al. 
2007) 
 let-7f-1: 
9q22.32;  
let-7f-2: 
Xp11.22 
 
let-7g↓ HCC (Budhu, Jia et al. 
2008) 
OSCC (Kozaki, Imoto 
et al. 2008) 
Prostate cancer 
(Porkka, Pfeiffer et al. 
2007) 
Colon cancer (Nakajima, 
Hayashi et al. 2006) 
Lung cancer 
9q22.32 HMGA2 (Kumar, 
Erkeland et al. 2008)  
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         Control        Treatment          Cy3/Cy5(Control/Treatment  
               comparison) 
 
Figure 3.1: Representative heat map diagram of miRNA expression levels in control and 5-FU 
treated MCF7 cells. The image was displayed in pseudo colors to expand visual dynamic range, 
and the signal intensity increases from blue to green, to yellow, and to red.
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Figure 3.2: miRNA expression profile in human MCF7 breast cancer cell line. 
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Figure 3.3: Signal distribution of all analyzed miRNAs in MCF7 cells by miRNA microarray 
assay. 
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Figure 3.4: Comparison of signal distribution between control and 5-FU-treatment human breast 
cancer cell MCF7. 
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Figure 3.5: Fold change in the expression of significantly altered miRNA after 5-FU exposure 
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Figure 3.6: Confirmatory studies of selected miRNAs by TaqMan Real-Time PCR. The results 
are represented as mean ± SEM of triplicate samples. 
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Chapter 4: Effect of 5-fluorouracil on the Expression of Selected MicroRNAs in a Dose- 
and Time- Dependent Manner 
Abstract 
MicroRNAs (miRNAs) are a newly identified class of gene regulators which have been 
shown to play an important role in human cancers. The ability of 5-fluororacil to alter the 
expression levels of miRNAs in MCF7 cells was previously observed. In this study, we further 
investigate the dose- and time-dependent modification in miRNA expression levels after 5-FU 
treatment. Eleven miRNAs previously identified in the microarray to be differentially expressed 
after treatment were selected to analyze their responsiveness to eight different 5-FU dosages of 
0.001, 0.005, 0.01, 0.1, 0.7, 1, 5 and 10µM. The selected miRNAs included miR-365, miR-374b, 
miR-483-5p, miR-574-3p and miR-575, which were shown to be highly dysregulated in the 
microarray analysis. Additionally, let-7g, miR-10b, miR-15a, miR-16, miR-21, miR-27a were 
investigated based on previous reports of their connection to breast cancer. Of these, miR-10b, 
miR-21, miR-365 and miR-483-5p were found to be significantly regulated in a beneficial way 
for cancer treatment. Time-response data was also generated for miR-10b, miR-21, miR-483-5p, 
miR-574-3p and miR-575 following 12, 24, 36, 48, 60 and 72 hours of treatment with 0.1 (low), 
0.7 (moderate) and 10 (high) µM 5-FU concentrations. At 0.7µM for short treatment duration, 
expression levels of miR-10b, miR-21, miR-574-3p and miR-575 were significantly altered; 
while treatment with high 5-FU dose for shorter time points showed a significant down-
regulation of miR-21and miR-574-3p. The data suggests that miRNA expression in MCF7 cells 
is sensitive to 5-FU therapy at low doses and shorter treatment durations. The down-regulation of 
an important oncomir, miR-21; and alteration in the expression of three new miRNAs with no 
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previous breast cancer association, miR-483-5p, miR-574-3p and miR-575 indicates that miRNA 
might play an important role in 5-FU therapy. 
Keywords: 5-fluorouracil, microRNA, qRT-PCR, breast cancer, MCF7 
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Introduction 
Breast cancer is one of the leading causes of deaths worldwide, claiming more than 
40,000 deaths in US in the year 2009 (Jemal, Siegel et al. 2009), and is expected to account for 
27% of all new cancer cases among women for 2009 (Jemal, Siegel et al. 2009). The breast 
cancer cases are principally graded based on the cellular histology and the expression pattern of 
specific proteins such as estrogen receptor (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (HER2/neu). The expression profiles of these proteins play an 
important role in differentiating between benign and malignant breast tumors. About 65% of 
breast cancer cases are ER+ (Teixeira, Reed et al. 1995), which is important in predicting 
treatment options and final prognosis.  The absence of estrogen receptor in primary breast tumors 
is associated with early recurrence and poor prognosis (Knight, Livingston et al. 1977; Hahnel, 
Woodings et al. 1979). Approximately 15-20 % of breast cancers have an amplification of the 
HER2/neu gene or over-expression of its protein product (Slamon, Clark et al. 1987; Slamon, 
Godolphin et al. 1989); which, in turn, is associated with increased disease reoccurrence and 
poor prognosis (Slamon, Clark et al. 1987). Similarly, several other oncogenes and tumor 
suppressor genes have been identified which show a differential expression in breast tumors 
compared to normal breast tissues (Chapter I, Table 1.1). 
Several treatment options are available for breast cancer, mainly surgery, radiation 
therapy and chemotherapy. A combination of these approaches is usually adopted to achieve 
maximum therapeutic efficiency. However, the prevalent side effects due to chemotherapeutic 
drugs and the associated low quality of life after chemotherapy have urged an extensive need for 
more targeted and effective treatment options. Several drugs targeting the oncogenes and tumor 
suppressor genes have been designed. Trastuzumab (Herceptin®), a humanized monoclonal 
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antibody against HER-2/neu, has been shown to benefit patients with HER-2/neu-positive 
metastatic breast cancer (Slamon, Leyland-Jones et al. 2001; Vogel, Cobleigh et al. 2002; 
Baselga, Carbonell et al. 2005; Marty, Cognetti et al. 2005). Hormonal therapy with tamoxifen, a 
selective estrogen receptor modulator, showed a better prognosis in advanced metastatic breast 
cancer patients (Mouridsen, Palshof et al. 1978; Legha, Buzdar et al. 1979; Frasor, Weaver et al. 
2009). Recently, genetic screening tools, such as the Oncotype DX™, have also been used as 
diagnostic tools to predict recurrence prognosis and therapeutic response in breast cancer cases 
(Cronin, Sangli et al. 2007). Further research to identify novel intracellular targets and to design 
tumor specific drugs is needed to improve the effectiveness of cancer therapy. 
MicroRNAs (miRNAs) are small endogenous non-coding single-stranded RNA 
molecules which act as post-transcriptional gene regulators and cause a decrease in gene 
expression (Bartel 2004). As a new level of gene regulation mechanism, several diverse 
functions of miRNAs have been identified, including cellular differentiation, proliferation and 
apoptosis (Cheng, Byrom et al. 2005; Croce and Calin 2005). Thus, deregulation of miRNAs 
could lead to a variety of disorders, including cancers. For instance, miRNAs have been reported 
to play a role in cancer initiation, progression (Calin and Croce 2006) and metastasis (Cheng, 
Byrom et al. 2005), with about 50% of miRNA genes being localized in cancer-associated 
genomic regions or in fragile sites (Calin, Sevignani et al. 2004). Aberrant miRNA expression 
levels have been reported in almost all human cancers (Iorio, Ferracin et al. 2005; Lu, Getz et al. 
2005; Calin and Croce 2006; Blenkiron, Goldstein et al. 2007; Zhang, Pan et al. 2007). Certain 
miRNAs have also displayed unique expression profiles in specific types of cancers (Lu, Getz et 
al. 2005), making them important biomarkers for classifying these cancers. Many miRNAs target 
protein-coding genes which act as oncogenes or tumor suppressor genes, and are involved in 
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tumorigenesis (Zhang and Farwell 2008). For example, miR-21 targets important tumor 
suppressor genes such as PTEN (Meng, Henson et al. 2007) and TPM1 (Zhu, Si et al. 2007; Zhu, 
Wu et al. 2008); while miR-15a and miR-16 have been shown to regulate BCL2 (Cimmino, 
Calin et al. 2005; Calin, Pekarsky et al. 2007). These studies highlight the importance of 
miRNAs as both stimulators and inhibitors in breast cancer. 
5-fluorouracil (5-FU), an antimetabolite, is a clinically useful chemotherapeutic agent 
approved for treatment of breast (Fumoleau, Bonneterre et al. 2003), colorectal (Wils, O'Dwyer 
et al. 2001) and head and neck cancers (Posner, Colevas et al. 2000). It is a pyrimidine antagonist 
which inhibits the activity of enzyme thymidylate synthase (TS), resulting in arrest of the de 
novo DNA synthesis pathway (Santi, McHenry et al. 1974; Sommer and Santi 1974). In addition, 
5-FU toxicity is also caused by misincorporation of FdUTP and FUTP into DNA (Mitrovski, 
Pressacco et al. 1994; Aherne, Hardcastle et al. 1996) and RNA (Randerath, Tseng et al. 1983; 
Kanamaru, Kakuta et al. 1986; Santi and Hardy 1987; Doong and Dolnick 1988; Samuelsson 
1991; Patton 1993; Ghoshal and Jacob 1994) strands respectively. The advancement in genetic 
analysis techniques have helped discover the ability of several chemotherapeutic drugs to alter 
gene expression profile in different tumors. For instance, p53 and FAS have been shown to be a 
potential target of 5-FU (Hernandez-Vargas, Ballestar et al. 2006) (Tillman, Petak et al. 1999). 
Similar studies have also been performed on other antineoplastic drugs (Kudoh, Ramanna et al. 
2000; Daoud, Munson et al. 2003), suggesting a connection between disease prognosis, 
efficiency and resistance to chemotherapy and genetic expression profiles (Krajewski, Blomqvist 
et al. 1995; Thottassery, Zambetti et al. 1997). Currently, a growing body of evidence has 
suggested the importance of miRNAs in modulating the chemosensitivity and chemoresistance 
of tumor cells (Meng, Henson et al. 2006; Blower, Verducci et al. 2007; Blower, Chung et al. 
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2008). Si (Si, Zhu et al. 2007) reported that suppression of miR-21 sensitized MCF7 cells to 
anticancer drug topotecan. Similar studies have been reported for the drugs gemcitabine, 
doxorubicin and tamoxifen (Kovalchuk, Filkowski et al. 2008; Miller, Ghoshal et al. 2008; Zhao, 
Lin et al. 2008) illustrating the importance of miRNAs in drug sensitivity and resistance. Thus, it 
could be suggested that a distinct association is prevalent between cytotoxicity of chemotherapy 
drugs, their alteration of genetic profiles and the gene regulatory role of miRNAs. 
In our previous study, we have demonstrated that miRNA expression profile in MCF7 
breast cancer cells is sensitive to 5-FU treatment and a distinct set of miRNAs with differential 
expression after 5-FU treatment was identified using microRNA microarray and qRT-PCR 
(Chapter III). Further study was required to obtain a detailed understanding of the miRNA 
regulatory effects of 5-FU and to exploit its potential therapeutic implications. However, there 
has been no organized study examining the relevance of dosage and treatment duration of a 
chemotherapy drug on the expression profile of miRNAs. We have therefore investigated the 
miRNA expression profiles of MCF7 breast cancer cells in response to various 5-FU 
concentrations for different lengths of treatment using qRT-PCR analysis. We report a 
characteristic miRNA expression profile in response to 5-FU treatment, wherein miRNAs in 5-
FU treated cells show a different profile at all 5-FU variables compared to the control MCF7 
samples. Most importantly, miRNA regulation was shown to be highly sensitive to 5-FU 
treatment at low doses and shorter duration of exposure. This could be an important clinical 
consideration that is relevant in improving 5-FU therapy, and suggests a potential role of miRNA 
specific therapies in cancer treatment. 
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Materials and Methods 
Cell line and Cell culture 
All cell culture reagents were purchased from Invitrogen, Inc, Carlsbad, CA.  The human 
breast adenocarcinoma cell line MCF7 (HTB-22™) was obtained from the American Type 
Culture Collection (ATCC, Rockville, MD). They were cultured in RPMI 1640 media containing 
L-Glutamine and 25 mM HEPES, and supplemented with 10% Fetal Bovine Serum (FBS), 10 
µg/ml gentamicin and 4 µg/ml insulin and sterilized using a 0.22µM polyethersulfone filter 
(Corning Inc., Corning, NY). The cells were maintained at 37˚C in a humidified incubator with 
5% CO2. The media was replaced every 48 hours, and the cells were passaged once a week by 
trypsinization using 0.05% trypsin/0.02% EDTA (Sigma, St. Louis, MO). 
5-fluorouracil drug treatment 
5-fluorouracil (5-FU) was purchased from Sigma-Aldrich (St. Louis, MO) and stored at 
4˚C, away from light and moisture. For cell treatments, a 10 mM stock solution of 5-FU was 
prepared in RPMI complete media and stored at 4˚C for not more than two weeks. The stock was 
filtered through a 0.22µM polyethersulfone filter prior to further dilution. Further dilutions were 
made from the stock solution as required. 
Dose- and time-dependent miRNA response analysis 
 The dose-dependence of miRNA expression profile in MCF7 breast cancer cells was 
analyzed at eight different 5-FU concentrations. For this purpose, cells were seeded at 50,000 
cells/cm2 (480,000 cells/well) in flat-bottom 6-well plates in 2ml of RPMI 1640 complete media. 
After 24 hours, media was replaced with fresh media (control group) or with 5-FU in complete 
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media (treatment group) and cells were incubated for another 48 hours. The treatments included 
0.001, 0.005, 0.01, 0.1, 0.7, 1, 5 and 10µM 5-FU. After 48 hours of incubation, the cells were 
detached by trypsinization and stored in RNAlater-ICE at -20º C till RNA extraction was 
performed. Each treatment was performed minimum in triplicates. 
 For time-dependent miRNA expression response, MCF7 cells were treated with 0.1, 0.7 
and 10µM 5-FU and analyzed at six different time points: 12, 24, 36, 48, 60 and 72 hours. 
Briefly, cells were seeded at 50,000 cells/cm2 (480,000 cells/well) in flat-bottom 6-well plates in 
2ml of RPMI 1640 complete media. After 24 hours, media was replaced with fresh media 
(control group) or with 5-FU in complete media (treatment group) and cells were incubated. 
Cells were subsequently trypsinized after 12, 24, 36, 48, 60 and 72 hours respectively, and stored 
in RNAlater-ICE at -20º C till further analysis. Each treatment was repeated three times at each 
time point. 
RNA isolation 
Total RNA was extracted from both groups with the mirVana™ miRNA Isolation Kit 
(Ambion, Austin, TX) according to manufacturer’s instructions. Briefly, the cells were pelleted 
and RNAlater-ICE was removed by centrifugation. Cells were lysed by adding 500 µl of 
Lysis/Binding Solution, followed by vortexing. miRNA Homogenate Additive (50 µl) was then 
added, mixed by vortexing and cells were incubated on ice for 10 min. The RNA was extracted 
by adding 500 µl of Acid-Phenol: Chloroform, vortexing for 60 sec and centrifuging for 5 min at 
10,000 X g to separate the aqueous and organic phases. The upper (aqueous) phase was 
transferred to another 2ml micro-centrifuge tube and its volume was noted. Room temperature 
100% ethanol was added at 1.25 times the volume to precipitate the RNA. The total RNA was 
then filtered onto a filter cartridge by centrifugation, followed by multiple washings. The filter 
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cartridge was first washed with 700µl Wash solution 1, centrifuged briefly and the flow through 
was discarded. The washing was then repeated twice with 500µl of Wash Solution 2/3. Finally, 
the total RNA was eluted with 100 µl of pre-heated (95º C) nuclease-free water. All the steps 
were performed on ice. RNA quantity and quality was analyzed using NanoDrop ND1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE) and immediately stored at -80˚C 
until further analysis. 
Quantitative Real Time PCR (qRT-PCR) of miRNA expression 
Eleven different miRNAs were analyzed for changes in their expression level following 
5-FU treatment. Primers for hsa-let-7g, hsa-miR-10b, hsa-miR-15a, hsa-miR-16, hsa-miR-21, 
hsa-miR-27a, hsa-miR-365, hsa-miR-374b, hsa-miR-483-5p, hsa-miR-574-3p, hsa-miR-575, and 
reference gene RNU48 were purchased from Applied Biosystems (Foster City, CA). The 
miRNAs were selected based on the microarray analysis (Chapter 3) and the importance of 
miRNAs in breast cancers. miR-365, miR-374b, miR-483-5p, miR-574-3p, miR-575 were shown 
to be differentially expressed with high fold change in the microRNA microarray data, while let-
7g, miR-10b, miR-15a, miR-16, miR-21, miR-27a have been reported to be associated with 
breast cancer. A single-stranded cDNA for a specific miRNA was generated by reverse 
transcription of at least 500 ng of total RNA using a miRNA-specific stem-looped RT primer and 
the Applied Biosystems TaqMan® microRNA Reverse Transcription Kit. A Reverse 
transcription reaction mixture contains total RNAs, 1.5µL 10X TR Buffer, 1mM of each dNTPs, 
0.188µL RNase Inhibitor, 3µL 5X Taqman® microRNA RT primer for a specific miRNA and 
1µL MultiScribe™ Reverse Transcriptase (50U/µL). An Eppendorf Mastercycler Personal PCR 
(Westbury, NY) was used to conduct the reverse transcription reaction at the following 
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temperature conditions: 16°C for 30 min, 42°C for 30 min followed by 85°C for 5 min and 
finally held at 4°C. 
Following reverse transcription reaction, quantitative RT-PCR was performed with 
Applied Biosystems 7300 Real-Time PCR system using the Taqman® MicroRNA Assay kit. 
The qRT-PCR reaction mixture contains 3µL RT PCR product (diluted 1:7 times), 10µL 
Taqman® 2X Universal PCR Master Mix (No AmpErase® UNG), 2µL Taqman® MicroRNA 
Assays 20X Taqman® Assay (qRT-PCR primers). The final volume was adjusted to 20µL with 
nuclease free water. The reactions were incubated in a 96-well optical plate at 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec. RNU 48 was used as an 
endogenous reference gene for normalizing the results. Each sample was analyzed in duplicate 
(technique replicates). The relative abundance of each miRNA was calculated using the 
comparative cycle threshold (2-∆∆Ct) method. The results are presented as fold change of each 
miRNA in 5-FU treated cells relative to the control MCF7 cells. 
Statistical Analysis 
All data are expressed as mean ± S.E.M. (Standard error of the mean). Statistical 
significance of the differences between the control and treated groups was determined by one-
way analysis of variance (ANOVA) using the PASW (Predictive Analytics SoftWare) Statistics 
17.0 (SPSS Inc., Chicago, IL). A two-way ANOVA analysis was also performed for the time-
response study using the PASW (Predictive Analytics SoftWare) Statistics 17.0 (SPSS Inc., 
Chicago, IL) to determine if there was any significant interaction between the concentration of 
treatment and the duration of treatment on the expression level of miRNAs in MCF7 breast 
cancer cells. Differences were considered significant if p < 0.05. 
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Results 
miRNA dose-response to 5-FU treatment 
 Eleven miRNAs (let-7g, miR-10b, miR-15a, miR-16, miR-21, miR-27a, miR-365, miR-
374b, miR-483-5p, miR-574-3p and miR-575) were analyzed to determine the dose-dependency 
of their expression profiles at eight different 5-FU treatments (0.001, 0.005, 0.01, 0.1, 0.7, 1, 5 
and 10µM) (Figures 4.1-4.11). Cells were treated with different 5-FU concentrations for 48 
hours, followed by RNA extraction, reverse transcription and qRT-PCR to determine the relative 
miRNA expression levels. Of the eleven miRNAs analyzed, three miRNAs (miR-10b, miR-21 
and miR-365) showed statistically significant alteration in their expression profile following 
treatment with different 5-FU concentrations. miR-10b showed up-regulation at 0.005 (40.4-
fold), while no major alteration was observed at other 5-FU concentrations. Conversely, miR-21 
showed a significant decrease in its expression levels in a dose-dependent manner (p = 0.026), 
with maximum down-regulation at 0.1µM (4.9-fold). This down-regulation decreased when 
treated with concentrations higher that 0.1µM 5-FU. miR-365 also showed a down-regulation 
compared to the control after 5-FU treatment, the highest down-regulation being at 0.005µM 
(4.4-fold, p = 0.03). 
miR-15a, miR-16, miR-483-5p and miR-575 were all up-regulated compared to the 
control following 5-FU treatment. miR-15a and miR-16 show a very similar bimodal trend in 
their expression profiles, with the fold change showing a peak at two separate concentrations. 
miR-483-5p shows a remarkable up-regulation between 0.001-0.7µM, with the highest increase 
at 0.1µM 5-FU (56.3-fold). miR-575 also shows an up-regulation between 0.001-1µM (up to 
17.7-fold). Let-7g, miR-27a, miR-374b and miR-574-3p showed a decrease in their expression 
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levels compared to control after treatment with 5-FU. let-7g and miR-27a both showed the 
highest down-regulation at 0.1µM (2-fold and 1.54-fold respectively). However, a slight up-
regulation was seen at 0.005 and 5µM for let-7g, and at 0.005, 0.7 and 10µM for miR-27a. miR-
374b, on the other hand, shows a dose-dependent increase in its down-regulation, with the 
maximum down-regulation between 0.01-0.7µM. The expression level however became similar 
to the normal control samples as the 5-FU concentration increased. miR-574-3p showed the 
highest decrease in its expression level at 0.005µM (1.9-fold) and at 10µM (2.7-fold) 
respectively. This study revealed that miRNA expression levels in MCF7 breast cancer cells 
were more sensitive to lower 5-FU concentrations, and these doses were sufficient to elicit an 
alteration in their expression levels. 
miRNA time-response to 5-FU treatment 
Based on the results obtained from the dose-dependent miRNA expression study, five 
miRNAs with high fold change (miR-10b, miR-21, miR-483-5p, miR-574-3p and miR-575) 
were selected to analyze any time-dependent changes in their expression. MCF7 cells were 
treated with 0.1, 0.7 and 10µM 5-FU for 12, 24, 36, 48, 60 and 72 hours, and analyzed for the 
expression levels of the selected miRNAs (Figure 4.12-4.26). 
At 0.1µM 5-FU treatment, the selected miRNAs did not show a significant change in 
their expression at different time points. The expression levels after treatment were almost 
similar to the control samples. Further, it was observed that treatment for more than 48 hours was 
required to elicit a small change in the expression at 0.1µM 5-FU. On the other hand, treatment 
with 0.7µM 5-FU showed an atypical behavior compared to the other two treatments. Of the five 
miRNAs analyzed, four (miR-10b, miR-21, miR-574-3p and miR-575) showed a significant 
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differential expression at 0.7µM. For miR-10b, the expression level was up-regulated after 
treatment up to 48 hours; however, the expression was down-regulated if the treatment was 
continued for 72 hours. Similarly, miR-21 was up-regulated after 12 and 24 hours of treatment, 
but showed a down-regulation when treated for 36 and 48 hours. Conversely, the expression 
levels returned to normal control levels if the treatment was continued for 72 hours. Further, 
miR-483-5p showed the highest up-regulation after treatment for 12 hours, which reduced with 
longer duration of exposure. A decrease in the expression was observed after 36 hours of 
treatment; however, this change in expression never significantly varied from the control. A 
similar trend was also seen for miR-574-3p and miR-575. The miRNAs were significantly up-
regulated after 12 and 24 hours of treatment, while the expression levels returned to normal if 
treated for longer duration of time.  
At the 10µM treatment level, miR-10b showed an increase in expression at 24 and 48 
hours of treatment, while the expression decreased after 60 and 72 hours of treatment, as was 
seen with the 0.1 and 0.7µM treatment. This suggests that expression of miR-10b is expressed 
differentially at different time points and is thus sensitive to duration of exposure to 5-FU. 
Similarly, miR-21 showed the highest down-regulation (7.1 fold) after 36 hours of treatment, 
while the expression decreased to control levels with increasing length of treatment. miR-483-5p, 
on the other hand, showed an up-regulation after 24 hours of treatment (2.4-fold), but the 
expression decreased significantly to 1.9-fold after 36 hours of treatment. These changes, 
however, were not significantly different from the control samples. Conversely, miR-574-3p 
showed a significant differential expression after treatment with 5-FU for different time 
durations (p < 0.001). The highest down-regulation was observed after 36 hours of treatment 
(4.4-fold), which reduced to 2-fold down-regulation after increasing length of treatment. Finally, 
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miR-575showed an up-regulation after treatment with 12 and 24 hours of treatment (2.3- and 
4.2-fold respectively), which was decreased to a down-regulation of 2.5-fold if the treatment was 
continued for 72 hours. 
The time-response data suggests that the expression of miRNAs in MCF7 breast cancer 
cells was more sensitive to shorter duration of treatment with 5-FU. The miRNAs showed a 
significant change in their expression levels when treated with 5-FU for shorter time length (p < 
0.01 and p < 0.05 for 12 and 24 hours of treatment, respectively) as compared to increased time 
durations. A two-way ANOVA analysis to investigate the effect of various 5-FU concentrations 
and duration of treatment with these concentrations revealed that expression of each miRNA 
analyzed was significantly affected by both 5-FU dosage and treatment durations (p < 0.05 for 
each miRNA). This confirms that miRNA expression in MCF7 cells is responsive to 5-FU 
treatment. Further, a significant interaction between treatment dose and duration was also 
observed for miR-21, miR-574-3p and miR-575. This shows that alteration in the expression 
levels of different miRNAs may play an important role in the therapeutic response to 5-FU.  
 
Discussion 
miRNAs constitute a novel target system for cancer treatment as each miRNA has the 
ability to regulate the expression of several hundred target genes, including several important 
oncogenes or tumor suppressor genes, and have the potential to function as a diagnostic and 
prognostic tool for a variety of human cancers (Blenkiron and Miska 2007; Tricoli and Jacobson 
2007; Lowery, Miller et al. 2008; Zhang and Farwell 2008). Extensive research is currently 
being focused on identifying differential expressed miRNAs that play primary roles in cancer 
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development and therapy. Thus, a study of the possible effects of chemotherapeutic drug 
treatment on the expression profile of miRNAs is of prime importance for cancer therapy and 
resistance. 5-FU is an important chemotherapeutic drug used for the treatment of breast cancer. 
Unfortunately, 5-FU is rarely used as a monotherapy now-a-days, and is mainly used in 
combination with other drug regimens. It has been shown to be a potent anti-proliferative agent 
capable of inducing apoptosis in MCF7 breast cancer cells (Chapter II). Further analysis to 
determine the role of miRNAs in the cytotoxicity of 5-FU in MCF7 cells showed that 5-FU is 
able to significantly dysregulate the expression levels of several miRNAs even at a low dose 
(Chapter III). In this study, we observed that higher and clinically relevant 5-FU doses also have 
a significant effect on the miRNA expression profiles in MCF7 breast cancer cells, but 
expression is more sensitive to lower treatment doses. The expression levels were also shown to 
be regulated by the time of exposure to 5-FU. The data presented here gives a detailed analysis 
of the expression profiles of miRNAs in response to 5-FU. 
Eleven miRNAs were selected to study their expression profiles in response to different 
5-FU concentrations. These include let-7g, miR-10b, miR-15a, miR-16, miR-21, miR-27a, miR-
365, miR-374b, miR-483-5p, miR-574-3p and miR-575, which were treated with 0.001, 0.005, 
0.01, 0.1, 0.7, 1, 5 and 10µM 5-FU. Of these, miR-10b, miR-15a, miR-16, miR-483-5p and miR-
575 were consistently up-regulated; while miR-21, miR-365 and miR-374b were consistently 
down-regulated at all 5-FU treatments. These results further confirm the microRNA microarray 
data obtained previously (Chapter III). Conversely, let-7g, miR-27a and miR-574-3p were 
differentially expressed at various 5-FU concentrations. This suggests that different miRNAs 
respond to 5-FU treatment in different ways. Recently, miR-10b was identified to be highly 
expressed in metastatic breast cancer cells and positively regulate cell migration, invasion and 
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metastasis (Ma, Teruya-Feldstein et al. 2007). However, MCF7 cells, which have little if any 
metastatic ability, were not shown to have a high expression of this miRNA (Ma, Teruya-
Feldstein et al. 2007). Up-regulation of miR-10b after 5-FU treatment was inconsistent with 5-
FU cytotoxicity and could play an important role in the resistance of certain metastatic breast 
cancers to 5-FU treatment. Further time-based study was performed to understand the role of 
miR-10b in response of 5-FU. On the contrary, miR-21, miR-27a and miR-365 have been shown 
to be up-regulated in breast cancer cells (Iorio, Ferracin et al. 2005; Mertens-Talcott, 
Chintharlapalli et al. 2007; Yan, Huang et al. 2008; Guttilla and White 2009). Down-regulation 
of these miRNAs after 5-FU treatment further confirms the active function of miRNAs in 5-FU 
induced cytotoxicity. Further, miR-16 is highly down-regulated in breast cancer (Iorio, Ferracin 
et al. 2005), but was up-regulated following 5-FU treatment. Finally, let-7g, miR-15a, miR-374b, 
miR-483-5p, miR-574-3p and miR-575 have not been previously implicated in breast cancers, 
but show differential expression with 5-FU treatment, suggesting their potential role in 5-FU 
activity. Thus, based on their fold change levels or their novelty in breast cancers, we selected 
five miRNAs (miR-10b, miR-21, miR-483-5p, miR-574-3p and miR-575) for further time-
dependent study. 
An important miRNA that was chosen for dose- and time-dependent study is miR-10b. It 
was not classified to be differentially expressed between control and 5-FU treated samples after 
microRNA microarray analysis due to the low signal intensity; however, a significant variation 
in its expression profile was observed after 5-FU treatment. miR-10b has been previously 
implicated in several human cancers (Table 4.1), including breast cancer (Iorio, Ferracin et al. 
2005; Ma, Teruya-Feldstein et al. 2007). Previous literature has also displayed a positive 
correlation between the expression of miR-10b and metastatic or invasive behavior of primary 
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breast carcinomas (Ma, Teruya-Feldstein et al. 2007), thus classifying it as an oncogenic miRNA 
or Oncomir. This has been partially correlated to the regulation of miR-10b by transcription 
factor Twist (Ma, Teruya-Feldstein et al. 2007), which is a master regulator of morphogenesis 
and plays an essential role in tumor metastasis (Yang, Mani et al. 2004). Several gene targets 
have also been identified for miR-10b. These targets include HOXD10 (Homeobox D10) (Ma, 
Teruya-Feldstein et al. 2007), which has been found to be progressively lost in breast tumors 
with increased malignancy (Carrio, Arderiu et al. 2005; Makiyama, Hamada et al. 2005) and 
regulates several genes that promote invasion, migration and tumor promotion, including uPAR 
and RhoC (Myers, Charboneau et al. 2002); and KLF4 (Krüppel-like factor 4) (Tian, Luo et al.), 
a zinc finger protein which is important in cell cycle regulation, differentiation, and in response 
to DNA damage (Shields, Christy et al. 1996; Zhang, Geiman et al. 2000). 
miR-10b showed a highly differential expression following 5-FU treatment. A significant 
up-regulation was observed compared to the control after 5-FU treatment at different 
concentrations (p < 0.01) (Figure 4.2). The expression level showed a significant increase at 
0.005µM (40-fold) compared to the control. Other treatments did not show considerable increase 
compared to the control. Up-regulation of an oncogenic miRNA after treatment with very low 
doses of 5-FU indicates that 5-FU could aggravate the disease state. Since miR-10b plays an 
important role in migration and invasion of breast cancer cells, this up-regulation could also 
suggest a role of the miRNA in acquired 5-FU resistance observed in certain metastatic breast 
cancer cases. Further, the return of the expression levels to normal at higher 5-FU concentrations 
implies that treatment with higher doses of 5-FU would be more beneficial for the therapeutic 
effect of 5-FU. A time-dependent analysis was carried out to further understand the expression of 
miR-10b in response to 5-FU.  
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A time-based response analysis was performed every 12 hours for 72 hours at 
concentrations 0.1, 0.7 and 10µM 5-FU to obtain further insights into the expression profile of 
miR-10b (Figures 4.12-4.14). At each 5-FU concentration, shorter duration of treatment (< 48 
hours) showed a significant difference in the expression levels compared to the expression 
changes after longer treatments for 60 and 72 hours. This indicates that treatment with 5-FU for 
longer duration would lead to beneficial miRNA regulation, while miR-10b does not seem to 
play an important role in 5-FU cytotoxicity if treated for shorter durations. A two-way ANOVA 
analysis showed that there was a significant main effect of the concentration of the treatment [F 
(3, 56) = 3.192, p < 0.05] as well as the duration of treatment [F (6, 56) = 4.760, p < 0.01] on the 
expression level of miR-10b in MCF cells. Conversely, no significant interaction effect of the 
concentration and duration of treatment [F (18, 56) = 1.531, p = 0.114] was observed. Thus, 
treatment with high 5-FU doses for a higher time span (such as a continuous i.v. infusion for 3 or 
4 days) would lead to a beneficial expression of miR-10b, while treatment for shorter length of 
time (a single dose i.v. infusion) could invoke potential problems.  
miR-21 is another important miRNA whose expression levels are highly dysregulated 
after 5-FU treatment. Extensive study has been carried out on miR-21 and it stands out as a 
miRNA most often found over-expressed in solid tumors (Volinia, Calin et al. 2006), and also in 
most of the human cancers (Table 4.1). Furthermore, miR-21 have also been reported to play an 
imported role in cancer-related processes such as cell proliferation, migration, apoptosis and 
tumor growth in breast, gastric and hepatocellular cancers (Meng, Henson et al. 2007; Si, Zhu et 
al. 2007; Zhang, Li et al. 2008). In breast cancer, miR-21 is found to be highly up-regulated in 
tumors as compared to the normal breast tissues (Iorio, Ferracin et al. 2005). It has been directly 
implicated in promoting tumor growth (Si, Zhu et al. 2007) and is also associated with advanced 
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clinical stage lymph node metastasis and poor patient prognosis (Yan, Huang et al. 2008). It has 
been found to target several important genes (Table 4.1). For importance are the tumor 
suppressor genes PDCD4 (Programmed Cell Death 4) (Asangani, Rasheed et al. 2008; Chen, Liu 
et al. 2008; Yao, Xu et al. 2009); PTEN (phosphatase and tensin homolog) (Meng, Henson et al. 
2007); and TPM1 (Tropomyocin 1) (Zhu, Si et al. 2007; Zhu, Wu et al. 2008). Based on its 
expression in cancers and its gene target, miR-21 can thus be classified as an oncogenic miRNA 
or oncomir. Down-regulation of an oncomir by 5-FU treatment suggests an important role of 
miRNA in 5-FU activity. 
From our dose-dependent results, miR-21 was shown to be significantly down-regulated 
compared to the control after treatment with all the 5-FU concentrations (p < 0.05) (Figure 4.5). 
The highest down-regulation was observed between 0.01-1µM 5-FU, which continued even at 
higher concentrations. Further, the bimodal dose-response curve of the MCF7 cells in response 
to 5-FU (Chapter II) can also be partially explained by the miRNA expression response to 
different 5-FU doses. The initial 5-FU dose-dependent reduction in the MCF7 cell numbers 
between 0.001-0.5µM (Chapter II, Figure 2.4) can be correlated with the dose-dependent 
decrease in the expression level of miR-21 at the same concentration range, with the highest 
down-regulation observed at 0.01µM. This decrease in the fold change gradually reduced in a 
dose-dependent manner after treatment with higher concentrations of 5-FU, which gave a second 
dose-response curve in Figure 2.4. Thus, miR-21 was shown to be sensitive to different 5-FU 
doses and might play a role in the bimodality of 5-FU. Further, the effective concentration range 
for the regulation of miR-21 expression in response to 5-FU was shown to be 0.01-1µM, which 
is much lower than the doses required to elicit 5-FU cytotoxicity in cancerous tissues. This 
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shows that miRNA expression displays greater sensitivity to 5-FU treatment and this could be 
used to reduce 5-FU dosage and thus eliminate the side effects associated with it. 
In order to further study the effect of 5-FU on miR-21, a detailed time-based response 
was performed at 0.1, 0.7 and 10µM 5-FU. The cells were treated with these 5-FU 
concentrations and the expression profile of miR-21 was analyzed every 12 hours for 3 days 
(Figures 4.15-4.17). Of these treatments, 0.7 and 10µM showed a significant alteration in the 
expression fold change as the time of exposure to 5-FU increased. Treatment with 0.1 and 10µM 
displayed a similar trend in the expression profile of miR-21. A decrease in the expression level 
compared to the control was observed till 48 hours of treatment, followed by an up-regulation if 
the treatment was continued till 72 hours. A significant difference in the expression between 
shorter and longer treatment durations was again observed. This shows that treatment with 5-FU 
concentration for shorter duration of time was enough to elicit a beneficial miR-21 regulation. 
Further, it also shows that a lower concentration of 5-FU (0.1µM) was capable of inducing a 
similar response as 10µM 5-FU. However, a different time-based response was observed 
following treatment of MCF7 cells with 0.7µM 5-FU. A significant up-regulation was observed 
at 12 and 24 hours of treatment, followed by a significant down-regulation between 36-48 hours, 
and finally the expression levels became similar to control if treatment was continued further till 
72 hours. This distinct miRNA expression profile at 0.7µM provides additional explanation to 
the atypical increase in cell numbers of MCF7 cells observed during growth analysis at the same 
concentration. The two-way ANOVA analysis demonstrated that there was a significant main 
effect of the concentration of the treatment [F (3, 56) = 4.727, p < 0.01] as well as the duration of 
treatment [F (6, 56) = 4.454, p < 0.01] on the expression level of miR-21. A significant 
interaction effect of the concentration and duration of treatment was also observed on the 
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expression level of miR-21 [F (18, 56) = 4.759, p < 0.01]. Thus, both concentration and duration 
of treatment with 5-FU were shown to play an important role in the regulation of miR-21 
expression levels in the MCF7 breast cancer cells. 
Another miRNA whose expression levels were shown to be notably altered following 5-
FU treatment is miR-483-5p. Recently, it has been identified to play an important role in 
differentiating between adrenocortical adenomas and adrenocortical carcinomas and also as a 
predictor of poor prognosis in adrenocortical cancers (Soon, Tacon et al. 2009). However, no 
definite role of miR483-5p has been recognized in breast cancers. Also, no potential targets of it 
have been identified yet. Thus, miR-483-5p has been identified for the first time in MCF7 breast 
cancer cells and alteration of its expression levels in response to 5-FU may indicate an important 
role for it in 5-FU efficacy.  
miR-483-5p was previously identified as one of the most up-regulated miRNAs in the 
miRNA microarray analysis of MCF7 cells treated with 0.01µM 5-FU for 48 hours (Chapter III). 
Those results are further supported by the dose-dependent study. It continues to be the most up-
regulated miRNA after treatment with various 5-FU concentrations (Figure 4.9). The highest up-
regulations were observed at 0.01 (56.4-fold) and 0.001 (33.8-fold)µM respectively. The up-
regulation became less substantial as the concentration increased, indicating that miR-483-5p 
expression in MCF7 cells was more sensitive to lower doses of 5-FU. The time-based study also 
showed similar results (Figures 4.18-4.20). 5-FU treatment for 12 hours was enough to elicit an 
up-regulation in its expression, suggesting that treatment for shorter time length was important 
for sensitivity to 5-FU. The expression levels were statistically significantly different after longer 
treatments compared to shorter treatments for each 5-FU concentration. On the contrary, a two-
way ANOVA analysis showed that there was a significant main effect of the concentration of the 
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treatment [F (3, 56) = 5.401, p < 0.01] as well as the duration of treatment [F (6, 56) = 2.609, p < 
0.05] on the expression level of miR-483-5p in MCF cells. No significant interaction effect of 
the concentration and duration of treatment [F (18, 56) = 1.188, p = 0.302] was observed. 
miR-574-3p was identified as one of the most up-regulated miRNAs in the microRNA 
microarray analysis previously performed (Chapter III). It has been shown to play an important 
role in liver development (Tzur, Israel et al. 2009), non-alcohol fatty liver disease (Estep, 
Armistead et al.), and myocardial infarction (Bostjancic, Zidar et al. 2009). Recently, it has also 
been identified to show a stage specific differentially expression in B cell lymphomas 
(Malumbres, Sarosiek et al. 2009). However, no direct gene targets have been identified to 
explain the role of miR-574-3p in cancer development or expression. Modification in its 
expression levels after 5-FU treatment may serve to better understand the function of miR-574-
3p in breast cancer in specific and human cancers in general. 
Dose-response analysis revealed that miR-574-3p is differentially expressed through 
different 5-FU concentrations (Figure 4.10). However, the expression levels were not found to be 
significantly different compared to control level by One-way ANOVA. An independent samples 
t-test showed a significant down-regulation in the expression levels at 0.005 and 10µM 5-FU 
concentrations. Time-response analysis showed a significant effect of duration of treatment at 
0.7µM and 10µM 5-FU (Figures 4.21-4.23). Higher down-regulation was observed with 
increased duration of treatment, indicating that longer exposure times were needed to induce an 
expression change in miR-574-3p after 5-FU treatment. The highest down-regulation was 
observed after 36 hours of treatment with both, 0.7µM (1.9-fold) and 10µM (4.4-fold) 5-FU 
respectively. However, a significant increase in the expression was observed after treatment with 
0.7µM 5-FU for 12 and 24 hours. The two-way ANOVA analysis demonstrated that there was a 
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significant main effect of the concentration of the treatment [F (3, 56) = 15.555, p < 0.001] as 
well as the duration of treatment [F (6, 56) = 7.067, p < 0.001] on the expression level of miR-
574-3p. A significant interaction effect of the concentration and duration of treatment was also 
observed on the expression level of miR-574-3p [F (18, 56) = 5.134, p < 0.001]. 
 miR-575 also showed a 5-FU responsive increase in its expression level. It is a novel 
miRNA which has not been previously linked to human breast cancer. It has, however, been 
shown to be down-regulated in gastric cancer cell line (Hong-chun Luo 2009) and meningiomas 
(Saydam, Shen et al. 2009). It is also differentially induced by 4-hydroxynonenal (Pizzimenti, 
Ferracin et al. 2009), and in lupus nephritis (Dai, Sui et al. 2009) and myocardial infarction 
(Bostjancic, Zidar et al. 2009). In our previous study, miR-575 was shown to be highly up-
regulated in the microRNA microarray of MCF7 cells after treatment with 0.01µM 5-FU. The 
dose-response data agree with the microarray data as miR-575 was consistently up-regulated at 
all 5-FU treatments (Figure 4.11). The maximum up-regulation was seen at 0.1µM (17.8-fold) 
and 0.7µM (17.6-fold) of 5-FU. The expression levels were however not found to be 
significantly different than normal control MCF7 cells. The time-response data also confirm with 
the dose-response data, as miR-575 was significantly up-regulated at 0.7µM and 10µM of 5-FU 
(Figures 4.24-4.26). However, expression was found to be more sensitive to short duration of 
treatment and the changes in the expression reduced if the treatment was continued for 72 hours. 
This is similar to expression profile of other miRNAs analyzed, suggesting that these miRNAs 
could help in improving 5-FU therapy in breast cancer patients. The two-way ANOVA analysis 
revealed a significant main effect of the concentration of the treatment [F (3, 56) = 6.279, p < 
0.01], the duration of treatment [F (6, 56) = 5.720, p < 0.001] as well as the interaction effect 
among the two variables [F (18, 56) = 2.383, p < 0.01] on the expression level of miR-574-3p. 
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 In our previous study, 5-FU was shown to have an atypical inhibitory on the proliferation 
of MCF7 breast cancer cells (Chapter II, Figures 2.4 and 2.5). An abnormal increase in cell 
number was observed at 0.7µM 5-FU treatment. We had hypothesized that 5-FU acts with a 
bimodal mechanism, wherein the lower 5-FU concentrations (0.001-0.1µM) act with a different 
method as compared to the higher doses (0.7-2000µM). This hypothesis was partially supported 
by the dose- and time-dependent data obtained in this study. Most of the miRNAs analyzed in 
the dose-response study showed a distinct expression profile at lower 5-FU doses than higher 
doses, for example, let-7g, miR-15a, miR-16 and miR-21. This could signify that a different 
inhibitory mechanism is adopted by 5-FU. The time-response results of some miRNAs further 
supported this observation. The time-based expression profile at low 5-FU dose (0.1µM) showed 
a different pattern as compared to the other two concentrations (0.7µM and 10µM), for example, 
miR-21, miR-574-3p and miR-575. Therefore, future studies will have to be performed to 
evidently explain the anomalous behavior of 5-FU in MCF7 breast cancer cells. 
The results presented here provide a detailed analysis of the miRNA expression profile in 
MCF7 breast cancer cells in response to 5-FU treatment. Several important miRNAs which have 
been previously linked with different human cancers were identified to play an important role in 
response to 5-FU treatment, such as miR-10b and miR-21. More importantly, each of these 
miRNAs was shown to be beneficially regulated after 5-FU treatment as compared to control 
breast cancer cells. This suggests an important therapeutic potential of these miRNAs in breast 
cancer treatment. In addition, novel miRNAs were identified for the first time to play a role in 
breast cancer and breast cancer chemotherapy. These include miR-483-5p, miR-574-3p and miR-
575. Further studies to determine the potential gene targets of these miRNAs are required to 
clearly understand their role in breast cancer chemotherapy. The dose- and time-dependent 
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response of miRNA expression illustrated that the expression profile changes were highly 
sensitive to 5-FU treatment, and that treatment with lower 5-FU doses for shorter durations was 
enough to obtain a beneficial miRNA response. This observation could be very helpful in 
improving 5-FU efficacy. The 5-FU drug regimen, which is rarely used as a monotherapy now-a-
days due to serious side effects and increased incidence of resistance, could be monitored and 
used at lower concentrations for shorter time spans if targeted delivery could be achieved. This 
would ensure a significant miRNA expression change and a subsequent change in the target 
genes, while eliminating the side-effects associated with high 5-FU doses. Thus our data further 
substantiates the importance of miRNA in chemotherapy and the potential application of 
miRNAs as novel targets for cancer therapy. 
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Table 4.1: Cancer association and verified gene targets of miRNAs selected for dose- and time-
dependent study 
miRNAs (up / 
down 
regulation) 
Associated cancers Validated Gene targets 
 Down regulation Up regulation  
let-7g↓ HCC (Budhu, Jia et 
al. 2008) 
OSCC (Kozaki, 
Imoto et al. 2008) 
Lung cancer 
(Kumar, Erkeland et 
al. 2008) 
Prostate cancer 
(Porkka, Pfeiffer et 
al. 2007) 
Colon cancer (Nakajima, 
Hayashi et al. 2006) 
 
HMGA2 (Kumar, Erkeland et al. 
2008)  
miR-10b 
(differentially 
expressed) 
Colorectal cancer 
(Arndt, Dossey et al. 
2009) 
Breast cancer (Ma, Teruya-
Feldstein et al. 2007) 
Chronic Lymphocytic 
Leukemia (CLL) (Calin, 
Liu et al. 2004; Calin, 
Pekarsky et al. 2007; Calin, 
Cimmino et al. 2008) 
Glioblastoma (Chan, 
Krichevsky et al. 2005; 
Ciafre, Galardi et al. 2005; 
Chen, Liu et al. 2008) 
Ovarian cancer (Dahiya, 
Sherman-Baust et al. 2008) 
Pancreatic cancer 
(Bloomston, Frankel et al. 
2007) 
Prostate cancer (Volinia, 
Calin et al. 2006; Prueitt, 
Yi et al. 2008) 
HOXD10 (Ma, Teruya-Feldstein 
et al. 2007) 
KLF4 (Tian, Luo et al.) 
miR-15a↑ CLL (Calin, Liu et 
al. 2004; Calin, 
Pekarsky et al. 2007; 
Calin, Cimmino et 
al. 2008)  
Pituitary adenoma 
(Bottoni, Piccin et 
al. 2005) 
HCC (Budhu, Jia et 
Kidney cancer (Chow, 
Youssef et al. 2009) 
BCL2 (Cimmino, Calin et al. 
2005; Calin, Pekarsky et al. 
2007),  
CDC25A (Lee, Masyuk et al. 
2008),  
CCND1 (Bandi, Zbinden et al. 
2009),  
CCND2(Bandi, Zbinden et al. 
2009), 
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al. 2008) 
Prostate cancer 
(Bonci, Coppola et 
al. 2008) 
CCNE1(Bandi, Zbinden et al. 
2009),  
WNT3A(Bonci, Coppola et al. 
2008),  
RARS (Calin, Dumitru et al. 
2002; Bottoni, Piccin et al. 2005) 
miR-16↑ Breast cancer (Iorio, 
Ferracin et al. 2005) 
CLL (Calin, 
Pekarsky et al. 2007) 
Gastric cancer (Xia, 
Zhang et al. 2008) 
Pituitary adenoma 
(Bottoni, Piccin et 
al. 2005) 
Prostate cancer 
(Porkka, Pfeiffer et 
al. 2007; Schaefer, 
Jung et al. 2009) 
Lung cancer (Yanaihara, 
Caplen et al. 2006) 
BCL2 (Cimmino, Calin et al. 
2005; Xia, Zhang et al. 2008), 
Caprin-1 (Kaddar, Rouault et al. 
2009), 
CGI-38 (Kiriakidou, Nelson et 
al. 2004),   
CCND1 (Liu, Fu et al. 2008; 
Bandi, Zbinden et al. 2009), 
CCND3 (Liu, Fu et al. 2008),  
CCNE1 (Liu, Fu et al. 2008), 
CDK6 (Liu, Fu et al. 2008),  
HMGA1 (Kaddar, Rouault et al. 
2009),  
WNT3A (Bonci, Coppola et al. 
2008),  
RARS (Calin, Dumitru et al. 
2002) 
miR-21↓  Breast cancer (Iorio, 
Ferracin et al. 2005; Yan, 
Huang et al. 2008) 
Cervical cancer (Lui, 
Pourmand et al. 2007) 
Cholangiocarcinoma 
(Meng, Henson et al. 2006) 
CLL (Marton, Garcia et al. 
2008) 
Colorectal cancer (Volinia, 
Calin et al. 2006) 
Diffuse large B cell 
lymphoma (DLBCL) 
(Lawrie, Gal et al. 2008) 
Esophageal cancer (Feber, 
Xi et al. 2008) 
Glioblastoma (Chan, 
Krichevsky et al. 2005; 
Ciafre, Galardi et al. 2005; 
Chen, Liu et al. 2008) 
Head & Neck cancer (Tran, 
McLean et al. 2007; Chang, 
Jiang et al. 2008) 
BTG2 (Liu, Wu et al. 2009),  
MARCKS (Li, Li et al. 2009), 
SERPINB5 (Zhu, Wu et al. 
2008), 
PDCD4 (Asangani, Rasheed et 
al. 2008; Chen, Liu et al. 2008; 
Yao, Xu et al. 2009), 
PTEN (Meng, Henson et al. 
2007),  
TPM1 (Zhu, Si et al. 2007; Zhu, 
Wu et al. 2008),  
HNRPK (Papagiannakopoulos, 
Shapiro et al. 2008), 
TAp63 (Papagiannakopoulos, 
Shapiro et al. 2008), 
LRRFIP1 (Li, Li et al. 2009) 
JAG1 (Hashimi, Fulcher et al. 
2009), 
WNT1 (Hashimi, Fulcher et al. 
2009) 
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HCC (Meng, Henson et al. 
2007) 
Kidney cancer (Chow, 
Youssef et al. 2009) 
Lung cancer (Yanaihara, 
Caplen et al. 2006) 
OSCC (Kozaki, Imoto et al. 
2008) 
Ovarian cancer (Iorio, 
Visone et al. 2007) 
Pancreatic cancer 
(Bloomston, Frankel et al. 
2007) 
Prostate cancer (Volinia, 
Calin et al. 2006; Prueitt, 
Yi et al. 2008) 
Stomach cancer (Volinia, 
Calin et al. 2006) 
Uterine leiomyomas 
(Wang, Zhang et al. 2007) 
miR-27a↓ OSCC (Kozaki, 
Imoto et al. 2008) 
Breast cancer (Mertens-
Talcott, Chintharlapalli et 
al. 2007; Guttilla and White 
2009) 
Kidney cancer (Chow, 
Youssef et al. 2009) 
Gastric cancer (Liu, Tang et 
al. 2009) 
Prostate cancer (Porkka, 
Pfeiffer et al. 2007) 
Uterine leiomyomas 
(Wang, Zhang et al. 2007) 
Myt1 (Mertens-Talcott, 
Chintharlapalli et al. 2007),  
MDR1(Zhu, Wu et al. 2008) , 
FOXO1 (Guttilla and White 
2009),  
PHB (prohibitin) (Schaar, 
Medina et al. 2009), 
ZBTB10 (Mertens-Talcott, 
Chintharlapalli et al. 2007) 
miR-365↓  Breast cancer (Yan, Huang 
et al. 2008) 
No previously reported targets 
miR-374b No previously reported association No previously reported targets 
miR-483-5p↑  Adrenocortical cancers 
(Soon, Tacon et al. 2009) 
No previously reported targets 
miR-574-3p↓  B cell lymphomas 
(Malumbres, Sarosiek et al. 
2009) 
No previously reported targets 
miR-575↑ Gastric cancer cell 
line (Hong-chun Luo 
2009) 
Meningiomas 
(Saydam, Shen et al. 
2009) 
 No previously reported targets 
177 
 
 
Figure 4.1: Average fold change in expression of let-7g in response to 5-FU concentrations from 
0.0001µM to 10µM. The results are represented as mean ± SEM. Statistically significant changes 
in the expression between concentrations are designated by single letters on error bars (p ≤ 0.05). 
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Figure 4.2: Average fold change in expression of miR-10b in response to 5-FU concentrations 
from 0.0001µM to 10µM. The results are represented as mean ± SEM. Statistically significant 
changes in the expression between concentrations are designated by single letters on error bars (p 
≤ 0.05). 
 
a
a
b
a
a
a
a
a
a
0
10
20
30
40
50
60
70
0 0.001 0.005 0.01 0.1 0.7 1 5 10
Av
er
a
ge
 
Fo
ld
 
C
ha
n
ge
5-FU Treatments (µM)
miR-10b
p = 0.008
179 
 
 
Figure 4.3: Average fold change in expression of miR-15a in response to 5-FU concentrations 
from 0.0001µM to 10µM. The results are represented as mean ± SEM. Statistically significant 
changes in the expression between concentrations are designated by single letters on error bars (p 
≤ 0.05). 
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Figure 4.4: Average fold change in expression of miR-16 in response to 5-FU concentrations 
from 0.0001µM to 10µM. The results are represented as mean ± SEM. Statistically significant 
changes in the expression between concentrations are designated by single letters on error bars (p 
≤ 0.05). 
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Figure 4.5: Average fold change in expression of miR-21 in response to 5-FU concentrations 
from 0.0001µM to 10µM. The results are represented as mean ± SEM. Statistically significant 
changes in the expression between concentrations are designated by single letters on error bars (p 
≤ 0.05). 
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Figure 4.6: Average fold change in expression of miR-27a in response to 5-FU concentrations 
from 0.0001µM to 10µM. The results are represented as mean ± SEM. 
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Figure 4.7: Average fold change in expression of miR-365 in response to 5-FU concentrations 
from 0.0001µM to 10µM. The results are represented as mean ± SEM. Statistically significant 
changes in the expression between concentrations are designated by single letters on error bars (p 
≤ 0.05). 
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Figure 4.8: Average fold change in expression of miR-374b in response to 5-FU concentrations 
from 0.0001µM to 10µM. The results are represented as mean ± SEM. 
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Figure 4.9: Average fold change in expression of miR-483-5p in response to 5-FU concentrations 
from 0.0001µM to 10µM. The results are represented as mean ± SEM. Statistically significant 
changes in the expression between concentrations are designated by single letters on error bars (p 
≤ 0.05). 
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Figure 4.10: Average fold change in expression of miR-574-3p in response to 5-FU 
concentrations from 0.0001µM to 10µM. The results are represented as mean ± SEM. 
Statistically significant changes in the expression compared to the control is indicated by 
asterisks (by Independent samples t-test). 
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Figure 4.11: Average fold change in expression of miR-575 in response to 5-FU concentrations 
from 0.0001µM to 10µM. The results are represented as mean ± SEM. 
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Figure 4.12: Average fold change in expression of miR-10b after treatment with 0.1µM of 5-FU 
for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.13: Average fold change in expression of miR-10b after treatment with 0.7µM of 5-FU 
for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.14: Average fold change in expression of miR-10b after treatment with 10µM of 5-FU 
for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.15: Average fold change in expression of miR-21 after treatment with 0.1µM of 5-FU 
for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.16: Average fold change in expression of miR-21 after treatment with 0.7µM of 5-FU 
for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.17: Average fold change in expression of miR-21 after treatment with 10µM of 5-FU 
for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
 
b
a
a
a
b
b
b
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 12 hrs 24 hrs 36 hrs 48 hrs 60 hrs 72 hrs
Av
er
a
ge
 
Fo
ld
 
C
ha
n
ge
Time of treatment
miR-21 at 10µM 5-FU
p < 0.05
194 
 
 
Figure 4.18: Average fold change in expression of miR-483-5p after treatment with 0.1µM of 5-
FU for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. 
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Figure 4.19: Average fold change in expression of miR-483-5p after treatment with 0.7µM of 5-
FU for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.20: Average fold change in expression of miR-483-5p after treatment with 10µM of 5-
FU for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.21: Average fold change in expression of miR-574-3p after treatment with 0.1µM of 5-
FU for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. 
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Figure 4.22: Average fold change in expression of miR-574-3p after treatment with 0.7µM of 5-
FU for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.23: Average fold change in expression of miR-574-3p after treatment with 10µM of 5-
FU for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.24: Average fold change in expression of miR-575 after treatment with 0.1µM of 5-FU 
for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. 
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Figure 4.25: Average fold change in expression of miR-575 after treatment with 0.7µM of 5-FU 
for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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Figure 4.26: Average fold change in expression of miR-575 after treatment with 10µM of 5-FU 
for 12, 24, 36, 48, 60 and 72 hours. The results are represented as mean ± SEM. Statistically 
significant changes in the expression between concentrations are designated by single letters on 
error bars (p ≤ 0.05). 
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